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OVERALL INTRODUCTION TO THESIS 
The body of work presented here is a compendium of the multiple steps required for an investigator 
initiated trial of an existing medication (Valproic Acid- VPA) for a new indication (Retinitis Pigmentosa 
– RP). The chapters are listed in logical and chronological order of the process. In order to access 
patient records an expedited Institutional Review Board (IRB) application for retrospective chart 
review was submitted (Chapter 1). These records enabled the statistical analysis which not only laid 
the framework for the trial design, but also became the basis for two manuscripts (Chapter 2). 
Protocol development informed by the preliminary human studies (Chapter 3) was an instrumental 
part of the Investigational New Drug (IND) application (Chapter 3.5). This protocol along with the 
extensive case report forms that detail the intended data to be collected are included in the IND 
application.  Because the Phase II clinical trial proposed attempting to identify the specific RP 
mutations of the subjects utilizing a National Eye Institute (NEI) study that enabled free genotyping 
services, two IRB applications were submitted (Chapter 3.6).  The first was for approval of the NEI 
genotyping protocol, the second involved the VPA intervention.  Two very different sources of 
funding for this trial were attempted (Chapter 4) – the NIH via the Challenge Grant mechanism and a 
private eye disease foundation (Foundation Fighting Blindness).  In Chapter 5 I detail the alternate 
study designs that were considered and developed for this trial (and ultimately abandoned).  Finally, 
in Chapter 6,  I formally detail my suggestions to aid in the development of a comprehensive 
investigator initiated core facility at UMMMC. 
The goal of this project was two-fold.  The first was to learn the entire process of trial and protocol 
design both from a Umass Institutional perspective as well as from the perspective of the FDA.  The 
second goal was the very real prospect of helping patients with a blinding disease.  This work was 
successful on both counts. IRB approval was received for all the submitted applications.  The 
complexity and uniqueness of many aspects of these submissions culminated in a comprehensive 
learning experience. The process of working with the Umass Research Pharmacy as well as 
developing the industry contacts and know-how to develop a workable and financially feasible 
placebo were both particularly important learning experiences. FDA approval of the IND submission 
was also received, and the process of pre-communication and delving into the considerable and ever-
changing rules and regulations resulted in an extensive and valuable knowledge base.  While the 
practicality of funding has limited the ability of this trial to move forward at this point, given the 
extensive framework laid by this body of work, we are actively pursuing other opportunities.   
The third outcome of this work, while not as intentional, was the considerable process of determining 
the specific competencies and infrastructure that exist at UMMMC to enable investigator initiated drug 
intervention studies.  While this institution is clearly moving rapidly in the direction of translational 
research, the many needs of these studies are often only clearly understood when the process is 
specifically undertaken.  In completing the approval of this Phase II clinical trial, I was not only able 
to better understand and define the existing capabilities of UMMMC for this kind of research, I was 
able to add to that infrastructure when the existing knowledge or skill set was not available.  In this 
 6 
 
manner, I was able to inform and guide many of the support personnel who guided me and have 
become a part of the strategic direction of UMMMC towards clinical translational research.    
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CHAPTER 1: RETROSPECTIVE REVIEW OF CHARTS OF PATIENTS TREATED OFF-LABEL WITH 
VPA AT UNIVERSITY OF FLORIDA 
1.1 INTRODUCTION 
The inception of the trial design required an analysis of the preliminary clinical data from patients 
treated off-label with VPA.  Practitioners are strictly speaking allowed to prescribe their patients 
medications for indications other than what they are approved or marketed for.  Dr.Kaushal treated 
both patients with RP, who have no real existing treatment options, and patients with Age Related 
Macular Degeneration (AMD), who failed standard therapy, with VPA. The scientific basis for using 
VPA as a retinal therapeutic is detailed exhaustively in the manuscript in Chapter 2 (page 19). In 
brief, prior work has shown that VPA has multiple biologic properties including apoptosis inhibition, 
microglial activation and even stimulation of photoreceptor differentiation from glial cells.  In the 
Kaushal laboratory, VPA was identified as a potent molecular chaperone, increasing the yield of 
properly folded mutant rhodopsin, a protein important for many forms of RP.  Further work from our 
laboratory has also shown that VPA can protect retinal cells from oxidative stress which is thought to 
be important in the progression of cell loss in RP and AMD. 
VPA was approved by the FDA for use as a broad spectrum anticonvulsant in 1978 and is also used 
for acute and maintenance therapy of bipolar disease, for migraine prophylaxis, and occasionally for 
chronic pain syndromes. Therefore the pre-clinical, pharmacokinetic, manufacturing, safety and 
tolerability analysis were extensively completed previously.  The off-label use of this medication 
allows for a preliminary analysis of its affect on retinal function as well as its tolerability in this specific 
patient population. Of course a clinical trial is required to rigorously analyze the efficacy and safety of 
VPA for retinal disease indications.   
 
1.2 THE PROCESS 
Dr.Kaushal had recently transferred here from University of Florida (UF), so our access to medical 
records were limited to only those patients that transferred their records to this institution.  As this was 
my first foray into the IRB process, my initial approach was to familiarize myself with the resources in 
the UMMMC Office of Research IRB website.  My first goal was to understand whether the 
retrospective chart review (that would occur here at UMMMC) of records of patients treated at a 
different institution (UF) would qualify for an exemption.  This required extensive searching of the 
institutional web resources as well as the Collaborative IRB Training Initiative (CITI) materials.  
Ultimately a meeting was scheduled with Shayne Deal, a protocol specialist in the IRB office.  I 
carefully detailed the information we proposed to collect and the complexity of the situation.  She 
consulted with her superiors and ultimately confirmed that the chart review would be appropriate for 
an exemption. 
I prepared and submitted the IRB exemption form and the data abstraction form and submitted it to 
Shayne for several rounds of pre-review and edits.  Through this process it became clear that a 
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HIPPA waiver was also required so I prepared that as well.  All three documents were submitted in 
hard copy to the IRB office. 
 
1.3  ISSUES AND RECOMMENDATIONS 
While the Office of Research offers a variety of resources to investigators for human subjects‟ 
research, the information is not centralized and often requires prior knowledge of where to look or 
who to contact to efficiently locate the information. The lack of centralization in human subjects‟ 
research resources is clearly going to be addressed by the establishment of the UMass Center for 
Clinical and Translational Science and their co-pilot program to guide investigators through the 
process.  It will be important not only to establish this conceptually however, as existing Office of 
Research staff will need to be continually informed and updated to the changing requirements and 
developing needs of the research community. While I now understand Umass IRB exemptions 
because I went through the process, it will be important to develop a tool that allows a naïve 
investigator to view and distill the entire process from start to finish.  Electronic submission and 
tracking of the forms to the IRB office would streamline the process considerably.  
The fact that Dr. Kaushal had recently transferred here ultimately served to be the biggest obstacle as 
access to medical records is strictly limited to those patients who plan on continuing to receive their 
care from Dr. Kaushal.  Not only does this potentially bias the records, but also severely reduced the 
number of records we had access to.  An additional and very real complication was that most of the 
records were faxed by the medical records Department at UF which was wholly inadequate for much 
of the outcomes of interest. 
1.4 OUTCOME  
Once the exemption was approved by the IRB, I was then given access to the records of UF patients 
as their records were transferred to UMMMC.  A secure filing system was established in my office, 
and I began the considerable process of teaching myself to understand an Ophthalmologic patient 
record so I could abstract the required information.  Through contact with the UMMMC Department of 
Ophthalmology clinic staff, and online web resources, I learned how to read and understand the clinic 
notes, and diagnostic measures and ultimately abstracted the data from approximately 14 RP 
patients and about 20 AMD patient‟s records.  I established password protected Excel spreadsheets 
and de-identified the data.   
The adequacy of the medical records was addressed ultimately by my working with Mark Krebs, who 
is on staff at UF.  I was able to identify the appropriate records for him and he would go to the medical 
records department, take the appropriate records to a high resolution color copy machine in another 
building to duplicate them.  He would then send those records to me. This ensured both that all the 
data was preserved and that the reproduction of the visual fields was performed with no change in 
size.  I was able to receive good data in this manner for seven RP patients that had baseline and 
follow up measures while on VPA. 
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1.5 EXPEDITED IRB APPLICATION FOR RETROSPECTIVE CHART REVIEW OF PILOT DATA 
1.5.1 IRB EXEMPTION APPLICATION 
 
REQUEST FOR EXEMPTION 
Shalesh Kaushal, MD, PhD 
Christine Clemson, PhD 
 
Department: Department of Ophthalmology 
Campus:  University  
Telephone Number:  856-4808 
E-mail address: shalesh.kaushal@umassmemorial.org; christine.clemson@umassmed.edu 
Title of project: 
Retrospective Chart Review of Patients on Valproic Acid 
Briefly describe the purpose of the study. 
This retrospective, chart-review of  medical records transferred here from patients that Dr Kaushal previously 
treated at the University of Florida. There is no need for a HIPAA waiver given these are not currently patients 
at Umass and they signed the HIPAA form in Florida. The information to be abstracted was not collected for 
research, but is from the treatment of these patients by Dr. Kaushal who utilized both standard therapy and an 
off label medication – valproic acid.  The retrospective chart  review will be peformed to assess these specific 
clinical outcomes in patients treated with oral valproic acid (VPA):  1) visual acuity,  2) visual field  3) retinal 
anatomy,  4) perceived benefit as described in patient interviews and 5) safety profile. These outcomes will be 
used  to assess the rates of  vision loss (primary outcomes) and  adverse events(secondary outcome) in patients 
prior to and during a regimen of oral valproic acid for a period of upto 12 months.  This information will be 
used to inform our study design, IND, IRB and NIH grant submissions for a clinical trial here at Umass to 
determine the efficacy and safety of this medication for the treatment of retinal diseases. 
Briefly describe what procedures will be employed.  If subjects are to be involved, describe how they will 
be involved, how they will be recruited or identified, and how long each procedure will take.  Attach all 
surveys, interview questions, or other instruments to be used.   
This is a retrospective study. There will be no new procedures performed on patients.  We will perform a 
thorough chart review of  several diagnostic  measures including Snellen Standard chart protocol,  
Electroretinography (ERT);  Goldman perimetry, Optical Coherance Tomography (OCT),  blood chemistry. 
The patients involved will have all signed medical records release forms to allow the transfer of their records to 
UMMHC .   The majority of these patients will continue to be treated by Dr. Kaushal here at Umass. Patients 
that will transfer their care to Umass so as to continue to receive care from Dr. Kaushal will sign Umass HIPAA 
forms (the new patient information that will be collected at Umass is not, of course, covered under this 
exemption request). 
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Briefly describe how the data be recorded and who will have access to the data. 
All data will be kept in a computer file, at all times to be accessed only by the primary investigator. A master 
Excel data collection sheet will be created for the statistical analysis. The paper data sheets information will be 
transferred to an Excel file for the final analysis. 
Briefly explain the procedures to be taken to assure anonymity and confidentiality. 
The patients will be de-identified by the creation of a master list assigning a study number to each patient.  The 
database will be protected and will include the study number with a reference to the medical record number.    
Please list all research personnel involved in the conduct of the study and their role in the study. All 
research personnel must complete a human subjects educational training program.  Please visit our website at 
http://www.umassmed.edu/subjects/human/education/  for more information. 
Shalesh Kaushal, MD, PhD Primary Investigator 
Christine Clemson, PhD.  Co Invesitigator 
Citation of Exempt Category (check one):  ___ 1 ___ 2   ___ 3  _X 4*  ___ 5   ___ 6 
* If you have chosen exempt category #4, please complete the questions to follow. 
_____________________________________________________________________________________ 
EXCEPTIONS:  Research involving vulnerable populations such as the mentally or congnitively impaired, prisoners, parolees, 
pregnant women, and fetuses cannot be exempt from review even though it meets the criteria below.  Research using survey 
procedures or interview procedures upon children cannot be exempt.  Research involving observation of children’s behavior cannot be 
exempt if the investigator is a participant in the behaviours observed.  
Exempt Category #4:  COMPLETE THIS SECTION IF YOU ARE REQUESTING PERMISSION TO 
STUDY EXISTING DATA, DOCUMENTS, RECORDS, AND/OR BIOLOGICAL SPECIMENS.  Each 
section must be completed. 
What is/are the type(s) of data/biological specimens to be used? 
Patient demographic information including age, gender, diagnosis, comorbidities, medications and medical 
history will be obtained.  Ocular treatments, retinal thickness, visual fields, length of treatment and dose of 
VPA, intraocular pressure, anterior and posterior exam data, retinal photographic changes, blood chemistry 
including chem 7, CBC and electrolytes, and patient comments on adverse effects and subjective improvement 
will be collected from the outpatient medical record.   
What is the source of the data/biological specimens?  Are these publicly available? 
Data will be extracted from outpatient clinic charts of patients treated by Dr. Kaushal between January  2008 
through the submission of this application.   
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Are data/biological specimens originally collected solely for research purposes?   
            Yes ___  No __X 
How are data/biological specimens identified when they are made available to your study team?  (Please 
indicate by marking the appropriate box below.) 
i. _____Direct Identifier (i.e., subject name, address, social security, medical record number, etc.).  If 
receiving identifiers, this may require expedited or full IRB review. 
ii. ___X_Indirect Identifier (i.e., an assigned code which could be used by the investigator or the 
source providing the data/biological specimens to identify a subject, such as a pathology tracking 
number or tracking code used by the source.) 
iii. _____No Identifier (i.e., neither the researcher nor the source providing the data/biological 
specimens can identify a subject based upon information provided with the data/biological 
specimens.) 
If (i) or (ii) is checked above and you are requesting permission to study biological specimens, will the 
identifier provided with the specimens be removed and destroyed upon receipt by your study team?   Yes ____      
No_____   Does not apply____X__ 
If (i) or (ii) is checked above and you are requesting permission to study archived data, will you abstract and 
record any subject identifiers as a part of the data collection process?   Yes ___X_   No _____  Does not apply 
_____ 
Will any data or biological specimen(s) be collected from subjects after the submission of this application?   
Yes* _____  No ___X__ 
*If yes, your research does not qualify for exemption from IRB review. 
If you will have access to any protected health information for the data/specimen collection, you will be required to complete the 
HIPAA Waiver of Authorization and submit a signed copy for IRB review.  Please visit our webpage 
www.umassmed.edu/subjects/human/HIPAA for the Waiver of Authorization. 
Investigator’s Assurance:  I certify that the information provided is complete and correct.  I understand 
that as Principal Investigator, I have responsibility for the conduct of the study, the ethical performance 
of the project, and the protection of the rights and welfare of human subjects.   
 
 
 
          Principal Investigator’s Signature                        Date  ______________________________________________          2-19-09____________________ 
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1.5.2 HIPPA WAIVER  
 
UMass Memorial Medical Center 
HIPAA IRB WAIVER OF AUTHORIZATION 
 
Principal Investigator:  Shalesh Kaushal, MD PhD 
IRB Docket # H-  
Protocol Title: Retrospective Chart Review of Retina Patients on Valproic Acid 
 
1. The use or disclosure of Protected Health Information (PHI) involves no more than a minimal risk to the 
privacy of individuals.  Explain why?  Include a detailed list of the PHI to be collected and a list of the 
source(s) of the PHI.  
Patient demographic information including age, gender and medical history will be obtained.  Ophthalmologic 
exam, diagnostic data and patient comments will be collected from the outpatient medical record.   
2. Describe the plan to protect identifiers and indicate where PHI will be stored and who will have access 
(researchers must list all of the entities that might have access to the study’s PHI such as IRB, sponsors, 
FDA, data safety monitoring boards and any others given authority by law). 
The patients will be de-identified by the creation of a master list assigning a study number to each patient.  
The database will be protected and will include the study number with a reference to the medical record 
number and name during data collection phase. Then it will be de-identified by removing the name and 
medical record for a final analysis.  All data will be kept in a computer file, at all times to be accessed only by 
the primary investigator. A  de-identified master Excel data collection sheet will be created for the statistical 
analysis. 
 
3. When will identifiers collected during the study be destroyed?  Also, please describe the procedure used 
to destroy the identifying data (electronically, paper, audio/video, photography, other).   
The identifiers collected during the study will be destroyed upon completion of the statistical analysis of the 
study data.  Electronic sources of data will only be stored on the hospital secure server and will be deleted 
from storage.  Any paper containing identifying data will be shredded and placed in secured disposal bins 
available throughout the hospital. 
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4. Are research subjects contacted during the course of this research study?  If yes, describe  in detail, the 
recruitment plan.  
Patients will be contacted only for them to complete a Medical Records Release form from the University of 
Florida to allow their records to be transferred to UMMHC. 
5. The research could not practicably be conducted without the waiver because (explain below).  
It would be an additional cumbersome step that is costly and bothersome to the patients, most of whom are 
severely handicapped due to vision loss.  The Medical Records Release Form request already is a burdensome 
and time consuming step that is a direct result of Dr. Kaushal’s move here to Umass.  Additional steps and 
forms will only serve to prolong establishing a clinical trial here at UMMS of this highly promising treatment 
for patients who are experiencing catastrophic debilitating vision loss. 
6. The research could not practicably be conducted without access to and use of the PHI because (explain 
below).  
The necessary data is contained within patient medical charts. 
 
 
7.The HIPAA regulation requires reasonable efforts to limit protected health information to the minimum 
necessary to accomplish the intended purpose of the use, disclosure or request.  Please note that researchers are 
also accountable for any PHI released under a waiver.  Explain why PHI obtained for this study is/are the 
minimum information needed to meet the research objectives. 
Patient demographics, comorbidities and other medications  are required to establish that we have avoided a 
selection bias and to identify potential confounding factors.  Ophthalmologic exam and diagnostic test 
information is required for the primary outcomes, assessing vision loss.  Blood chemistry information is 
required for the secondary outcomes related to patient safety. 
 
The information listed in the waiver application is accurate and all research staff will comply with the HIPAA 
regulations and the waiver criteria.   
I assure that the information I obtain as part of this research (including protected health information) will not 
be reused or disclosed to any other person or entity other than those listed on this form, except as required by 
law.  If at any time I want to reuse this information for other purposes or disclose the information to other 
individuals, or other entities, I will seek approval by the IRB. 
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1.5.3 ACCOUNTING OF RESEARCH DISCLOSURE FORM 
UMass Memorial Medical Center 
 
ACCOUNTING OF RESEARCH DISCLOSURES* 
Attachment A 
 
 
 
Patient/Subject Name: __________________________________________________ 
 
Medical Record # : ___________________                 DOB: ___________________ 
 
 
Information on the patient/study subject noted above was disclosed to the researcher listed below (or his/her designee) 
after approval was received for (check one): 
 
 Data Collection for Review Preparatory to Research 
 Decedent Research  
X Waiver of Authorization  
 
 
Name of Researcher: Shalesh Kaushal, MD PhD_____________________________ 
 
Department @ UMMS: Ophthalmology__________________   Phone: _508-856-4808_______ 
 
Brief Description of Information Disclosed: age, gender, race, history, blood chemistry, ophthalmologic diagnostic exams, 
patient comments 
 
Disclosure made by UMass Memorial Medical Center.  
 
Date: ________________  
 
*This Accounting of Research Disclosures form should be used by the researcher in the event of PHI 
disclosures in any of the following circumstances: 
 
1) The researcher’s request to conduct Data Collection for Review Preparatory to Research has been 
approved by the Office of Research 
2) The researcher’s request for PHI solely for research on decedents has been acknowledged by the IRB 
chair or designee 
3) The researcher’s Request for Waiver of Authorization has been approved by the IRB 
 
After customizing this document with name and MR #, either place this form directly in the last section of the 
medical record (Incoming Letters and Reports) or send to: 
 
Health Information Management 
UMass Memorial Medical Center  
55 Lake Avenue North  
Worcester, MA. 01655 
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CHAPTER 2:  ANALYSIS OF DATA ABSTRACTED FROM PATIENT RECORDS  
2.1 INTRODUCTION 
While the natural history of RP has been described in the literature, the disease is quite heterogenous 
and is really a collection of many retinal dystrophic disorders.  Therefore, it was important to use the 
data abstracted from the records of patients as a guide and a feasibility check on the study design. 
Specifically, the changes in outcome measures of interest (visual field, retinal thickness and visual 
acuity) are hard to predict among diverse RP patient populations, so this data was critical in designing 
the endpoints for the study.  Additionally, the tolerability of VPA, even at relatively low doses in 
population of patients with RP and AMD is an open question, so any information abstracted on side 
effects and adverse events is valuable. 
2.2 THE PROCESS  
To get help in the rigorous biostatistical analysis of the data, I first contacted the UMMS institutional 
biostatistician, Stephen Baker.  However, he didn‟t have the time or the resources to dedicate to this 
project long term.  An adequate analysis of this data would involve not only an understanding of 
biostatistics but also the specific ophthalmologic outcome measures (which are psycho-physical and 
inherently prone to measurement bias) and the patient population (which is extremely 
heterogeneous).   
I was able to convince Carol Bigelow, PhD., who teaches the three Master in Clinical Investigation 
Biostatistics and Data Management classes, to partner with me on this analysis.  Her time was quite 
limited, so we agreed to merge her understanding of data analysis with my burgeoning understanding 
of the science of RP outcome measures which was based in large part on the work by Eliot Berson at 
the Massachusetts Eye and Ear Infirmary. His group is highly regarded in their statistical approach 
which is informed by an in-depth understanding of the RP patient population and clinical measures. 
Carol Bigelow provided a preliminary analysis that became the template for the full analysis I 
performed on the RP patient data.  I incorporated this completed analysis into the manuscript that 
follows (Chapter 2.5). 
During the summer of 2009, a medical student intern, Jenna Checchi, who has considerable 
experience in data abstraction of chart records from her tenure at the NIH, worked with me to finalize 
abstraction of the complete AMD patient‟s records.  She also was instrumental in fine tuning both the 
RP and AMD Excel spreadsheets I had designed, to make them much more fascicle tools.  We 
worked together on the AMD patient data to perform the analysis.  This analysis was incorporated 
into the manuscript in Chapter 2.6. 
2.3 ISSUES AND RECOMMENDATIONS 
The lack of adequate biostatistical support staff at UMMMC is a known issue and one that is being 
addressed by the establishment of the new Department of Quantitative Health Sciences.  It is 
important to emphasize that even relatively small projects such as this one, require considerable 
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investment of time and effort on the part of the biostatistical consultant.  As more medical records 
were received, and other potential outcome measures were considered, the analysis was continually 
evolving. Fortunately between my training in biostatistics and the template analysis Carol had initially 
provided I was able to complete the analysis on my own with final feedback from Carol.  I was also 
able to transfer this knowledge to the AMD study and adapt it to the specific outcome measures for 
that population, training Jenna in the process. 
As with every aspect of this project, I embraced the fact that I would be primarily responsible for the 
data analysis as it provided me with yet another opportunity for experiential learning.  I was glad, 
however, to have guidance and proofing by Carol Bigelow to ensure that the analysis was performed 
properly.  As more and more Umass investigators pursue clinical research, the demand for 
biostatisticians will only increase.  The current model of pockets of expertise dispersed among many 
different departments will not address this need.  A robust supply of analysts, who are not fully 
occupied with other projects will be needed to provide core service to the UMMMC research 
community. 
While the analysis of the seven RP patients is suggestive of therapeutic benefit, given the low 
numbers, and extremely short length of follow up, the statistical analysis is considered speculative.  
The lack of sufficient data is what I would consider the largest issue to this analysis.  The marginal 
statistical significance in the RP patient set is superior to the AMD results, which combine to paint a 
very different picture from what Dr. Kaushal sees in the UMMMC Ophthalmologic Clinic.   
The complications of the restricted patient population are such that that we cannot access more 
records from the UF patients who have been treated with VPA unless they happen to transfer their 
records to UMMMC.  It was hard to predict a priori how many patients would transfer their records 
from UF to UMMMC and clearly, Dr. Kaushal‟s expectations were optimistic.  In retrospect, instead of 
proposing a larger randomized controlled trial as in Chapter 3 it would have been prudent to propose 
an intermediate trial.   A small pilot study of standardized patients at the UMMMC clinic that are 
consented, on a standard course of VPA and consistently analyzed for a variety of measures would 
provide more and better information than I could retrieve from this limited data set.  
2.4 OUTCOME  
Both manuscripts will be submitted to the British Journal of Ophthalmology.  Rad Tzekof, PhD, a 
senior scientist with considerable expertise in eye studies who has recently joined our laboratory, is 
helping me to convert the visual field areas to the more robust degrees2.  Once this conversion is 
complete we expect to submit the manuscripts immediately. 
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2.5 MANUSCRIPT 1:  VALPROIC ACID AS A POTENTIAL THERAPEUTIC FOR RETINITIS PIGMENTOSA 
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2.6  MANUSCRIPT 2: VALPROIC ACID AS A POTENTIAL THERAPEUTIC FOR AGE-RELATED MACULAR 
DEGENERATION 
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CHAPTER 3:  CLINICAL TRIAL DEVELOPMENT 
 
3.1 INTRODUCTION 
This aspect of the project was the most labor intensive, and although through this effort I authored 
countless documents, there was a wealth of my work in this regard that was not recorded in the 
corresponding submitted documents.  This is an indication of the large amount of behind the scenes 
information gathering and connection building that was required.  Since I hope to annotate below the 
unrecorded processes important for trial development, the introductory section to this chapter is the 
most lengthy.  Additionally, this aspect of the project intersected the most with the missing 
infrastructure/core expertise here at UMMMC. Therefore the Issues and Recommendations section at 
the end of this introduction is also the most comprehensive. 
 
While many steps were taken concurrently, the general order of the process as I undertook it was: 1) 
study design; 2) protocol development; 3) placebo development; 4) case report form design and 
production; 5) IND submission and 6) IRB submission. 
 
The lynchpin step in the process was to produce the protocol. This document is the basis for the IRB 
and IND submissions. The protocol is the distillation of the specifics of the trial incorporating the fine 
detail of every aspect of the study from the exact procedures performed at every visit to the definition 
of adverse events.  
 
Trial design is based on incorporation of the preliminary studies and known rates of progression of 
RP into a power analysis.  Additionally the structure of the study design is deeply dependent upon the 
disease and patient population.  I had never developed or even seen a study protocol prior to this 
project, and finding good models to use as templates was difficult.  These kinds of documents are 
highly proprietary, and the ones I could get access to weren‟t necessarily the most appropriate for an 
ophthalmologic study.  This was even more true for the case report forms, it was hard to find any 
available electronic copies  that contained relevant ocular diagnostics. 
 
In planning the trial, I found that ultimately the cost associated with an investigator initiated trial is rate 
limiting, and the concepts of sound study design and the realities of fiscal concerns are very much in 
competition. For example, the cost of the drug for the entire study period is about $7000.  The cost to 
manufacture an ideal placebo is about $50,000. This exemplifies the constant push and pull during 
the design process; understanding what was feasible was just as important as what the right steps 
were.   
 
3.2 THE PROCESS 
I considered multiple trial designs for this study, basing them on established prior studies in 
neurodegenerative disorders such as the delayed start, crossover and futility designs often used in 
Parkinson‟s Disease.  The first design I settled on (and still to this day believe is the best for our 
circumstances) was a one-armed self-controlled study.  Given the extreme heterogeneity of the RP 
disease progression and genotype, I was concerned about controlling for the treated subjects with 
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unrelated controls. I proposed a rigorous genotyping analysis coupled with a longitudinal baseline 
screening of subjects to define the rates of vision function loss for each subject.  This design, which 
was modified and vetted over a period of many months, ultimately was informally rejected by the 
FDA.  The details of this trial design can be found on page 191 as this was the design included in the 
Challenge grant submission.  
 
3.2.1 COMMUNICATION WITH THE FDA 
Pre-communication with the FDA was happening in tandem with the data analysis and study design.  
Dr. Kaushal‟s prior contact with the Ophthalmologic Products Division Chair, Wiley Chambers, M.D. 
was instrumental.  During the six months from trial development to IND submission, I communicated 
with Dr. Chambers via phone calls and email.  Fortunately this division of the FDA is small and 
streamlined.   Dr. Chambers emphasized that his division preferred informal communications during 
the entire process such that when the IND was submitted they had thorough knowledge of its 
contents.  (The process is such that his staff would have about 10 to 20 days with which to decide to 
put a study on “clinical hold” or by default allow it to proceed.  Constant communication with the 
investigators allows them to review the protocol over a longer period of time, and even shape the 
study to some degree).   
 
It was during these pre-communications with Dr. Chambers that I learned a central tenet of this 
aspect of human subjects‟ research:  Find out what the FDA wants.  Despite his acceptance of the 
soundness of the one-armed self-controlled study (and his agreement that it‟s a great design for RP 
subjects), Dr. Chambers asserted that as a rule placebo controlled trials are considered more 
rigorous by the FDA. At his insistence, I then redesigned the trial as a randomized, placebo controlled 
study.  This single aspect doubled the numbers we needed to enroll, increased the costs to the point 
that I question the feasibility that we will ever get fully funded with no pharmaceutical backing, and 
also meant that we needed to partner with a second site as 90 patients was an untenable recruitment 
goal for UMMMC.    
 
The second site was selected by Dr. Kaushal – the Retina Foundation of the Southwest.  The 
principal investigator at this site, David Birch, PhD is a highly regarded clinical trialist in RP and was a 
great resource to me.  His clinical trial coordinator, Kirsten Locke RN, worked closely with me to 
coordinate the equipment and operating procedures between sites. Furthermore this clinic has an 
extensive set of families and fully characterized RP patients.  Ultimately the addition of this site added 
immeasurably to our study. 
 
Utilizing the data from the preliminary human study, with help and guidance both from Stephen Baker 
and Carol Bigelow, I performed a power calculation to understand how many subjects we would need 
to power the study.  It was determined that 90 subjects total (45 placebo and 45 treated) were 
required.  The details of my analysis are included below in the protocol (page 65) and the Challenge 
grant application (page 191).  
 
The whole process of submitting an Investigational New Drug application to the FDA, for the 
uninitiated such as myself, involves a steep learning curve and a lot incredible and frustratingly 
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difficult information gathering.  There is no available core expertise within the UMMMC community so 
my knowledge was gained through a combination of on-line resources (primarily the FDA CDER 
website) and communication with knowledgeable contacts such as Wiley Chambers, David Birch and 
Marg Humphries RN, who is the clinical trial coordinator for the ongoing gene therapy trial here at 
UMMMC.   
 
The IND submission for this trial, given that it is for a new indication for a well established medicine 
and is an investigator initiated study simplified the process.  However, there were many new and 
changing regulations (the requirement for posting to the clinicalTrials.gov website for example), that 
even the experts at the FDA were unsure of how to implement. 
 
3.2.2 CASE REPORT FORMS 
An unexpected (and extremely time consuming) requirement for the IND submission was the 
inclusion of case report forms (CRFs).  The creation of these documents cemented the fine details of 
every piece of data we expected to collect on each subject. With screening, baseline and four follow 
up clinic visits, multiple follow up phone calls and repetitive measures of many in-depth 
ophthalmologic tests, I created a set of about 150 case report forms (a sample set is included in 
Chapter 3.5.1 page 84).  In order to do this I had to understand not only what we were proposing to 
measure, but also the details of the many pieces of new ocular equipment we were proposing to use.  
Ultimately, as with much of this project, the CRF creation required an invaluable in-depth 
understanding of the data we would collect. The CRFs were extremely helpful in coordination of 
processes and equipment between the two-sites.  I also see the value of these forms as I currently 
work with the Business Systems Department in the UMMMC Information Services to create a data 
management tool for this trial.  These forms lay a very firm foundation for the database, so much so 
that Business Services will be implementing the submission of CRFs as part of the workflow for 
clinical trial data management processes in the future. 
 
3.2.3 PLACEBO DEVELOPMENT 
Placebo development was another unexpected aspect to the study design. I initially worked with 
Lucie Lajuenesse, the Research pharmacist here at UMMMC, to both source the VPA and develop a 
workable placebo.  Identifying exactly which lot of the generic form of VPA (absolutely required for the 
IND submission) was anything but straightforward.  With quite a bit of effort and help from Madeline 
Karcasinas  in purchasing, I was able to find the name of the supplier (McKesson) that the hospital 
can purchase the study drug from.  (Typically UMMMC trials of this sort have pharmaceutical 
sponsors who provide both placebo and study drug).  I contacted this supplier (who is rarely the 
actual manufacturer of the drug), and was able to get a lot # of the study drug that would at least 
partially cover our initial VPA dosing.  (Wiley Chambers informed me that a simple amendment to the 
IND application could be filed if and when the lot# changed).   
 
VPA is oil soluble and is dispensed in large soft-gel capsules.  The inexpensive method of placebo 
creation that is typically used here at UMMMC is to over-encapsulate the study drug (ie. put it into 
another larger empty capsule).  Then a standard placebo tablet is also over-encapsulated into the 
same size empty capsule.  In theory this placebo solution seemed functional, but in practicality it did 
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not work.  First, we would need about 50,000 capsules of both the study drug and the placebo. The 
research pharmacy here at UMMMC does not have the resources for this.  Second, the “standard” 
placebo was actually a tablet and was easily identifiable versus the study drug as it shook inside the 
empty capsule while the study drug was immobilized in the empty capsule.   Even if we expected that 
patients would not figure out the difference, clearly the clinic staff would be unblinded as they 
administered the vials of study drug and placebo.  Third, the only empty capsule that would accept 
the large 250mg VPA capsule was a size 00 – which is very large and hard to swallow. At this point I 
started the quest for a workable placebo from extramural sources. 
 
 Lucie referred me to a local pharmaceutical compounding center, Boulevard Pharmaceutical 
Compounding in Worcester.  The proprietor, Joe Rosetti, is an eccentric, loveable 75 year old man 
with lots of experience and long-winded stories about the nature of his business.  His facility was 
certainly capable of over-encapsulating the study drug.  We worked together to come up with a 
cheaper solution to the placebo.  He could not find a smaller capsule to accept the VPA so he would 
fill the same large, size 00 capsules with powdered methylcellulose (brand named Avicel).  This 
would at least have a closer appearance to the over-encapsulated study drug.  I had Joe provide me 
with 100 capsules of a placebo created in this manner and Jenna Checchi pilot tested this placebo on 
5 staff members in Dr. Kaushal‟s clinic and laboratory.  One person felt that it got stuck in their throat 
and one person refused to try to swallow it once he saw the actual capsule size.  Given that VPA can 
cause difficulty swallowing, it seemed clear that a new solution should be found.  Additionally, the 
cost of this low-tech solution was about $15,000. 
 
I next contacted Frontage Laboratory, a contract pharmaceutical manufacturer.  They worked with me 
to develop a quote to manufacture a small, hard capsule filled with the VPA excipient oil (soft gels are 
expensive to produce and rarely manufactured by small facilities).  The cost to provide this placebo 
was about $40,000.  Besides the cost, the downside of this solution was that the placebo still didn‟t 
look like the study drug.  However, since over encapsulation was not involved, the size of both the 
study drug and the placebo was much smaller. 
 
Throughout this entire process I was continually contacting manufacturers of VPA in an attempt to 
entice them to be involved in the study and provide materials for the trial.  My first contact was to 
Abbott, who holds the original patent on Valproic Acid (Depakene).  While this patent has long 
expired, the extended release version (Depakote) was still under their patent protection and I 
reasoned that Abbott would absolutely want a new indication for this soon to expire intellectual 
property.   If you have ever tried to reach someone at a big (or small) pharma company, you learn 
quickly that it is difficult to get the names and contact information of the decision makers.  However, 
through friends at Abbott here in Worcester, and a lot of “creative” conversations with the 
receptionists at Abbott‟s facilities in Illinois, I was able to speak directly with the medical directors who 
make the decisions on resources for new indications for VPA.  I was told emphatically on many 
different occasions, from multiple people at Abbott, that they had exhaustively partnered with 
investigators such as ourselves over the years who were studying VPA.  They had committed untold 
resources in an attempt to find new indications, and none were successful.  The official position was 
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that Abbott was letting their patent protection expire and was not investing any more money in 
investigator-initiated studies on this medication. 
 
I aslo contacted four manufacturers of generic VPA (with the continuing mergers of many of these 
pharmaceutical companies it is difficult to tell exactly who is manufacturing the drugs and the 
information on the FDA website is clearly outdated).  It turns out that Catalent Pharmaceuticals, who 
manufactures VPA, also has a small contract manufacturing business.  They could produce 50,000 
identical soft gel placebos in their pilot facility AND source 50,000 capsules of an identical lot of study 
drug (at cost).  This solution cost about $45,000 (plus the cost of the study drug).  This solution was 
clearly the most robust in terms of keeping the trial blinded and keeping the capsule size to a 
minimum.  Catalent also provided stringent placebo manufacturing standards and could guarantee 
that the placebo was identical to the study drug in excipients since they also manufactured VPA.  I 
chose to proceed with the Catalent placebo solution. 
 
3.2.4 THE IRB APPLICATIONS 
The next part of the process was to prepare and submit the IRB applications.  While this process was 
lengthy, I fully understood the scope of the process so this effort was not unexpected.  Because the 
genotyping of the subjects was to be covered under a separate protocol from the National Eye 
Institute, a separate IRB application was required.  I found that genetic analysis is an area of concern 
for the UMMMC IRB and felt that this previously approved NIH protocol was scrutinized even more 
thoroughly and engendered more comments and revisions than the VPA intervention study 
application that followed. The consent forms were a particularly grueling aspect as the wording on the 
consent form from the NEI was not always in acceptable standard UMMMC language.  Each change 
to this consent had to be approved both by the Umass IRB and the NEI protocol liaison.  Additionally, 
since we wanted this free genotyping service to be available to all UMMMC Ophthalmology patients 
regardless of whether they were enrolled in a clinical trial or not, I created two separate consent forms 
for these distinct patient populations which added yet another layer of complexity. 
 
The application process involved several rounds of pre-submission of the applications to the IRB.  
The application form and the consent forms were scrutinized by the IRB office and a series of 
changes were requested. The Research Pharmacy office produced the Institutional Pharmacy form 
that is required for the application (they usually need about 2 weeks to produce this).  Once these 
changes were made, 20 hard copies of the application and extensive supporting material were 
officially submitted (including one copy with original signatures).  The UMMMC copy center required 
extensive lead time for this job so I relied on Fedex/Kinkos to copy and collate the documents.   
 
After the committee review, there was another round of edits and inclusions to address their 
concerns.  Once these changes were made and approved, there was a cumbersome process of 
swapping out modified pages into the existing documents in an attempt to not have to reproduce the 
20 hard copies of each portfolio again. 
 
3.3 ISSUES AND RECOMMENDATIONS 
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3.3.1 BIOSTATISTICAL RESOURCES 
I envision a “one-stop shopping” resource for investigators that would be housed at the Umass Center 
for Clinical and Translation Science web portal.  A critical component of this resource would be 
educational links as well as connections to in-house core services for trial design and biostatistical 
analysis.  From power analysis to statistical analysis of pre-clinical studies, this would provide the 
critical framework for the study design.  These designated biostatisticians would be involved with the 
project from inception to final data analysis.  They would also be involved in contributing to the 
specifics of the protocol including detailing the statistical methods used to analyze the trial data during 
and after the completion of the study.  This information is not only critical for ensuring the soundness 
of the study design, but also will define the endpoints for early termination due to safety concerns.  
Finally, these biostatistics consultants would be part of the data management team as their history 
with the specific project will be instrumental in influencing the design of the database.  During review 
of the protocol and data by the FDA or other entities, the statistician would be already up to speed 
and available to aid in communication and clarification. 
 
3.3.2 ELECTRONIC SUBMISSIONS 
Electronic submission of IRB forms would alleviate the need for the cost and hassle of manually 
producing multiple copies of hundreds of pages of documents.  Moreover, with the dynamic nature of 
the review process, it is clear that hard copies complicate the process, making it more prone to errors 
and omissions.  (This is not to mention the cost to the environment).   
 
As the electronic submission of both application and trial data are increasingly being required by the 
FDA, Information Services at UMMMC will need to understand these requirement and develop and 
maintain both the hardware and software compatible for these very specialized requirements.  This is 
an opportunity for the institution to proactively design an enterprise solution instead of the typical 
development of highly specialized and insulated pockets of expertise that often appear when there is 
no centralized solution. 
 
While not always appreciated as a critical path, preparing, copying and binding the portfolio of 
documents required for these kinds of submissions is a critical piece of the equation.  There is a 
general confusion about the resources and capabilities for copy and document production services 
here at UMMMC.  For instance, if you call the help desk, you will invariably be told, that there is no 
Copy Center here on site.  However, if you know a priori about the Copy Center on B level (or can 
find it by doggedly searching the UMMMC website) you will find that small scale projects can be 
easily produced in-house.  Larger projects are sent to an off-site facility, but they often take at least a 
week to deliver the job.   However, it would be great to have the ability to not only get projects simply 
reproduced or bound, but to coordinate these jobs with smart sets of the specific requirements that 
are associated with each submission.  For example, an online tool that will assemble your IRB 
application (much like a grant generator) into the correct order and notify the researcher if a critical 
piece is missing.  This correctly assembled document (that automatically inserts correct logos, cover 
letter addresses and validated electronic signatures) could then be sent to a designated copy center 
that produces the proper number of copies and delivers a complete portfolio to the correct recipient.  
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In this manner the process is not only clearly communicated and streamlined, but even the copy 
center staff are educated as to the particulars of these kinds of documents. 
 
It would be extremely helpful for the Clinical Research Office to provide sample and templates for 
protocol development. I used Microsoft Word and Powerpoint to create the CRFs (using hard copy 
samples generously provided from Marg Humphries and Kirsten Locke as templates for some of the 
forms).  In hindsight, these software programs were wholly inadequate as form creation and font 
conversion issues disallow proper printing from certain printers.   Therefore, templates and software 
packages for CRF generation would also be important additions to the resources provided by the 
Office of Research.   
 
 
3.3.3 FDA KNOWLEDGE BASE DEVELOPMENT 
It will be important to have online resources available at the Umass Center for Clinical and 
Translation Science web portal that educate investigators as to the FDA requirements, but also 
maintain a current set of links to the appropriate contacts in each division.  Correlatively, UMMMC 
should recruit and/or develop in house FDA liaisons whose not only help investigators and trial 
coordinators navigate the requirements; but would also be responsible for establishing and 
developing relationships with key personnel within the FDA.  Each division works differently.  Some, 
like the Blood and Biologics Division, prefer “formalized” pre-communications regardless of whether 
the study is sponsored by an investigator or pharmaceutical company.  Other divisions, like the Anti-
Infective and Ophthalmologic Division, prefer informal communications as the more formal process is 
encumbering and slows things down.  Still other divisions have distinctly different policies based on 
whether an investigator or pharmaceutical company is the sponsor.  Most of these policies are 
unofficial and as dynamic as the turnover of personnel at the FDA.  Therefore, they are only well 
understood by constant direct communication with key decision makers. 
 
 
3.3.4 RESEARCH PHARMACY 
The Research Pharmacy at UMMMC is grossly understaffed and currently in a facility far too small for 
even their limited capabilities.  Major resources should be invested in recruitment and infrastructure 
for this critical piece of human subjects‟ research at UMMMC.  Some specific services the Research 
Pharmacy should expand are:  placebo design and production (including developing a network of 
outsourcing pharma resources); developing a dosing consulting service that can be utilized in the trial 
design phase; and development of networked online tools for randomization so remote trial sites 
(both UMMMC clinics and their co-sites) can communicate during recruitment in real time.  
 
3.4 OUTCOMES 
After submission to the FDA we received a standard communication by mail acknowledging receipt of 
our application and detailing when we could begin recruitment if we received no other communication 
to the contrary (that date 9/4/2009 was exactly 30 days from their receipt of the application).  Also in 
the letter was a notification that we had not addressed the requirement of reporting to 
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clinicaltrials.gov.  This was confusing to me as I had communicated with Dr. Chambers directly about 
this and he indicated that we would not have to submit to this website until we were ready to recruit.  
The critical question for me was (and I have read the legislation that resulted in this new regulation 
many times and it is not clear on this point) - are we allowed to claim an exemption due to the fact 
that we are not ready to start recruiting for at least 6 months after the IND submission? I sent several 
emails to the designated clinicaltrials.gov official at the NIH and received no response.  The phone 
number listed on the NIH website was no longer in service and I left several messages at the new 
number provided and received no response.  Several phone calls to the FDA administrator listed on 
the letter made it clear that: 1) The FDA really is not sure how to proceed when the trial may not 
happen for sometime after the IND application is submitted and 2) The FDA clearly has a 
responsibility to show that all IND applications have the proper clinicaltrials.gov form 3674– but they 
are not prepared to guide investigators in how to fill the form out.   Ultimately, with the approval of 
Maureen Parker, the program management staff chief at the FDA Ophthalmology division, I submitted 
the form 3674 (page 83) claiming an exemption to clinicaltrials.gov due to the fact that we were not 
prepared to publicize the trial until we were funded.   
 
The IND application was reviewed without incident and through their lack of communication to the 
contrary, we received the de facto approval for this trial as of September 4, 2009.   
 
The IRB applications were both approved pending minor modifications which were immediately 
addressed. We are currently approved to implement both the NEI genotyping and VPA intervention in 
the Ophthalmology clinic. 
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Re: Initial IND submission 
 Valproic Acid for treatment of Retinitis Pigmentosa 
 
Dear Dr. Chambers,  
 
Enclosed, for your distribution, are three copies (1 original and 2 photocopies) of our IND application for the use of 
Valproic Acid (VPA) in adult patients with Retinitis Pigmentosa (RP) that we have discussed with you. 
 
Rationale 
In vitro data supports that VPA has multiple biologic properties that make it an ideal candidate for a retinal therapeutic.  
First, we have shown that VPA effectively increases yields of properly folded mutant rhodopsin, and that VPA protects 
cells from oxidative stress induced apoptosis.  Work by others has demonstrated that VPA is a potent inhibitor of histone 
deacetylase (HDAC) and the inflammatory response pathway via apoptosis of microglial cells. Importantly, we have 
preliminary clinical data that suggests that VPA has the potential to not only stop the progression but may also reverse 
loss of visual field in patients with RP. 
 
General Investigational Plan 
This is a two- site, interventional, prospective, placebo-controlled, blinded study of 90 subjects with retinitis pigmentosa 
undergoing treatment with oral VPA for a total of 12 months (45 treated and 45 controls).  For the intervention, VPA 
dosage will vary by weight and will be lower than the recommended for anticonvulsant therapy (from 500 to 1000 mg 
total daily dose).   
 
The main measure of visual function will be visual fields as measured by semi-automated kinetic perimetry (SKP). Visual 
function will be quantified at baseline screening and at 12 months after start of study medication in order to determine 
whether VPA administration affects visual/retinal function. Secondary outcome measures of visual function will include 
static perimetry measurements to test the sensitivity values with the central 30: and the 25 item National Eye Institute 
Visual Function questionnaire to assess quality of life (QOL).  Outcomes for efficacy for both eyes will be determined.   
 
Participants will be followed closely for adverse reactions to VPA.   Clinic visits at 2 and 6 months will include safety labs, 
physical and ocular exams.  Participants will be contacted by telephone on months not scheduled for clinic visits. Safety 
variables will include the incidence of adverse events, marked changes in visual acuity, changes in vital signs, marked 
changes in clinical laboratory data (especially liver and pancreatic function)  and findings during physical examinations. 
 
 
This application has been reviewed and approved by the University of Massachusetts, Worcester IRB; John Sullivan, MD,  
the Vice Provost for Research and Terry Flotte, MD, Exec. Dep. Chancellor and Dean of the Medical School at the 
University of Massachusetts, Worcester.  
 
If you have any questions, please direct them to me as the sponsor-investigator of this IND application at (508) 334-0687 
or Shalesh.Kaushal@umassmemorial.org 
 
Sincerely, 
 
 
 
 
Shalesh Kaushal, MD PhD 
Chair and Associate Professor 
Department of Ophthalmology 
University of Massachusetts Medical School 
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3.5.3 FORM 1571 
DEPARTMENT OF HEALTH AND HUMAN SERVICES 
FOOD AND DRUG ADMINISTRATION 
 
INVESTIGATIONAL NEW DRUG APPLICATION (IND) 
(TITLE 21, CODE OF FEDERAL REGULATIONS (CFR) PART 312) 
Form Approved: OMB No. 0910-0014. 
Expiration Date: May 31, 2009 
See OMB Statement on Reverse. 
NOTE: No drug may be shipped or clinical 
investigation begun until an IND for that 
investigation is in effect (21 CFR 312.40). 
1. NAME OF SPONSOR 2. DATE OF SUBMISSION 
Shalesh Kaushal, MD PhD  08/01/2009 
3. ADDRESS (Number, Street, City, State and Zip Code) 4. TELEPHONE NUMBER (Include Area Code) 
University of Massachusetts Medical School 
55 Lake Avenue North Rm S6-410 
Worcester, MA 01655 
 508  334 0687 
5. NAME(S) OF DRUG (Include all available names: Trade, Generic, Chemical, Code) 6. IND NUMBER (If previously assigned) 
Depakene, Valproic Acid, 250 mg oral capsule        
7. INDICATION(S) (Covered by this submission) 
Retinitis Pigmentosa 
8. PHASE(S) OF CLINICAL INVESTIGATION TO BE CONDUCTED: 
  PHASE 1   PHASE 2   PHASE 3  OTHER 
       
(Specify)  
9. LIST NUMBERS OF ALL INVESTIGATIONAL NEW DRUG APPLICATIONS (21 CFR Part 312), NEW DRUG OR ANTIBIOTIC APPLICATIONS (21 CFR Part 314), 
 DRUG MASTER FILES (21 CFR Part 314.420), AND PRODUCT LICENSE APPLICATIONS (21 CFR Part 601) REFERRED TO IN THIS APPLICATION. 
(NDA) 018081;  (ANDA) 073229   Study drug manufactured by Catalent Pharma Solutions, 250 mg soft gel capsules lot# 3888975; 
soft gel capsule placebo to be manufactured by Catalent Pharma Solutions, CMC materials for placebo attached. 
10. IND submission should be consecutively numbered. The initial IND should be numbered 
 "Serial number: 0000." The next submission (e.g., amendment, report, or correspondence) 
 should be numbered "Serial Number: 0001." Subsequent submissions should be numbered 
 consecutively in the order in which they are submitted. 
SERIAL NUMBER 
 
  
 
         
 
 
 
      
11. THIS SUBMISSION CONTAINS THE FOLLOWING: (Check all that apply) 
  INITIAL INVESTIGATIONAL NEW DRUG APPLICATION (IND)   RESPONSE TO CLINICAL HOLD 
PROTOCOL AMENDMENT(S):  INFORMATION AMENDMENT(S):  IND SAFETY REPORT(S): 
 NEW PROTOCOL    CHEMISTRY/MICROBIOLOGY    INITIAL WRITTEN REPORT 
 CHANGE IN PROTOCOL    PHARMACOLOGY/TOXICOLOGY    FOLLOW-UP TO A WRITTEN REPORT 
 NEW INVESTIGATOR    CLINICAL 
 RESPONSE TO FDA REQUEST FOR INFORMATION   ANNUAL REPORT   GENERAL CORRESPONDENCE 
 REQUEST FOR REINSTATEMENT OF IND THAT IS WITHDRAWN,   OTHER 
 INACTIVATED, TERMINATED OR DISCONTINUED 
       
(Specify)  
CHECK ONLY IF APPLICABLE 
JUSTIFICATION STATEMENT MUST BE SUBMITTED WITH APPLICATION FOR ANY CHECKED BELOW. REFER TO THE CITED CFR 
SECTION FOR FURTHER INFORMATION. 
 TREATMENT IND 21 CFR 312.35(b)   TREATMENT PROTOCOL 21 CFR 312.35(a)   CHARGE REQUEST/NOTIFICATION 21 CFR312.7(d) 
FOR FDA USE ONLY 
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CDR/DBIND/DGD RECEIPT STAMP DDR RECEIPT STAMP DIVISION ASSIGNMENT: 
IND NUMBER ASSIGNED: 
12. CONTENTS OF APPLICATION 
 This application contains the following items: (Check all that apply) 
 1. Form FDA 1571 [21 CFR 312.23(a)(1)] 
 2. Table of Contents [21 CFR 312.23(a)(2)] 
 3. Introductory statement [21 CFR 312.23(a)(3)] 
 4. General Investigational plan [21 CFR 312.23(a)(3)] 
 5. Investigator‟s brochure [21 CFR 312.23(a)(5)] 
 6. Protocol(s) [21 CFR 312.23(a)(6)] 
     a. Study protocol(s) [21 CFR 312.23(a)(6)] 
    b. Investigator data [21 CFR 312.23(a)(6)(iii)(b)] or completed Form(s) FDA 1572 
     c. Facilities data [21 CFR 312.23(a)(6)(iii)(b)] or completed Form(s) FDA 1572 
    d. Institutional Review Board data [21 CFR 312.23(a)(6)(iii)(b)] or completed Form(s) FDA 1572 
 7. Chemistry, manufacturing, and control data [21 CFR 312.23(a)(7)] 
    Environmental assessment or claim for exclusion [21 CFR 312.23(a)(7)(iv)(e)] 
 8. Pharmacology and toxicology data [21 CFR 312.23(a)(8)] 
 9. Previous human experience [21 CFR 312.23(a)(9)] 
 10.  Additional information [21 CFR 312.23(a)(10)] 
13. IS ANY PART OF THE CLINICAL STUDY TO BE CONDUCTED BY A CONTRACT RESEARCH ORGANIZATION?   YES   NO 
 IF YES, WILL ANY SPONSOR OBLIGATIONS BE TRANSFERRED TO THE CONTRACT RESEARCH ORGANIZATION?   YES   NO 
 IF YES, ATTACH A STATEMENT CONTAINING THE NAME AND ADDRESS OF THE CONTRACT RESEARCH ORGANIZATION, 
 IDENTIFICATION OF THE CLINICAL STUDY, AND A LISTING OF THE OBLIGATIONS TRANSFERRED. 
14. NAME AND TITLE OF THE PERSON RESPONSIBLE FOR MONITORING THE CONDUCT AND PROGRESS OF THE CLINICAL 
 INVESTIGATIONS 
Shalesh Kaushal, MD PhD 
15. NAME(S) AND TITLE(S) OF THE PERSON(S) RESPONSIBLE FOR REVIEW AND EVALUATION OF INFORMATION RELEVANT TO THE 
 SAFETY OF THE DRUG 
Shalesh Kaushal, MD PhD 
I agree not to begin clinical investigations until 30 days after FDA’s receipt of the IND unless I receive earlier notification by 
FDA that the studies may begin. I also agree not to begin or continue clinical investigations covered by the IND if those 
studies are placed on clinical hold. I agree that an Institutional Review Board (IRB) that complies with the requirements set 
fourth in 21 CFR Part 56 will be responsible for initial and continuing review and approval of each of the studies in the 
proposed clinical investigation. I agree to conduct the investigation in accordance with all other applicable regulatory 
requirements. 
16. NAME OF SPONSOR OR SPONSOR‟S AUTHORIZED 
 REPRESENTATIVE 
17. SIGNATURE OF SPONSOR OR SPONSOR‟S AUTHORIZED 
 REPRESENTATIVE 
 Shalesh Kaushal, MD PhD  
18.  ADDRESS (Number, Street, City, State and Zip Code) 19.  TELEPHONE NUMBER (Include Area Code) 20. DATE 
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University of Massachusetts Medical School 
 55 Lake Ave N  Rm S6-410 
Worcester  MA 01655 
 
 (508) 334-0687  08/01/2009 
(WARNING: A willfully false statement is a criminal offense. U.S.C. Title 18, Sec. 1001.)  
Public reporting burden for this collection of information is estimated to average 100 hours per response, including the time for reviewing instructions, searching 
existing data sources, gathering and maintaining the data needed, and completing reviewing the collection of information. Send comments regarding this burden 
estimate or any other aspect of this collection of information, including suggestions for reducing this burden to:  
Department of Health and Human Services 
Food and Drug Administration 
Center for Drug Evaluation and Research 
Central Document Room 
5901-B Ammendale Road 
Beltsville, MD  20705-1266 
Department of Health and Human Services 
Food and Drug Administration 
Center for Biologics Evaluation and Research (HFM-99) 
1401 Rockville Pike 
Rockville, MD 20852-1448 
"An agency may not conduct or sponsor, and a 
person is not required to respond to, a 
collection of information unless it displays a 
currently valid OMB control number." 
Please DO NOT RETURN this application to this address. 
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3.5.4 STUDY PROTOCOL 
 
Project Title 
A Phase II Multiple Site, Randomized, Placebo-Controlled Trial of Oral Valproic Acid 
for Retinitis Pigmentosa Protocol #H-13371 
 
Trial Sites and Site Principal Investigators 
University of Massachusetts Worcester 
Shalesh Kaushal, MD PhD, Chair and Assoc. Professor 
Christine Clemson, PhD Co-Investigator 
Department of Ophthalmology 
University of Massachusetts Medical Center 
Biotech 5, Suite 250 
381 Plantation Street 
Worcester, MA 01605 
 
 
Retina Foundation of the Southwest (RFSW) 
David G. Birch, Ph.D. 
Chief Scientific and Operating Officer 
Director, Rose-Silverthorne Retinal Degeneration Laboratory 
Retina Foundation of the Southwest 
Adj. Professor of Ophthalmology 
Director, Visual Electrophysiology 
University of Texas Southwestern Medical School  
9900 North Central Expressway, Ste. 400 
Dallas, TX 75231 
 
 
 
Total enrollment:    90 subjects 
Expected initiation:     Q4 2009 
Expected Duration: Twenty-Four months from first-subject-in to last-subject-out. 
Recruitment:   9 months (last-subject-in).  
Treatment:   360 days of oral valproic acid.  Follow up: 3 months after last treatment 
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Background and Rationale 
RP is a severe neurodegenerative disease of the retina characterized initially by night blindness with 
progression to tunnel vision and eventual loss of central vision and total blindness.  Targeted therapies for RP 
are complicated by the identification of more than 30 genes linked to the dominant and recessive forms of the 
disease.  Further compounding this complexity is the rarity of this disorder: although RP is one of the most 
common inherited eye diseases with an incidence of ~1:3000, its prevalence is relatively rare.  RP affects 
approximately 100,000 individuals in the U.S., qualifying it as an orphan disease.  Given the huge costs 
associated with the preclinical and clinical phases of drug development, pharmaceutical companies are 
generally reluctant to invest in developing new therapeutics for RP.  While a few new approaches for RP 
treatment have recently been investigated including nutritional supplementation, light reduction and gene 
therapy (Delyfer et al., 2004; Gaby, 2008; Hartong et al., 2006), of these, vitamin A supplementation is the 
most promising, but its benefits are modest and side effects are problematic.  Therefore, currently there is no 
therapy to substantially alter or reverse the progression of RP.   
 
Scientific Rationale 
Recently, we have demonstrated the use of retinoids and other small molecules as pharmacological 
chaperones to increase the yield of properly folded RP mutant rhodopsins in heterologous cell culture 
(Noorwez et al., 2008).   We have tested whether other known small molecules can provide similar effects.  
We identified valproic acid (VPA) through this screen. In vitro data supports that VPA has multiple biologic 
properties that make it an ideal candidate for a retinal therapeutic.  First, our in vitro assay shows that VPA 
effectively increases yields of properly folded mutant rhodopsin (Figure 1, Appendix A. Pre-Clinical Data).  
Second, VPA protects cells from oxidative stress induced apoptosis (Figure 2, Appendix A. Pre-Clinical Data), 
most likely through upregulation of the heat shock response (not shown).  Other work demonstrates that VPA 
is a potent inhibitor of histone deacetylase (HDAC) (Gottlicher et al., 2001) and the inflammatory response 
pathway via apoptosis of microglial cells (Chen et al., 2007; Dragunow et al., 2006; Kim et al., 2007). 
 
Preliminary Clinical Data 
Seven RP patients were treated off-label with oral VPA (250 mg BID).  Visual fields were measured using 
kinetic perimetry (Figure 3,  Appendix B.  Pilot clinical study).  Results varied from patient to patient, however 
6 of 7 patients showed no progression of their disease on VPA , one patient experienced a loss of VF and  5 
patients experienced an increase in their visual field (e.g. Figure 3, Appendix B), which no other therapeutic 
has previously shown.  Overall, we detected an average increase in visual field/month (Figure 4, Appendix B.  
Pilot clinical study).  These results suggest that VPA has the potential to not only stop the progression but may 
also reverse loss of visual field 
 
Study Objectives 
RP is an incurable and untreatable group of heterogeneous retinal degenerative diseases that cause severe 
visual loss. There is currently no therapeutic that substantially slows the progression of this disease, and 
certainly none that can restore vision in RP patients. The objective of this study is to provide efficacy 
information on the ability of VPA to both slow the progression of visual function loss and/or to restore of 
visual function in patients with RP and collect safety and tolerability information. This collective data will be 
used for larger Phase III studies for patients with RP.  
 
Study Design and Methods 
This is a two- site, interventional, prospective, placebo-controlled, blinded study of 90 subjects undergoing 
therapy with oral VPA.  Patients will undergo clinical examinations and evaluations of retinal function and 
structure prior to consideration of the subject as a candidate for clinical trials. Clinical examinations will 
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include refraction, static and kinetic perimetry, fundus photography and visual acuity. Measures of visual 
function will include full-field electroretinography.  Optical coherence tomography will be used to measure 
retinal structure. Methods of these measures are detailed below. During these evaluations, medical and 
ophthalmic histories will be elicited from subjects and their families to ensure that there are no comorbid 
medical or ocular genetic conditions that may prevent study participation. While the equipment proposed for 
use in this trial is state of the art and as such will provide the highest level of quantitation available, the quasi-
subjective nature inherent in many standard ocular tests make day-to-day variation an important confounder 
to our analysis. All diagnostic measures will be calibrated and standardized such that intervisit and interocular 
variances for each outcome measure will be quantified and included in our analysis.  This will involve 
sequential repeated measures for the same patients on these machines.   
 
The study design flow chart can be found in Appendix C. Study Schedule Flow-chart. 
 
Subgroup Analysis 
It is likely given the vastly different nature of the proteins involved in RP, that certain therapies will have 
varying beneficial effects on patients with different mutations. Indeed our preliminary clinical analysis 
suggests a varied response to VPA among the 7 RP patients treated (Figure 4, Appendix B.  Pilot clinical 
study), and indicates that certain individual or patient populations may preferentially respond to this 
medication.   Patients included in this preliminary clinical analysis, were not well characterized in regards to 
their RP genotype. To examine this in more detail, we propose to enroll around 20 patients with P23H opsin 
mutations, and perform molecular genotype analysis on each enrolled patient.  Performing stepwise 
regression analysis adjusting for each mutation, we will correlate primary and secondary outcome measures 
with genotype to determine if VPA has a general benefit to all patients or if it effect is specific for certain 
populations of RP patients.  
 
The genotyping in families with autosomal dominant pedigrees will be done through the NEI eyeGENE  
protocol.   Genotyping is not a prerequisite for this study.  If participants are interested in obtaining 
genotyping information , blood samples will be collected after informed consent  and will be mailed to the NEI 
eyeGENE coordinating center and shipped to the appropriate testing facility where it will be screened for the 
most common RP mutations.  Due to the rarity and sporadic nature of the many mutations associated with RP, 
it is likely that specific mutation information will not be identified for over half of our enrolled patients,  
however, the additional information gained from the patients that can be genotyped will be valuable in 
understanding the potential mode of VPA action and targeted effectiveness of therapy.   
 
Outcomes 
Primary Endpoint- Visual Field  
INTACT VISUAL FIELD WILL BE QUANTIFIED AT SCREENING, BASELINE AND AT THE END OF THE STUDY (12 MONTHS AFTER 
START OF STUDY MEDICATION) IN ORDER TO DETERMINE WHETHER VPA ADMINISTRATION AFFECTS 
VISUAL/RETINAL FUNCTION.  VISUAL FIELDS WILL BE MEASURED USING THE OCTOPUS 900 SEMI-AUTOMATED 
KINETIC PERIMETRY (SKP) MODULE (SEE PAGE 59VISUAL FIELD 
VISUAL FIELD 
);  the specific stimulus used will be defined for each patient based on their intact visual field upon screening. 
The same stimulus will then be used for all subsequent analysis. 
 
The study is powered to detect a change in mean visual field area using semi-automated kinetic perimetry, as 
the primary endpoint (see page 65).  Secondary analyses will be exploratory, but in order to test several 
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additional endpoints we will also adjust for multiple comparisons either using the very strict Bonferroni 
adjustment or by relying on an omnibus test.  Secondary outcome measures of visual function will include 
static perimetry measurements to test the sensitivity values with the central 30:; best corrected ETDRS visual 
acuity; color contrast sensitivity as measured by the Chroma Test; retinal anatomy as measured by Optical 
Coherance Tomography (OCT) and  rod and cone responses as analyzed by electroretinography (ERG), fundus 
photography; the 25 item National Eye Institute Visual Function questionnaire to assess quality of life (QOL); 
efficacy as predicted by specific mutation; the dose response profile of VPA as measured by serum VPA levels 
and the toxicity and safety profile of VPA in RP patients.  Outcomes for efficacy for both eyes will be 
determined.   
 
Inclusion Criteria  
 To be eligible for the study, subjects must fulfill all of the following criteria: 
 Understand and sign the IRB-approved informed consent document for the study. 
 Age  18 years. 
 Weight  40 Kg and ≤158.9 Kg 
 Diagnosis of Retinitis Pigmentosa including photoreceptor degeneration established by visual field 
constriction, night blindness, marked reduction of ERG responses, and the clinical signs of RP including 
waxy pallor of the optic nerve, vascular attenuation and/or the presence of intraretinal pigment on 
clinical examination. 
 Visual acuity of 20/200 or better in at least one eye. 
 All subjects of reproductive potential must commit to using an acceptable method of barrier or 
hormonal contraception up to at least 3 months after stopping the study drug.  
 Females who have attained menarche must have a negative pregnancy test at study entry. 
 Willingness to comply with the protocol. 
 
Exclusion Criteria   
Potential participants meeting any of the following criteria will be excluded from the study: 
1. Medical problems that make consistent follow-up over the treatment period unlikely (e.g. stroke, 
severe MI, end stage malignancy), or in general a poor medical risk because of other systemic diseases 
or active uncontrolled infections. 
2. Other retinal diseases: Glaucoma, retinal inflammatory disease, (Note:  CME is allowable), cataract 
worse than +2 NS or herpes simplex virus of the eye.  
3. Intact visual field of 5: or less.  
4. Diabetes or cancer.  
5. A hemoglobin concentration below the lower limit of normal (less than 14 gm/dL);  a platelet count 
below the lower limit of normal (less than 140K/mm3) or an absolute neutrophil count below the lower 
limit of normal (less than 1600/mm3 at study entry).  
6. Suspected liver dysfunction determined by having alanine aminotransferase (ALT),  aspartate 
aminotransferase (AST) and bilirubin values elevated above the upper limit of normal.  
7. History of pancreatitis by clinical features and/or laboratory abnormalities in the last 12 months.  
8. Renal dysfunction based on serum creatinine using the MDRD equation.   
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9. Subjects suffering  from urea cycle disorders will be excluded. 
10.  Subjects with history of neurological conditions including epilepsy, history of brain injury, encephalitis, 
or any organic brain syndrome will be excluded. 
11.  Subjects with a history of schizophrenia, schizoaffective disorder, bipolar disorder, suicidality or 
organic mental disorders will be excluded. 
12. Subjects already receiving valproic acid or other anti-convulsants will be excluded. 
13. Sensitive to or have ever had an allergic reaction to Valproic Acid. 
14. Sensitive to or have ever had an allergic reaction to peanuts as peanut oil is an inactive ingredient in 
valproic acid capsules and the placebo. 
15. At least 2 weeks since prior drugs specifically known to interact with valproic acid including: aspirin, 
felbamate, rifampin, amitriptyline/nortriptyline, carbamazepine, clonazepam, diazepam, ethosuximide, 
lamotrigine, phenobarbital, primidone, phenytoin, tolbutamide, warfarin, or zidovudine   
16. Pregnant or Lactating mothers who are breast feeding their babies will not be eligible. 
17.  RP patients involved in other clinical trials within the last 3 months are ineligible for this study.  
 
Study Drug  
The scientific rationale for VPA as a retinal therapeutic was described above.  It is critical to emphasize 
however, that the extensive history and well established safety and tolerability profile of VPA makes it an 
ideal candidate for a Phase II study, which streamlines the time to treatment in humans considerably relative 
to new drug design.  VPA was approved by the FDA for use as a broad spectrum anticonvulsant in 1978 and is 
also used for acute and maintenance therapy of bipolar disease, for migraine prophylaxis, and occasionally for 
chronic pain syndromes (Henry, 2003).  
 
VPA is well tolerated in most patients and adverse events are rare (reviewed in Peterson and Naunton, 2005).  
The primary concern is hepatoxicity which is rare in low risk patients occurring in fewer than 0.29 in 10,000 
patients (Bryant and Dreifuss, 1996). Subjects will be carefully screened 
for comorbid conditions and concomitant medications to ensure that 
only patients at the lowest risk for serious adverse events are enrolled 
(see Exclusion Criteria).   
 
In the event of a non-serious adverse effect such as gastric disturbance, 
the participant will be counseled to take the medication with food.  If 
that does not resolve the issue, or if the non-serious effect is not gastric 
related (such as feelings of lethargy), the drug dose will be lowered.   If 
that does not resolve the issue, or the adverse event is more serious, 
then the participant will be withdrawn from the study. 
 
Dose Rationale 
Treatment dosages were selected based on our proof of concept 
preliminary studies described above and known safety and 
tolerability profiles of VPA. For the intervention, VPA dosage will vary 
by weight (Table 1) and will be less than the starting dosage 
recommended for anticonvulsant therapy (2). 
 
TABLE 2:  RECOMMENDED S AR ING V A 
DOSAGE SCHEDULE FOR ANTI-CONVULSANT 
THERAPY . (DEPAKENE(R) ORAL CAPSULES, 
ORAL SYRUP, 2006)  
Pounds (lbs) Kilograms (Kg) Total Daily 
Dose (mg) 
22 -54.9 10 - 24  250  
55 - 87.9 25 - 39.9 500 
88 - 131.9 40 - 59.9 750 
132 -164.9 60 -74.9 1000 
165-197.9 75-89.9 1250 
 
 
TABLE 1:  VPA DOSAGE SCHEDULE BY 
WEIGHT   
Pounds (lbs) Kilograms (Kg) Total Daily 
Dose (mg) 
  
 
 
 
Excluded fr 
m stu  
88  16  40  74 9 5  
1 7 9 75   
19 -349  90 158 9 100  
0  5  Ex e   
st  
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Source of VPA and Placebo 
The study drug will be a soft gel 250 mg valproic acid capsule, purchased from Catalent Pharma Solutions 
(2725 Scherer Drive North, St. Petersburg,  FL  33716, 866-720-3148), lot # 3888975.  The placebo will also be 
manufactured by Catalent Pharma Solutions, and will look identical to the study drug.  It will be a soft gel 
capsule of same, color, size and shape.  The placebo capsule will be filled with peanut oil, the identical 
excipient in the study drug.   
 
Examination Requirements   
 
Screening Visit   
The Screening visit consists of the following examinations and procedures:    
 
1. Explanation of study and a copy of the Consent forms (if not mailed ahead of the visit)  
2. Signing of the Informed Consent for the trial  
3. Signing of the Informed consent for genotyping  (not necessary for enrollment in study)    
4. Complete medical and ocular history  
5. Urine test for pregnancy (if  female and of child bearing capacity) 
6. Blood draw for hepatic and pancreatic function screen (and genotyping if enrolled).  
7. Visual acuity examination  
8. Ocular examination  
9. Semi-Automated Kinetic Perimetry,  with static measurements in the 30: central field (in Duplicate) 
10. Fundus photographs  
 
 
Baseline Visit    
Qualified participants will be asked to return to the clinic within 30 to 120 days after the Screening Visit. 
Randomization will occur only after the participant is confirmed to be eligible. Participants are considered 
eligible if they meet all the inclusion criteria, and do not meet one or more exclusion criteria and return to the 
clinic within 120 days following the Screening Visit, and sign the randomization consent form.  
 
Participants must be re-qualified if randomization does not occur within 120 days of the Screening Visit.  Re-
qualification requires that the responses to each of the eligibility questions be verified and ocular exams and 
fundus photographs re-performed.  
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The UMMMC research pharmacy will assign bottle numbers. The master randomization list for both centers 
will be maintained at the UMMMC Coordinating Center.    
The Baseline Visit consists of the following examinations and procedures:  
1. Signing of the genotyping consent form (if not signed at the Screening  Visit)- not a prerequisite for 
study    
2. Blood draw for safety labs and genotyping. 
3. Urine test for pregnancy (if  female and of child bearing capacity)     
4. Ocular Examination 
5. Visual acuity and refraction at 3 meters via the Electronic Visual Acuity Tester (EVA) using the 
Electronic ETDRS (E-ETDRS) Testing Protocol  
6. Semi-Automated Kinetic Perimetry,  with static measurements in the 30: central field (in Duplicate) 
7. Optical Coherence Tomography (OCT) in duplicate 
8. Color-Contrast Sensitivity Analysis (Chroma Test) in duplicate 
9. Full-Field Electroretinogram   
10. Quality of Life Questionaire(QOL)  
11. Concomittant Medications 
12.  Distribution of Study Medication (or placebo) and administration directions.  
13.  Assignment of Bottle Numbers  
 
Participants who consent to participate will be contacted by telephone within 24 hours to answer questions 
and assure full understanding of dosing instructions and procedures.   
  
 
Follow-up Visits  
In-clinic follow-up visits will occur at 60, 180 and 360 days after initiating VPA treatment for evaluation of their 
clinical status and to assess adverse events.  Participants will be asked to provide information on any side 
effects they are experiencing.  Subjects will be followed up with phone calls after the week 1 and at month 1, 
3, 4, 5, 7, 8, 9, 10 and 11. The purpose of these phone calls is to assess adherence to study medication, assess 
adverse events, schedule additional clinic visits if needed, and clarify study procedures.  These phone calls will 
be particularly useful as we expect that quite a few patients may live at some distance from the clinic sites.  In 
all cases, participants will be followed for a period of 3 months after the study ends.   
 
The in-clinic follow-up visits will consist of the following examinations and  
procedures:  
 
1. Safety Labs 
2. Concomitant Medications 
3. Visual acuity and refraction examination via the Electronic Visual Acuity Tester (EVA) using the 
Electronic ETDRS (E-ETDRS) Testing Protocol  
4. Ocular examination  
5. Adverse Event assessment  
6. Collection and re-issuance of study medication bottles  
7. Assessment of study drug adherence via self-report, VPA blood levels, and pill counting 
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8. Semi-Automated Kinetic Perimetry,  with static measurements in the 30: central field (in Duplicate) (at 
month 12 follow-up visit) 
9. Optical Coherence Tomography (OCT) in duplicate (at month 12 follow-up visit.) 
10. Color-Contrast Sensitivity Analysis (Chroma Test) in duplicate (at 12 month follow-up visit.) 
11. Full Field Electroretinogram (ERG) (at month 12 follow-up visit.) 
12. Fundus Photogaphy (at 12 month follow up visit). 
13. Quality of Life Questionaire(QOL)  (at 12 month follow up visit). 
 
The full schedule of study visits can be found in Appendix D. Scheduled Study Evaluations Table.  
 
 
 
Study Assessments   
VISUAL FIELD 
Visual field measurements will be made as described for patients with severe vision loss (Nowomiejska et al., 
2005; Nowomiejska et al., 2008) using the Octopus 900 (Haag-Streit International) with the semiautomatic 
kinetic perimetry (SKP) module.  Stimuli of selected size and luminance according to the Goldmann 
classification are moved along user-defined vectors having a constant angular velocity of 3° per second. 
Vectors are drawn manually using an electronic pen. The stimulus is moved almost perpendicularly towards 
the presumed scotoma border from nonseeing towards seeing areas of the VF. Fixation is monitored by a 
digital infrared camera, which provides a highly magnified image of the tested eye. The stimulus movement 
along each vector is terminated by the response of the patient, who is instructed to look straight ahead at the 
fixation point (green cross) and press a button as soon as the stimulus is perceived. The respective stimulus 
location is marked on the screen automatically by the software with a size- and intensity-specific symbol, and 
after several repetitions with different vectors, the symbols are connected, and enabling isopters are drawn in 
selectable color. The area enclosed by an isopter is automatically quantified by the software using 
triangulation in square degrees of eccentricity. 
REFRACTION AND BEST-CORRECTED VISUAL ACUITY (BCVA)   
Visual acuity is measured at a distance of 3 meters on a calibrated computer screen, using the program EVA-
ETDRS.   A separate sequence will be used for each eye.  Patients will be allowed as much time as necessary 
and encouraged to read each letter, and asked to guess if unsure.   The vision score is then calculated by the 
program.       
 
COLOR CONTRAST SENSITIVITY 
The ChromaTest psychophysical vision testing system (CH Electronics) will be used to measure color contrast 
sensitivity.  For this test the subject is seated at a fixed distance from a large format standardized and 
calibrated NEC Spectraview LCD monitor.  Alphabetical letters displayed on a background of equiluminance at 
a constant angle and size create an image that tests the central 6.5 degrees of the retina. The computer finds 
the endpoint of the test by a Modified Binary Search method; if response is correct, on the next presentation 
the color difference between letter and background is halved. If response is incorrect, the color -contrast is 
doubled.  Incorrect responses prolong the test, but do not influence the final threshold. This method of 
determining thresholds leads to finite steps which reach a plateau at the color contrast sensitivity threshold at 
a test sensitivity of 1% (Wong et al., 2008). The thresholds for each major color axis will be defined for each 
patient at baseline.   
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OPTICAL COHERENCE TOMOGRAPHY (OCT)   
Spectral –domain OCT (Spectralis – Heidelberg Engineering) will be used to estimate the existence and the 
extent of retained photoreceptors.  In patients with stable fixation, the OCT studies will involve groups of 
raster scans to sample the retinal region of interest.  
FUNDUS PHOTOGRAPHY 
Pupils will be dilated to 6 mm or larger with two sets each of 2.5% Neo-Synephrine and 1% Mydriacyl, or 
equivalent. Contact lens examinations should be avoided prior to photography. A modified 3-standard field  
color photography and fundus reflex procedure will be used. 
 
FULL-FIELD ELECTRORETINOGRAM (ERG) 
Full field ERGs will be performed according to ISCEV standards.  Special protocols for the recording of 
‘submicrovolt’ ERGs have already been used in two clinical trials that included patients with relatively severe 
forms of retinitis pigmentosa (RP). For this proposal, methods of recording submicrovolt ERGs will be similar to 
those previously used in very severe retinal degenerative diseases (Jacobson et al., 1998). Full-field 29 OR 30 
Hz flicker will be presented with the standard stimulus on the 7 cd.m-2 white background and 100 sets of 
flicker trains consisting of three consecutive responses will be recorded.  
 
QUALITY OF LIFE (QOL) 
QOL will be assessed using the 25-Item National Eye Institute Visual Function Questionnaire (Mangione et al., 
2001).  The questionnaire will be administered in an interview format at the baseline visit and at the 12 month 
visit. 
 
GENOTYPING ANALYSIS 
The genotyping test will be performed as a part of the eyeGene clinical research study at the National 
Institutes of Health (NIH).  10 ml of whole blood will be obtained by routine phlebotomy using plastic 
vacutainers containing K2 EDTA. All samples will be stored exclusively at room temperature with overnight 
shipping.  Participants will be screened for the most common RP mutations including:  ABCA4, RHO, RDS, 
IMPDH1, PRPF31, PRPF3, RP1, PRPF8, NR2E3, TOPORS, RPGR, RP2, CNGA1, CRB1, C1QTNF5/ CTRP5, MERTK, 
PDE6A, PDE6B, RGR, RLBP1, RPE65, TULP1, CA4.  Dr. Kaushal or Dr. Asdourian will provide pre and post-test 
genetic counseling to all participants. 
 
SERUM VPA ASSAY 
Compliance is an issue in self administered study drug clinical trials.  Medication monitoring will occur at every 
follow up visit.  Patients will be instructed to bring prescription bottles to every visit for counting.  Additionally, 
serum VPA levels will be assayed at regular intervals for bioavailability determination as well as validation of 
participant compliance to protocol.  Serum concentrations will be assayed by a fluorescence polarization 
immunoassay system (Ax-Sym analyzer; Abbott Diagnostic Division, Irving, TX). 
 
Since the results of this test would obviously unblind any research staff, arrangements will be made to have 
the VPA blood levels held by the clinical testing lab facility until the end of the study.  Given that the VPA 
serum level is being used primarily for a research question, and likely does not afford useable safety 
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information, we feel this will not compromise subject safety.  If however, serious adverse events occurred, 
then this information would be available if and when a subject is unblinded. 
 
Randomization, Masking and Unmasking  
The research pharmacy at UMMMC will be responsible for randomization. Two codes will be used for the two 
types of capsules (placebo and VPA) provided to patients. All patients will be assigned to receive capsules 
following a computer-generated block randomization.  
 
CAPSULE CODE 
The capsule code information will be kept on a password-protected computer with the password known only 
to the capsule coordinator in the research pharmacy at UMMMC. The randomization code for the groups will 
consist of 2 single-letter identifiers for the two capsule types (A or B). The capsule codes are a temporary 
identifier of capsule bottles as the capsule coordinator will place a label with each individual’s ID number over 
the capsule code. This will prevent laboratory personnel from associating the patient ID with capsule code 
assignment.  
COORDINATING CENTER 
UMMMC will be the coordinating center and the research pharmacy will randomly assign the study 
intervention.  
Participants and investigators will be masked to the treatments. Participants will be unmasked if deemed 
clinically necessary by the examining physician and if the Study Chair and Data Safety and Monitoring Board 
(DSMB) Chair are in agreement. A written request for unmasking, after approval by the Study Chair and DSMB 
Chair, will be made to the Coordinating Center, who will inform the site Principal Investigator of the treatment 
assignment. All instances of unmasking must be reported to the IRB, the DSMB and the FDA.  
 
Monitoring Participants and Criteria for Withdrawal  
Data Safety and Monitoring Board 
 
The study will be monitored in compliance with the relevant parts of 21 CFR and according to the ICH GCP 
Guidelines. 
 
The procedures outlined in the protocol and case report forms will be carefully reviewed by the Investigators 
and staff prior to Study initiation to ensure appropriate interpretation and implementation.  No deviations 
from the protocol shall be made except in emergency situations where alternative treatment is necessary for 
the protection, proper care and well being of subjects. 
 
Amendments will be submitted to the IRB for their review and approval prior to implementation.  When an 
amendment to a protocol substantially alters the study design or increases potential risk to the study subject, 
the Informed Consent form will be revised and if applicable, subject’s consent to continue participation will 
again be obtained. 
 
To ensure safety of human subjects and integrity of data in this trial, a data and safety monitoring plan will be 
established.  The levels of monitoring will include: 
1) Dr. Shalesh Kaushal, MD, PhD as and Dr. David Birch as site Principal Investigators, will 
continuously monitor patient safety and be responsible for reporting serious and 
unexpected adverse reactions as regulated to the FDA, DSMB and IRB. 
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2) The DSMB will provide safety oversight of the trial, to monitor the progress of the study, and 
to recommend modification of the trial, as appropriate.  The DMSB will review safety data 
after the first two months of oral dosing and after 6 months of oral dosing.  Serious and 
unexpected adverse reactions will be reviewed by the DSMB or subcommittee. 
3) Approval of the IRB will be obtained before enrolling subjects in this clinical trial.  Following 
the beginning of enrollment, the IRB will conduct continuing reviews of the trial at intervals 
appropriate to the degree of risk to human subjects. 
 
A detailed Data and Safety Monitoring Plan will be submitted to the IRB prior to the accrual of human 
subjects. 
 
 
Adverse Experience Reporting  
All adverse events, either observed by the Investigator or one of his/her medical collaborators, or reported by 
the participant spontaneously, or in response to direct questioning, will be reported. Any serious adverse 
event (SAE) regardless of severity or potential association with the study drug, must be documented in study 
records by the site Investigator and promptly reported to the Coordinating Center (within 24 hours of learning 
about the event). Non-serious adverse events can be collected in a routine manner using case report forms.  
 
Obligations of Site Investigators  
Site Investigators will report all adverse events, regardless of their severity or potential association with the 
study drug. When submitting adverse event information to the Coordinating Center, a site Investigator may 
not delegate someone other than a listed study physician the responsibility for reviewing the accuracy of the 
contents of the adverse event report. When reporting an adverse event, the site Investigator must assign a 
severity grade to each event and also declare an opinion on the relatedness of the event to the study drug.  
  
Serious adverse events are defined below on page 63.  For any such event, the Coordinating Center must be 
notified within 24 hours of when the Investigator first learns of the occurrence of the event. Adequate 
information must be collected with supporting documentation. 
 
 
 
Serious Adverse Event Reporting Responsibilities of the Site  
When an SAE is identified, the site Investigator (or the site Study Coordinator) shall promptly:  
 
A. Notify the site PI (if a different person) in person or by telephone about the SAE.  
B. The site PI (or another designated study physician) is responsible for reviewing and approving the 
serious adverse event report contents (including the event description, grading of event severity, and 
attribution of relatedness to the study drug).  
C. Submit the initial serious adverse event report to the UMMMC Coordinating Center within 24 hours of 
recognizing the event.  Submission to the local IRB is based on each site’s responsibilities per the site’s 
IRB.  
D. The adverse event report and each page of any attached materials must describe the study participant 
only by their coded study identifier(s). Any personally identifying information (e.g., name, telephone 
number, address, etc.) must be removed or obscured before delivery to the Coordinating Center.  
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E. If the Coordinating Center requests additional information, or if further pertinent details become 
available (e.g., laboratory reports, follow-up evaluations, discharge summaries, autopsy reports, etc.), 
promptly submit them to the Coordinating Center.  
F. If a death occurred, complete the death case report form. Be sure to include a statement regarding the 
causality assessment on the form.  
G. If a hospitalization occurred for more than 24 hrs, complete a serious adverse event form.  
 
Obligations of Coordinating Center  
The UMMMC Coordinating Center, must immediately investigate each reported serious adverse event and 
notify the FDA (and other relevant regulatory authorities), the DSMB, and all participating investigators within 
15 days of any adverse experience that is associated with the use of the study drug and that is both serious 
and unexpected.  
 
Serious Adverse Events Defined  
A serious adverse event (SAE) is defined for this protocol as an adverse event of Grade 3 , 4 or 5.  
 
 
Grading Severity of Adverse Events  
The site Investigator must grade the severity of all reported adverse events into one of four categories: Grade 
1 (Mild), Grade 2 (Moderate), Grade 3 (Severe), Grade 4 (Life-Threatening) or Grade 5 (death). 
 
GRADE 1—MILD  
Transient (< 48 hours) or mild discomforts, no or minimal medical therapy or intervention required, 
hospitalization not necessary, no or little limitation in normal activities, nonprescription or single-use 
prescription therapy may be employed to relieve symptoms (e.g., aspirin for simple headache, acetaminophen 
with codeine for post-surgical pain). Mild adverse events may be listed as expected consequences of the 
therapy for any given protocol, and standard supportive measures for such an expected event do not 
necessarily elevate the event to a higher grade.  
 
GRADE 2—MODERATE  
Mild to moderate limitation in activity, some assistance may be needed; possibly none but usually minimal 
intervention/therapy required, hospitalization possible.  
 
GRADE 3—SEVERE  
Marked limitation in activity, some assistance usually required; medical intervention/therapy required; 
hospitalization possible or likely.  
 
GRADE 4—LIFE-THREATENING  
Extreme limitation in activity, significant and immediate assistance required; significant medical/therapy 
intervention required to prevent loss of life; hospitalization, emergency treatment or hospice care probable. 
This grade is used when the participant was, in the view of the Investigator, at substantial risk of dying at the 
time of the adverse event or it was suspected that use or continued use of the study drug would have resulted 
in the participant’s death. (This does not include a reaction that, had it occurred in a more serious form, might 
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have caused death. For example, drug-induced hepatitis that resolved without evidence of hepatic failure 
would not be considered life-threatening even though drug-induced hepatitis can be fatal.)  
 GRADE 5 - DEATH 
A death (Grade 5 event) occurring during the study, whether or not considered treatment-related.  
 
RELATEDNESS OF EVENT TO STUDY DRUG  
The site Principal Investigator (or an authorized study physician) must submit an attribution for the 
relatedness of the reported adverse event to the study drug. The attribution should take into account both the 
temporal association and any known physical, physiological or toxicological information regarding the study 
drug that could reasonably infer causality. Relatedness should only be considered for the study drug and not 
for any standard study examination or diagnostic procedures. The five attribution categories are:  
 
 1) Definitely Related—Clearly related to the study drug.  
An adverse event that follows a temporal sequence from administration of the study drug; follows a known 
response pattern to study drug; and, when appropriate to the protocol, is confirmed by improvement after 
stopping the study drug; and by reappearance of the reaction after repeat exposure; and cannot be 
reasonably explained by known characteristics of the participant’s clinical state or by other therapies.  
 
 2) Probably Related—Likely related to the study drug.  
An adverse event that follows a reasonable temporal sequence from administration of study drug; follows a 
known response pattern to the study drug, is confirmed by improvement after stopping or lowering the 
dosage; and cannot be reasonably explained by the known characteristics of the participant’s clinical state or 
other therapies.  
 
 3) Possibly Related—May be related to the study drug.  
 An adverse event that follows a reasonable temporal sequence from administration of study drug and follows 
a known response pattern to the study drug, but could have been produced by the participants' clinical state 
or by other therapies.  
 
4) Probably Not Related – Likely not related to the study drug 
An adverse event that either does not follow a reasonable temporal sequence from administration of study 
drug or have a known response pattern to the study drug.  Stopping the medication or reducing the dosage 
and rechallenge may or may not be performed to adequately  support no relationship. 
 
 5) Definitely Not Related—Clearly NOT related to the study drug.  
An adverse event that does not follow a reasonable temporal sequence after administration of the study drug 
and is not a known response pattern to the study drug and most likely is explained by the participant’s clinical 
disease state or by other therapies. In addition, a lowering the dosage or stopping the medication and a 
negative rechallenge to the study drug would support an unrelated relationship.  
 
  
Withdrawal Criteria  
Participants may choose to withdraw from this study for any reason at any time without penalty or prohibition 
from enrolling in other protocols. Participants who develop an adverse reaction to the study drug or a serious 
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complication associated with or aggravated by continuation of study drug may be withdrawn from the study 
drug. Following study drug discontinuation, participants will return for a final assessment.  
  
 
Monitoring Guidelines  
At a minimum, the DSMB will review the study data at the time points defined the section entitled “Interim 
Safety Analysis on page 66 to identify any issues with safety or the general conduct of the study. The DSMB 
may recommend temporary suspension, or to close enrollment, or stop the study at any time due to safety 
concerns, demonstration of efficacy or lack of efficacy, or slow  
enrollment.  
 
Before recommending closing enrollment or stopping the study, the DSMB will consider:  
 
• Internal consistency of primary and secondary results.  
• Distribution of baseline prognostic factors among the treatment groups.  
• Consistency of primary and secondary results across clinical centers. 
• Sensitivity of the results to adjust for missing data and the possible impact of missing data from missed 
participant visits for assessment of the primary and secondary response variables.  
• Any other considerations that the DSMB may want to review.  
 
Statistical Considerations    
Sample Size and Power    
Attainable recruitment goals and functional outcome data from our preliminary analysis were both used to 
estimate sample size for the Phase II trial.  Our pilot analysis demonstrated a potential dramatic annual 
change in VF annually in VPA treated RP patients (Figure 4). Reports in the literature allow us to 
conservatively estimate a 5% reduction in VF annually in untreated RP patients (Berson et al., 2002). If we 
reduce our estimate of delta from that calculated in the pilot study to boost the statistical validity of the trial, 
and assume a 60% difference in the rate of visual field change in Phase II, statistical significance for a two-
sided test using a significance level of 0.05 and 80% power would require around 40 patients per group.   
 
In general, RP patients are highly motivated to comply as evidenced in the similarly designed RFSW based 
Phase I trial of DHA where drop-out rates were 0% at year 3 and 7% at year 4. Because we will likely enroll 
sibling pairs into the trial, the total number of “active” participants has been increased from 80 to 90 to permit 
statistical compensation of these sibling pairs. 
 
 
Efficacy Analyses  
The primary efficacy variable is the mean change in Visual Field Area (VFA) from baseline to 12 months using  
semi-automated kinetic perimetry (SKP) using the Octopus 900 (Haig-Strait) .   
 
Secondary efficacy variables will include:  static perimetry measurements in the 30: central field;  mean 
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change from baseline in Best Corrected Visual Acuity (BCVA), Color contrast sensitivity and changes in ERG, 
Optical Coherence Tomography (OCT), fundus images and vision-related quality of life (NEI-VFQ25) . 
 
 
Safety Analyses  
Safety variables will include the incidence of adverse events, marked changes in visual acuity, changes in vital 
signs,  marked changes in clinical laboratory data (especially liver and pancreatic function) , and findings during 
physical examinations. 
 
Interim Safety Analyses   
Participants will be followed closely for adverse reactions to VPA.   Clinic visits at 1, 2 and 6 months will include 
safety labs and subjects will be qualitatively assessed by physical and ocular exams.  Participants will be 
contacted by telephone on months not scheduled for clinic visits. 
 
Statistical Methods 
Data will be analyzed using student t tests (paired and unpaired).  Multiple predictor regression models will be 
created using exponential change (to better approximate normality) in VF area, sensitivity measurements in 
the 30: central field, visual acuity, color contrast sensitivity, ERG amplitude and central foveal thickness as 
outcomes.  Predictor covariates will be age, age at presentation, VF area at baseline, genotype, inheritance 
pattern, average rate of VF loss (as predicted by screening and baseline values),  average serum VPA value and 
dose of VPA.  Analysis will be performed based on an intention to treat analysis.   
 
The study is powered to detect a change in mean visual field area using semi-automated kinetic perimetry, as 
the primary endpoint. Secondary analyses will be exploratory, but in order to test several additional endpoints 
we will also adjust for multiple comparisons either using the very strict Bonferroni adjustment or by relying on 
an omnibus test. 
 
Potential Risks 
Potential risks to study subjects include the well known and characterized risks associated with administration 
of the therapeutic agent and with study procedures. Valproic acid can cause serious and fatal hepatoxicity 
especially in individuals with liver disease, organic brain disease, serious seizure disorders, congenital 
metabolic disorders, those on multiple anticonvulsants and children under the age of 2.  Therefore individuals 
with contraindicating diseases and concomitant medications as well as children under 18 will be excluded 
from this study. The risk of hepatoxicity usually occurs within the first 6 months of treatment and decreases 
considerably in older age groups. Serious or fatal hepatotoxicity may be preceded by non-specific symptoms 
such as malaise, weakness, lethargy, facial edema, anorexia, and vomiting.  
 
In the pilot study (Appendix B.  Pilot clinical study) no abnormal liver function or blood chemistries were 
noted with patients on 500 mg total daily dose of VPA.  The most common side effects were mild and included 
tiredness (10%) and stomach irritation (13%).  
 
Valproic acid can cause serious and fatal pancreatitis. Some of the cases have been described as hemorrhagic 
with a rapid progression from initial symptoms such as abdominal pain, nausea, vomiting, and/or anorexia to 
death. Cases have been reported shortly after initial use as well as after several years of use 
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Valproate can produce teratogenic effects such as Spina Bifida, therefore woman of child bearing potential will 
be screened for pregnancy prior to administration of the study agent and must maintain use of contraception 
during the study period.   
 
The risks associated with ophthalmic procedures include redness, discomfort or allergic reaction to topical 
medications used to dilate the pupil prior to visual function tests. High blood pressure, cardiac dysrhythmias 
and closed angle glaucoma may be exacerbated by some of these medications and light sensitivity may be 
experienced when the pupil is dilated.  Corneal abrasions may result from the contact lenses used in 
performing electroretinography testing. The risks of drawing blood from a vein include discomfort at the site 
of puncture; possible bruising and swelling around the puncture site; rarely an infection; and, uncommonly, 
faintness from the procedure.  
 
Adequacy of Protection Against Risks  
Recruitment and Informed Consent  
Patients will be recruited from the Department of Ophthalmology at the University of Massachusetts Medical 
Center; the Retina Foundation of the Southwest and through the Foundation Fighting Blindness.  This protocol 
will be listed in the Clinical Trials Data Bank of the NIH.  Potential study patients who demonstrate an interest 
in participating in the study will receive an explanation of the terms, procedures, and requirements of the 
study from an investigator of the research team in language they can understand. They will receive a copy of 
the Informed Consent Form to read and share with family or friends.  Subsequently, an investigator will 
answer questions and request the patient's permission to participate in the study. Volunteer participants who 
sign a study-specific patient informed consent form approved by the Institutional Review Board will then be 
scheduled for a screening evaluation to determine their eligibility.  Children under 18 are not included in this 
study. 
 
Protections Against Risk  
The subjects will be informed of possible consequences of the study from one of the delegated study staff 
members in a language they can understand.  They will be informed that they may withdraw from the study at 
any time and for any reason without jeopardizing their future treatment.  They will be asked to follow-up with 
necessary safety evaluations if they have received study agent prior to their desire to withdraw.  They will be 
given full information regarding potential side effects of VPA and the procedures involved.  The medical 
history and physical examination performed prior to study agent administration will identify patients with 
medical conditions that would increase the risks associated with study procedures and those subjects will be 
excluded from participation.  The administration of the study agent and all procedures related to the study will 
be performed by trained and licensed medical and health professionals.  They will be provided with contact 
numbers for any questions or concerns arising regarding the possible effects of the VPA and encouraged to 
call if they feel that an adverse event is occurring.  In the event of an adverse event associated with the clinical 
trial, immediate medical care will be provided.   
 
Patients will be followed closely, especially in the first 6 months for known adverse reactions to VPA.  Safety 
labs regarding liver and pancreas toxicity will be drawn prior to and periodically during dosing with VPA.  
Results of all laboratory and safety exams performed to ensure subject eligibility and safety will be reviewed 
by an investigator during the study.  Subjects with known risk factors such as liver disease, pancreatic 
conditions, metabolic disorders, organic brain diseases, seizure disorders and those on anti-convulsants will be 
excluded from the study. Female subjects of child bearing potential must have a negative pregnancy test at 
the baseline visit and prior to study agent administration.  Female subjects of reproductive ability must be 
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willing to use effective contraception for the duration of the study, one year.  Lactating mothers will not be 
included in this study.   
 
We will not include children under 18 in this study due to increased risk of adverse events with VPA in children 
combined with the fact that the majority of RP patients recruited will be over 18. 
 
The Data Safety Monitoring Board (DSMB) will be established with members who have an understanding of 
the disease, ethics, and biostatistics.  They will review the study results and notify the PI of their findings and 
recommendations for study continuation or modification.  The DSMB will be charged with monitoring the 
conduct of the trial and assessing patient safety on an ongoing basis.  This group will review all safety data, 
including serious adverse events, adverse events, and laboratory data.  Confidentiality of the subjects will be 
maintained in the process of review by the DSMB. The DSMB will provide committee recommendations after 
each review.  Adverse events will be reported to the IRB, NIH, and FDA as regulated to insure the safety of 
subjects. 
 
The study will be monitored in compliance with the relevant parts of 21 CFR and according to the ICH GCP 
Guidelines. 
 
 
Confidentiality and Access to Source Data/Documents   
Confidentiality will be assured by limiting access to the subject database to key research personnel.  Individual 
identifiers will be stored in the computerized database and will also be the only identifier on analyzed and 
stored subject specimens.  Access to the database will be controlled by a user code.  The log identifying the 
subject names with the subject numbers, as well as Case Report Forms, Informed Consent Forms, laboratory 
study reports, and demographic profiles will be kept locked in an investigator’s office.  The subjects will be 
informed of the information stored and the review of that information by the DSMB, UMass and RFSW IRB, 
and UMass and RFSW clinical facility personnel, Data Management and Statistical personnel, research staff, 
and personnel performing the procedures.   
 
Sources of Materials 
Research material obtained from identifiable living human subjects includes reports of:  history and physical 
assessments, blood, urine, pregnancy tests, perimetry, optical coherence tomography, visual acuity 
measurements, color contrast sensitivity and electroretinography measurements, clinical assessments, 
adverse events, and autopsies.  Copies of case report forms, original test results, subject medical records, 
signed subject informed consent, correspondence, and any other documents of the subjects, relevant to the 
conduct of the study will be kept on file by the principal investigator.  All material or data collected as part of 
the study will be obtained specifically for research purposes.  
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Appendix A. Pre-Clinical Data 
 
 
 
FIGURE 2:   VPA RESCUES RETINAL PIGMENTED 
EPITHELIUM CELLS FROM HYDROQUINONE (HQ) 
INDUCED APOPTOSIS.  
ARPE-19 cells are protected from HQ mediated apoptosis by 
the presence of VPA.  
 
 
 
 
 
FIGURE 1:   VALPROIC ACID ALLOWS MUTANT P23H RHODOPSIN TO PROPERLY 
FOLD TO THE LEVEL OF WILD TYPE.  
HEK293 cells stably expressing an induc ble mutant P23H rhodopsin expression vector 
were grown to confluence and tetracycline was added to induce opsin expression. 3mM 
VPA was added for 48h. Rhodopsin was purified by immunoaffinity methods.  Yields of 
folded p23H opsin were quantified by spectrophotometry .  In the presence of 11-cis 
retinal, folded mutant rhodopsin levels (red) increase from baseline (blue) to that of wild 
type (green).   
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Appendix B.  Pilot clinical study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3   PERIMETRY TRACING OF A PATIENT 
TREATED WITH VPA  
Goldmann Kinetic Perimetry tracings (using V4e 
isopter) of Patient One before and after 
treatment with VPA 250 mg twice daily. 
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FIGURE 4  Visual Field Areas of Patients Treated off-label with VPA.  
A. Goldmann Kinetic Perimetry tracings (isopter V4e) from each eye (e.g. Figure 3) were digitized and areas were 
automatically calculated.  We defined percent change in visual field relative to baseline and accounted for 
duration of treatment.  
B.  Assessment of the statistical significance of the observed changes in visual field, relative to baseline was 
exploratory.  Three null hypotheses were considered:  (1) HO:  Median percent change per month with no 
treatment = 0; (2) HO:  Median percent change per month on no treatment = -0.5 percentage points; (2) HO:  
Median percent change per month on no treatment = -1.0 percentage points.  Significance levels were 
calculated using the signed rank test. 
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Appendix C. Study Schedule Flow-chart 
 
 
  
 
FIGURE 5:  STUDY VISIT SCHEDULE 
 Cells outlined in red represent clinic visits with full battery of outcome measures.  
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Appendix D. Scheduled Study Evaluations Table 
 
 
 
  
TABLE 3:  Scheduled Study Evaluations  
 
          
Time relevant to start of Oral VPA  
Screening 
Visit  
1 
Visit  
2 
Visit 
3 
Visit 
4 
Visit     
5 
Early 
term.
d 
b 
Month 0 2 6 12 15  
Week -12 to -4 0 8 24 48 60  
Informed Consent x x      
Inclusion/exclusion Criteria x x      
Medical/surgical history x       
Physical examination x       
Ophthalmic history x       
Safety Labs x x x x x x x 
Demographic data x       
Molecular Genotyping
a
 x x      
Ophthalmic  Exam
b 
 x x x x x x x 
Urine pregnancy test x x      
Visual Acuity (BCVA) x x x x x x x 
Perimetry x x   x  x 
Color Contrast Sensitivity  x   x  x 
Electoretinography  x   x  x 
Optical coherence tomography (OCT)  x   x  x 
Fundus photography (FP) x    x  x 
Quality of Life Questionnaire
 c
  x   x  x 
Remaining pill count for med. monitoring   x x x   
Provide Study Meds  x x x    
VPA level (labs)   x x x x x 
Concomitant medications x x x x x  x 
Adverse events assessment   x x x x x x 
a. If enrolled 
b. Ophthalmic examinations include:  slit lamp examination; tonometry, indirect ophthalmoscopy and retinal biomicroscopy.  
c. Quality of Life Assessed using the 25-Item NEI Visual Function Questionnaire 
d. For subjects that withdraw from the study at any time before visit  5. 
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3.5.5 CMC DATA FOR PROPOSED PLACEBO MANUFACTURE 
Clinical Manufacturing of Placebo 
Valproic Acid Softgels and Sourcing of 
Active Valproic Acid Softgels 
 
QTE-UOQ-0001.01 
 
Confidential for University of Massachusetts 
 
Prepared for Christine Clemson, PhD 
222 Maple Drive, Higgins Building 
Shrewsbury, MA 01545 
Phone: 774-258-0425 
 
Catalent Contact: Sarah Hauer 
Phone: 410-663-0394 
July 28, 2009 
 
 
 
 
 
 
 
 
     
 
 
 
 
 
 
Catalent Pharma Solutions  
Oral Technologies Business Unit 
Pharmaceutical Development Center 
Somerset, NJ 
 
 
 
 
Section 1. Scope of Work 
 76 
 
Catalent will source one active batch of Valproic Acid 250 mg softgels size 19 mm – off white in color  (lot # 3888975 – 
Manufactured by Catalent Pharma, St. Petersburg, FL, distributed by Watson Pharma, Inc., Corona, CA 92880 USA). 
Catalent will manufacture one batch of placebo (50,000 capsules) of identical size, shape and excipient fill to study drug. 
The following sections provide additional detail for the “Project” and the associated costs. 
 
Section 2.  Activities/Specifications 
2.1. Project Activities 
 
2.1.1. Catalent’s Responsibilities 
2.1.1.1. Project Initiation 
 
2.1.1.3. Clinical Batch Manufacturing 
Catalent will perform the following activities required for the manufacture of one 
placebo CGMP batch of Valproic Acid softgels: 
 
• Order excipients and sample for release. 
• Generate Master Batch Records and Production Batch Records for 
               UMASS‟ approval. 
• Prepare gel mass using the current, opaque colored gel mass 
  formulation, sufficient for manufacture of the clinical batch. 
• Manufacture one (1) CGMP placebo batch (50,000) of 19 mm soft-gel   
   off- white capsules using identical excipient fill to study drug (peanut oil    
   based fill). 
• Perform in-process encapsulation testing (fill and shell weights, seal 
  checks). 
• Perform a drying profile for the batch based on hardness. 
• Bulk package softgels for shipping to a packaging site designated by 
   UMASS. 
• Provide required batch documentation to UMASS. 
 
2.1.1.4. Excipients Sourcing and Testing 
Catalent will provide access to released excipients for clinical manufacture to include the following: 
 
• Source and supply excipients and components in support of 
   manufacture. 
• Store materials in a controlled CGMP warehouse. 
• Review documentation for each excipient. 
• Ensure test methods used are in compliance with USP. 
• Provide access to released excipient(s) for use in batch manufacture. 
• Provide Certificate of Analysis as required. 
 
2.1.1.5. Release of Clinical Batch 
Catalent will perform the following batch release testing activities: 
 
• Review documentation for the batches. 
• Write specifications for the placebo finished product. 
• Perform release testing for the placebo batch consisting of 
  appearance, absence of active, and MLT per USP/EP/JP Harmonized 
   Method. 
• Perform MLT one-time validation (as per USP/EP/JP Harmonized 
  Method) for the placebo batch. 
• Report results and issue Certificate of Analysis. 
• Complete QA audit of batch paperwork. 
• Provide batch paperwork and batch release documentation to 
   UMASS. 
 
Section 3. Cost Proposal 
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Section 4. Invoicing and Payment Terms 
 
Section 5. Scheduling/Deliverables 
5.1. Scheduling 
Catalent must receive a signed Quotation, a signed protocol, and all raw 
materials/intermediates/final product samples in order for this project to be scheduled. 
Subsequently, a Purchase Order number (where applicable) must be received within 28 days of 
receipt of the signed quote. Once scheduled, UMASS will be notified by Catalent of the 
anticipated start and completion date of the project activities. 
 
5.2. Deliverables 
5.2.1. Reports and Certificates of Analysis 
A report and/or Certificate of Analysis will be issued upon completion of each project 
phase. 
 
5.2.2. Communication 
In order to establish a collaborative relationship between UMASS and Catalent, both 
parties will appoint a Project Manager to serve as a point of contact to oversee progress 
on this project. Upon initiation of the project, Catalent and UMASS will establish a 
communication plan, that may include conference calls, visits, and timelines. UMASS 
communication is encouraged. To foster project planning, reviews/updates, and 
coordination meetings, Catalent will administer project team conference calls as 
reasonably required. 
 
Section 6. Additional Project Terms 
 
6.1. Safety 
 
6.1.1. Catalent’s Responsibilities 
Catalent will assess all vendor and UMASS MSDS and all handling data for the samples/materials associated with this 
project. If categorized as a CDS and/or Category 
4 or above, the samples/materials will require special handling precautions and will be 
subject to a Hazardous Material Fee for all handling and testing directly associated with the samples/materials. If 
applicable, this Hazardous Materials Handling Surcharge has 
been included in the project costs. 
 
6.2. Methods/Documentation 
 
6.2.1. Catalent’s Responsibilities 
Catalent will review all project-related documentation and methods received from 
                        UMASS associated with this project. 
 
6.3. Samples/Materials 
 
6.3.1. Catalent’s Responsibilities 
Catalent will, as necessary, log in all samples/materials according to current Standard Operating Procedures. The 
sample/material lot numbers will be recorded in the laboratory notebooks at the time of use. Upon issuance of the 
final report or Certificate of Analysis, Catalent will issue a request for approval of destruction of any remaining 
clinical supply materials/samples, during which time samples/materials will be stored in quarantine at Catalent for 
a period of 30 days. After a 30-day quarantine period, if additional storage is required, Catalent will issue a QAR 
for the additional cost. 
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3.5.6 CLAIM FOR CATEGORICAL EXCLUSION 
 
August 3, 2009 
 
I claim categorical exclusion (under 21 CFR 25.31[e]) for the study(ies) under this IND. To my knowledge, no extraordinary 
circumstances exist. 
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3.5.7 FORM 1572 
DEPARTMENT OF HEALTH AND HUMAN SERVICES 
FOOD AND DRUG ADMINISTRATION 
 
STATEMENT OF INVESTIGATOR 
(TITLE 21, CODE OF FEDERAL REGULATIONS (CFR) PART 312) 
(See instructions on reverse side.) 
Form Approved: OMB No. 0910-0014. 
Expiration Date: May 31, 2009. 
See OMB Statement on Reverse. 
NOTE: No investigator may participate in an 
investigation until he/she provides the sponsor with 
a completed, signed Statement of Investigator, 
Form FDA 1572 (21 CFR 312.53(c)). 
1.  NAME AND ADDRESS OF INVESTIGATOR 
Shalesh Kaushal, MD PhD 
Chair and Assoc. Professor of Ophthalmology 
University of Massachusetts Medical School 
Rm. S6-410 
Worcester, MA 01655 
2.  EDUCATION, TRAINING, AND EXPERIENCE THAT QUALIFIES THE INVESTIGATOR AS AN EXPERT IN THE CLINICAL INVESTIGATION OF THE
 DRUG FOR THE USE UNDER INVESTIGATION. ONE OF THE FOLLOWING IS ATTACHED. 
 CURRICULUM VITAE  OTHER STATEMENT OF QUALIFICATIONS 
3.  NAME AND ADDRESS OF ANY MEDICAL SCHOOL, HOSPITAL OR OTHER RESEARCH FACILITY WHERE THE CLINICAL 
INVESTIGATION(S) WILL BE CONDUCTED  University of Massachusetts Memorial Medical Center - Memorial Campus 
119 Belmont Street  
Worcester, MA 01605 
 
Retina Foundation of the Southwest (RFSW) 
9900 North Central Expressway, Ste. 400 
Dallas, TX 75231 
 
4.  NAME AND ADDRESS OF ANY CLINICAL LABORATORY FACILITIES TO BE USED IN THE STUDY.  
      
5.  NAME AND ADDRESS OF THE INSTITUTIONAL REVIEW BOARD (IRB) THAT IS RESPONSIBLE FOR REVIEW AND APPROVAL OF THE STUDY(IES).  
University of Massachusetts Medical School 
Institutional Review Board 
Human Subjects Office S1-859 
55 Lake Avenue North 
Worcester, MA 01655 
 
Western Institutional Review Board (WIRB) 
3535 Seventh Ave. SW 
Olympia, WA 98508-2029 
 
6.  NAMES OF THE SUBINVESTIGATORS (e.g., research fellows, residents, associates) WHO WILL BE ASSISTING THE INVESTIGATOR IN THE
 CONDUCT OF THE INVESTIGATION(S)  
David Birch, PhD (RFSW) 
Christine Clemson, PhD (UMMMC) 
George Asdourian, MD (UMMMC) 
Gary E. Fish, M.D (RFSW)  
Rand Spencer, M.D. (RFSW)  
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7.  NAME AND CODE NUMBER, IF ANY, OF THE PROTOCOL(S) IN THE IND FOR THE STUDY(IES) TO BE CONDUCTED BY THE INVESTIGATOR.  
A Phase II Multiple Site, Randomized, Placebo-Controlled Trial of Oral Valproic Acid for Retinitis Pigmentosa H-13371 
 
8. ATTACH THE FOLLOWING CLINICAL PROTOCOL INFORMATION: 
   FOR PHASE 1 INVESTIGATIONS, A GENERAL OUTLINE OF THE PLANNED INVESTIGATION INCLUDING THE ESTIMATED DURATION OF  
   THE STUDY AND THE MAXIMUM NUMBER OF SUBJECTS THAT WILL BE INVOLVED. 
   FOR PHASE 2 OR 3 INVESTIGATIONS, AN OUTLINE OF THE STUDY PROTOCOL INCLUDING AN APPROXIMATION OF THE NUMBER OF 
   SUBJECTS TO BE TREATED WITH THE DRUG AND THE NUMBER TO BE EMPLOYED AS CONTROLS, IF ANY; THE CLINICAL USES TO BE
   INVESTIGATED; CHARACTERISTICS OF SUBJECTS BY AGE, SEX, AND CONDITION; THE KIND OF CLINICAL OBSERVATIONS AND  
   LABORATORY TESTS TO BE CONDUCTED; THE ESTIMATED DURATION OF THE STUDY; AND COPIES OR A DESCRIPTION OF CASE 
   REPORT FORMS TO BE USED. 
9. COMMITMENTS:  
I agree to conduct the study(ies) in accordance with the relevant, current protocol(s) and will only make 
changes in a protocol after notifying the sponsor, except when necessary to protect the safety, rights, or 
welfare of subjects. 
I agree to personally conduct or supervise the described investigation(s). 
I agree to inform any patients, or any persons used as controls, that the drugs are being used for investigational purposes and I will ensure 
that the requirements relating to obtaining informed consent in 21 CFR Part 50 and institutional review board (IRB) review and approval in 21 
CFR Part 56 are met. 
I agree to report to the sponsor adverse experiences that occur in the course of the investigation(s) in accordance with 21 CFR 312.64. 
I have read and understand the information in the investigator‟s brochure, including the potential risks and side effects of the drug. 
I agree to ensure that all associates, colleagues, and employees assisting in the conduct of the study(ies) are informed about their obligations  
in meeting the above commitments. 
I agree to maintain adequate and accurate records in accordance with 21 CFR 312.62 and to make those records available for inspection in 
accordance with 21 CFR 312.68. 
I will ensure that an IRB that complies with the requirements of 21 CFR Part 56 will be responsible for the initial and continuing review and 
approval of the clinical investigation. I also agree to promptly report to the IRB all changes in the research activity and all unanticipated  
problems involving risks to human subjects or others. Additionally, I will not make any changes in the research without IRB approval, except 
where necessary to eliminate apparent immediate hazards to human subjects. 
I agree to comply with all other requirements regarding the obligations of clinical investigators and all other pertinent requirements in 21 CFR 
Part 312. 
INSTRUCTIONS FOR COMPLETING FORM FDA 1572 
STATEMENT OF INVESTIGATOR: 
1. Complete all sections. Attach a separate page if additional space is needed. 
2. Attach curriculum vitae or other statement of qualifications as described in Section 2. 
3. Attach protocol outline as described in Section 8. 
4. Sign and date below. 
5. FORWARD THE COMPLETED FORM AND ATTACHMENTS TO THE SPONSOR. The sponsor will incorporate 
 this information along with other technical data into an Investigational New Drug Application (IND). 
 INVESTIGATORS SHOULD NOT SEND THIS FORM DIRECTLY TO THE FOOD AND DRUG ADMINISTRATION. 
10. SIGNATURE OF INVESTIGATOR 11. DATE 
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(WARNING: A willfully false statement is a criminal offense. U.S.C. Title 18, Sec. 1001.) 
Public reporting burden for this collection of information is estimated to average 100 hours per response, including the time for reviewing instructions, 
searching existing data sources, gathering and maintaining the data needed, and completing reviewing the collection of information. Send comments 
regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to:  
Department of Health and Human Services 
Food and Drug Administration 
Center for Drug Evaluation and Research 
Central Document Room 
5901-B Ammendale Road 
Beltsville, MD  20705-1266 
Department of Health and Human Services 
Food and Drug Administration 
Center for Biologics Evaluation and Research (HFM-99) 
1401 Rockville Pike 
Rockville, MD 20852-1448 
"An agency may not conduct or sponsor, 
and a person is not required to respond to, 
a collection of information unless it displays 
a currently valid OMB control number." 
Please DO NOT RETURN this application to this address. 
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3.5.8 PROTOCOL OUTLINE 
 
A Phase II Multiple Site, Randomized, Placebo-Controlled Trial of Oral Valproic Acid for 
Retinitis Pigmentosa H-13371 
Outline 
 
1. Indication Investigated:   Retinitis Pigmentosa (RP) 
2. Number of Subjects:  45 treated; 45 controls (90) total – split evenly between 2 sites. 
3. Subject Characteristics:  Diagnosis of RP, age 18 or greater. 
4. Clinical Observations and Laboratory tests performed:  visual fields as measured by 
semi-automated kinetic perimetry (SKP), best corrected ETDRS visual acuity; color 
contrast sensitivity as measured by the Chroma Test; retinal anatomy as measured by 
Optical Coherance Tomography (OCT) and  rod and cone responses as analyzed by 
electroretinography (ERG), fundus photography; the 25 item National Eye Institute 
Visual Function questionnaire to assess quality of life (QOL); genotyping,  complete 
blood counts and comprehensive metabolic screeing, urine pregnancy tests and serum 
VPA levels.   
5. Estimated duration of study:  15 months (12 months treatment plus 3 months follow 
up). 
6. Case Report Forms:  Attached 
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3.5.9 CLINICAL TRIALS.GOV WAIVER (FORM 3674) 
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3.5.10 SAMPLE CASE REPORT FORMS 
 
Index of 
Visits 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Month Form Label  (weeks) 
Adverse Events  AE 
Concomitant Medications  CM 
Outstanding Action Item  OA 
Screening  -01 
Baseline (visit 1) and phone call 1 0 +00 
Phone call 2 (1 week) 0.25 (1 week) +01 
Phone call 3 (1 month) 1 +04 
Visit 2  (2 month ) 2 +08 
Phone call 4 (3 month) 3 +12 
Phone call 5 (4 month) 4 +16 
Phone call 6 (5 month) 5 +20 
Visit 3 (6 month ) 6 +24 
Phone call 7 (7 month) 7 +28 
Phone call 8 (8 month) 8 +32 
Phone call 9 (9 month) 9 +36 
Phone call 10 (10 month) 10 +40 
Phone call 11 (11 month) 11 +44 
Visit 4 (12 month) 12 +48 
Visit 5 (15 month) 15 +60 
Early Termination ?? ET 
End of Study Form ?? ES 
Phone call log ?? PC 
Investigator Comment Log ?? IC 
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3.6 IRB APPLICATIONS 
  3.6.1 GENOTYPING APPLICATION 
 
 
SECTION II 
PROTOCOL SUMMARY SHEET 
Today's Date: 7/22/09  
P.I. Name: Shalesh Kaushal Degree: MD PhD  
(PI Must be UMMS Faculty Member) Faculty Title: Chair and Assoc Professor 
Department: Ophthalmology 
Division Name:  Duration of the 
Study: 
24 months 
Phone # 508 856 4808  Total # of subjects at 
UMMHC: 
30 per year for 5 years 
Beeper/Pager#:   Total # of subjects at off-site 
locations :  
 
Email Address: Shalesh.kaushal@umassmemorial.org 
Title of Study: (type 
right) 
National Ophthalmic Genotyping and Phenotyping Network, Stage 1 — Creation of DNA 
Repository for Inherited Ophthalmic Diseases 
 
( Protocol # and version) 
06-EI-0236 March 
18, 2009/7.0 
March 18, 2009/7. 
 
 
 
 "X" below which sites will participate 
Contact Person Name Christine Clemson, PhD Phone # 856-4808 University:   
Pager 
# 
  Memorial : x 
Identify Condition being studied: Retinitis Pigmentosa Marlborough:  
 Shriver Center:  
 113 
 
Source of Funding: NIH/NEI Others:  
 
DEVICE INFORMATION                              DRUG INFORMATION 
Please provide IDE# if not approved by FDA   In the table below, list all drugs being used.  If the drug is 
considered investigational by the FDA you must include the 
IND# assigned by the FDA.  Please "X” approved or 
investigational. 
Device Name Approved Investigational IDE# 
    
    
    
 
USE SPACE BELOW FOR COMMENTS OR ADDITIONAL DRUG 
INFORMATION 
 
Drug Name: Approve
d 
Inves. IND# 
     
    
    
    
    
    
 
DECRIBE THE RESEARCH BY CHECKING ALL THE ITEMS “YES” OR “NO” 
 
Yes No  Yes No  Yes No  
x  On Site at UMMS/UMMMC x  Adults   Questionnaires (please provide) 
 x Multicenter Study x  Pregnant Women  x Filming/video/audio 
  Cooperating Institutions x  Minors (under 18)  x Marketed drugs 
x  Research Currently Funded x  Teenagers ( 12-17)  x Diagnostic Radiation  
 x Financial interest involved  x Prisoners  x Therapeutic Radiation 
 x Funding applied for  x Fetuses / Abortuses  x MRI 
 114 
 
 x UMMMC inpatients  x Randomization  x Ultrasound 
x  UMMMC outpatients  x Placebo  x Radioisotopes 
 x Normal volunteers  x Investigational drugs/device  x Radiation involved? 
 x Other  x Increased hospital costs  x Would receive radiation regardless 
x  Males  x Mental Impairment  x Radiation Safety Approval Needed? 
x  Females x  Data bank  x Biosafety Review Needed? 
 x Phase I Study  x Phase II Study  x Phase III Study 
 
SECTION V 
 DESCRIPTION OF RESEARCH PROJECT 
 
 
PERSONNEL ENGAGED IN THE RESEARCH STUDY.  List all personnel engaged in the study.  This list must agree 
with that in Section VI (Delegation of roles/responsibilities). 
 
Shalesh Kaushal, M.D. PhD. (UMMC) will serve as a Principal Investigator of this study providing pre and post 
test genetic counseling to participants who choose to be genotyped.  
 
Christine Clemson, PhD. (UMMS) will serve as the Study Coordinator of this trial, collecting all relevant clinical 
information, sending it to the coordination center and collating all genotype information as it is returned. 
 
George Asdourian, M.D. (UMMMC) will serve as a co-investigator and will help provide pre and post test 
genetic counseling to participants who choose to be genotyped.    
 
Judith Colbert, R.N. (UMMMC) will serve as the study nurse coordinator for the UMMMC site, she will 
perform the blood draws and prepare and mail the samples to the coordinating center. 
 
 
2.  GENERAL STATEMENT OF PROBLEM 
 Purpose: Include concise hypothesis to be tested by proposed research. 
 
Molecular genetics has the potential to revolutionize the diagnosis and treatment of inherited eye diseases.  
Progress in research on inherited eye disease would be augmented by the availability of patient DNA coupled 
to robust, anonymous phenotypic information.  The National Ophthalmic Genotyping Network (eyeGENE) has 
been created to answer this need.  With the creation of a national DNA and blood repository for inherited eye 
disease, samples will be gathered from clinical centers around the nation, such as UMMHC and will be coupled 
to anonymous, phenotypic descriptors. If requested, a portion of the sample submitted by a clinician will be 
used for appropriate, CLIA-certified molecular diagnostics that can be used in patient care. Once a sufficient 
repository is created, researchers will be able to request aliquots for their laboratory experiments. Participants 
will be provided the option to be re-contacted if an approved clinical study for which they might qualify is 
offered. 
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3.   BACKGROUND AND SIGNIFICANCE: 
a. Provide a summary of the facts which led to selection of the problem.  
Over the past 15 years, nearly 500 genes that contribute to inherited eye diseases have been identified. 
Disease-causing mutations are associated with many ocular diseases, including glaucoma, cataracts, 
strabismus, corneal dystrophies and a number of forms of retinal degenerations. This remarkable new genetic 
information highlights the significant inroads that are being made in understanding the medical basis of 
human ophthalmic diseases. As a result, gene-based therapies are actively being pursued to ameliorate 
ophthalmic genetic diseases that were once considered untreatable. 
 
To date, no other ophthalmic research groups/societies have attempted to carry out a study of this type and 
proportion. Once the repository is established, it would provide an outstanding tool for researchers and 
clinicians in the ophthalmic community. This repository of DNA and blood, coupled with phenotypic 
information, would be used by researchers for testing hypotheses related to eye disease. We hope, in the 
future, this study will enhance recruitment for clinical trials in inherited eye diseases. 
 
The overall goals of eyeGENE are as follows: 
To provide a repository of DNA and blood coupled to anonymous phenotypic information for researchers 
To provide molecular diagnosis to patients with inherited eye diseases 
To establish genotype-phenotype correlations for rare eye diseases 
To enhance recruitment for clinical trials and investigations in inherited eye diseases 
 
Specifically, Dr. Kaushal will enroll his patients in this protocol to determine, if possible, the specific mutation 
responsible for their eye disease.  This information will not only be used for patient care, but for facilitating 
specific sub group analysis in our ongoing clinical trials here at UMMHC. 
 
 
b. Please describe the Investigator’s previous work on the problem. 
In November 2003, the National Eye Institute convened a national meeting of researchers, clinicians, and 
genetics professionals to discuss the creation of a National Ophthalmic Genotyping Network (eyeGENE). The 
consensus from this meeting was that having a national repository of DNA and blood samples that was 
available to researchers and was anonymously coupled to important, select clinical and genotypic data would 
be a major asset to vision research.  If mutation analysis of known genes were performed according to CLIA 
standards, then this information could also be directly used to enhance patient care and to facilitate the use of 
clinical molecular testing in ophthalmology and optometry. 
 
Dr. Kaushal has been involved in genotyping his patients as part of standard of care in his practice for many 
years.  He is skilled at genetic counseling of patients with eye diseases who present with a variety of mutations 
and concomitant inheritance and disease severities.   
 
c. What are the aspects that justify the use of human subjects, human data, or specimens as part of this 
research? 
The ability to detect disease-causing mutations in many individuals with inherited ophthalmic diseases offers 
significant benefits for patients and their families. It is now possible to provide genetic testing for patients 
afflicted with ocular diseases by screening for these genes. This remarkable opportunity, however, has now 
created the challenge of providing genetic information to individuals who want to know whether they could 
benefit from the treatments that are being developed. Unfortunately, this type of molecular testing is not 
widely available. 
 116 
 
 
To date, no other ophthalmic research groups/societies have attempted to carry out a study of this type and 
proportion. Once the repository is established, it would provide an outstanding tool for researchers and 
clinicians in the ophthalmic community. This repository of DNA and blood, coupled with phenotypic 
information, would be used by researchers for testing hypotheses related to eye disease. We hope, in the 
future, this study will enhance recruitment for clinical trails in inherited eye diseases. 
 
 
4.  DETAILED DESCRIPTION OF RESEARCH PLAN (especially as it affects the subject) 
 
Include a schematic representation of what the research will entail (e.g. a table with the number of visits and 
what will happen at each visit or flow diagram of subject’s involvement over time). 
 
The following information will be collected on all participants, regardless of the nature of their disease: 1) 
name; 2) contact information; 3) date of birth; 4) gender; 5) race; 6) family history.  Medical, ophthalmologic, 
and genetic history will also be obtained and will be used to prepare a pedigree for each family. Demographic 
information and clinical information specific for the participant’s disease will be collected, such as the duration 
of symptoms, presence of night blindness, visual acuity, and the amplitude of a combined response 
electroretinogram. 
 
Participants will undergo phlebotomy to provide a blood sample to the repository.  Phlebotomy may be 
performed at the laboratory of the participant’s choice.  Around 24 to 30 ml of blood will be drawn from 
adults; the volume of blood drawn will be within NIH guidelines for children and will be no more than 7 ml/kg 
/6 week period and no more than 3ml/kg in a single draw. A minimum of 5 ml of blood is required from 
children and a minimum of 15 ml of blood is required from adults to be able to participate.  
 
Molecular genetics testing will be performed in a CLIA-certified lab, and individual participant results will be 
given back to the referring clinician, although it may take several months to complete the sample analysis. 
Participants who wish to receive results of the testing will receive pre- and post-testing genetic counseling. 
Referring clinicians are required to certify that they are able to provide or arrange for both pre- and post- 
testing genetic counseling before they are permitted to enroll participants in the study. 
 
 
   
b. Inclusion/Exclusion Criteria - As appropriate, explain what steps will be taken to insure that subjects meet 
the criteria (e.g. healthy, not pregnant, etc). 
 
Inclusion Criteria 
To participate in this protocol,  
1a. The participant must present with characteristics that meet minimal clinical criteria.  For a Diagnosis of 
Retinitis Pigmentosa this includes  photoreceptor degeneration established by reduced visual acuity, visual 
field constriction, night blindness, marked reduction of rod and cone ERG responses, and presence of 
intraretinal “bone-spicule” pigment on clinical examination..  
 OR 
1b. The participant must be a relative of an affected participant if analysis would help with the interpretation 
of an affected participant’s test results or to obtain some useful information as decided by the eyeGENE 
Research Study Group.  
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The participant must be willing and able to provide a suitable blood sample. 
 
Exclusion Criteria 
1. Severe systemic disease that compromises the ability of the referring clinician to obtain an adequate 
eye examination.  
2. Any disease or condition that makes it unsafe for a subject to provide a blood sample of at least 5 mL 
for children and at least 15 mL for adults. 
3. Inability to cooperate with phlebotomy and clinical examination. 
4. Those with impaired decision-making capability who do not have a legally-authorized representative. 
 
 
c. Discuss the number of experimental and control subjects, and explain the statistical basis for the 
numbers. 
The total number of participants to be enrolled for the entire eyeGENE study is 1,250; approximately 250 per 
year for five years.  At UMMHC, Dr Kaushal expects to enroll about 30 patients a year for 5 years. 
 
d. Does the study involve randomization?  
  
 
 
 If yes, please describe process. 
 
e. How long will each subject be enrolled in the study? 
The amount of time that each subject is involved with the eyeGENE study depends on how they choose to be 
affiliated with the study: 
If the participant wishes to take part in research, but do not want results of genetic testing or does not want to 
be re-contacted for future clinical study, the name and contact information of the participant will not be 
collected.  Age at the time when sample was donated will be recorded instead of date of birth. 
If the participant wishes to take part in research and in future clinical trials, but does not want results of 
genetic testing, the sample will remain identifiable in the central eyeGENE database to the personnel at NEI 
only. 
If the participant does not wish to be re-contacted in future clinical trials but wants the results of genetic 
testing, two years after clinical molecular diagnosis is complete the name and contact information of the 
participant will be removed and the date of birth will be converted to age (CLIA regulations require holding 
onto identifiable samples for two years after the sample has been processed if molecular test results are given 
back to the participant.). 
If the participant wants to be re-contacted for future clinical studies and wants the results of genetic testing, 
the samples will remain identifiable to personnel of NEI only.   
If the participant is an unaffected relative of an affected participant, s/he will not be contacted for future 
clinical studies, nor receive the results of genetic testing. The sample will remain identifiable in the central 
eyeGENE database to the personnel at NEI only. 
 
 
f. Provide a brief overview of what participation in the study will mean to each participant in terms of what 
he/she will experience.  Describe in order, each procedure, how long each procedure will take and how 
often each procedure will be performed.  Include doses & route of administration of any drugs and whether 
Yes  No x 
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the procedure or drugs would always, sometimes or never be required as part of the subject’s standard of 
care. 
 
Genetic testing is sometimes included as standard of care.   
Participants will undergo phlebotomy to provide a blood sample to the repository.  Phlebotomy may be 
performed at the laboratory of the participant’s choice.  Around 24 to 30 ml of blood will be drawn from 
adults; the volume of blood drawn will be within NIH guidelines for children and will be no more than 7 ml/kg 
/6 week period and no more than 3ml/kg in a single draw. A minimum of 5 ml of blood is required from 
children and a minimum of 15 ml of blood is required from adults to be able to participate.  
 
Molecular genetics testing will be performed in a CLIA-certified lab, and individual participant results will be 
given back to the referring clinician, although it may take several months to complete the sample analysis. 
Participants who wish to receive results of the testing will receive pre- and post-testing genetic counseling. 
Referring clinicians are required to certify that they are able to provide or arrange for both pre- and post- 
testing genetic counseling before they are permitted to enroll participants in the study. 
 
g. Is any aspect of this research study being conducted in the Medical School or a non-UMMMC facility?  If 
yes, please explain. 
 
no 
 
h. Will hospitalization be required as part of this research study? 
 
 
If yes, how long will subjects be hospitalized? 
 
i.   Will there be any material inducements or recruitment incentives given to research staff or research 
subjects as part of this research study?  (e.g., direct payments, free hospitalization, care) 
  
   
If yes, explain how much, the pay schedule, or any partial payments that will be given. 
 
 
DISCLOSURE OF CONFLICT OF INTEREST  
Investigators should disclose any financial arrangement they may have with a company whose product figures 
prominently in their research or financial arrangements they may have with company making a competing 
product.  The relationship should also be described in the informed consent documents.  In the case where 
the only relationship is that a company is sponsoring the research study, it is sufficient to prominently identify 
the sponsor on the front page of the consent form and to simply state “NONE” in the consent form under 
Conflict of Interest. 
 
Is there a conflict of interest?   
   
 
 
6.  RELATIONSHIP TO STANDARD THERAPY. 
Yes  No x 
Yes  No x 
Yes  No x 
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Describe the standard therapy that patients would receive if not in the research study.  Explain how this 
research intervention deviates from or replaces generally accepted standard therapy and justify the deviation. 
The alternative to participating in this study is not to participate.  This study does not provide treatment and 
does not replace any therapy that the participants’ doctors give them. 
 
 
 
7.  DESCRIBE THE POTENTIAL BENEFITS OF THIS PROJECT. 
Include hoped-for benefit to society, to the group of subjects or to individual subjects.   
In most cases there will be little or no direct benefit of this study to participants. Some subjects may benefit 
from the genetic testing and counseling provided under this protocol.  The study will yield generalizable 
knowledge about eye disease genetics. 
 
Address the risk/benefit ratio of the study.  If there are no direct subject benefits, this should be stated. 
 
This is a minimal risk study for adults. For minors, the research is category I: the research presents minimal risk 
to study participants.   
 
 
 
 
8.  DESCRIBE THE POTENTIAL RISKS TO SUBJECTS INCLUDE PSYCHOLOGICAL, ECONOMIC, LEGAL OR SOCIAL 
RISKS AS WELL AS PHYSICAL RISKS. 
 
Include the following information: 
 
a. Estimate likelihood of occurrence, severity, and duration.  If generally accepted quantitative estimates 
are available based on previous data, these should be stated.  Otherwise, qualitative estimates such as 
“rare”, “occasionally", or “frequently” may be used.  The committee needs scientific information about 
drug/device side effects so as to best judge the pros and cons of the study.  Do not simply cut and paste the 
consent form “Risk” section into this part of the protocol. 
The only physical risk or discomfort associated with this study is from phlebotomy to obtain the blood sample. 
Drawing blood may cause pain and carries a small risk of bleeding, bruising, dizziness and/or infection at the 
injection site. 
Medical information will only be obtained from an eye examination done as part of standard clinical 
evaluation for the subject’s condition. 
 
 
b. Explain what steps will be taken to protect against its occurrence, minimizing the harm, methods for early 
detection of harm, and what procedures will be followed to avoid serious injury (e.g. withdraw from study 
or dose reduction).   
While it is anticipated that the results of the molecular genetic studies will result only rarely in new 
information regarding a participant’s clinical diagnosis, genetic information resulting from these studies, if 
available, might affect their ability to obtain insurance coverage or employment.  In order to minimize this risk, 
when results of an NIH research study are reported in medical journals or at scientific meetings, the people 
who take part are not named and identified and pedigree structures are disguised in a fashion consistent with 
maintaining the scientific integrity of the report.  In most cases, the NIH will not release any information about 
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research involvement without written permission.  However, if the participant signs a release of information 
form, the NIH will give the requestor information from the participant’s medical record.  
 
This study involves the evaluation of a genetic condition and information relating to the family, such as 
adoption and paternity, may be revealed or information may become available about unsuspected family 
members who are affected.  This information will be maintained in confidential laboratory documents and 
medical records. 
Genetic pre and post test counseling will be provided to participants.   
 
 
d. Do you, as the PI, have equipoise regarding the study?  That is, are you comfortable with the risks in 
relationship to the knowledge gained?  If the study involves randomization, do you believe in the equality of 
the treatment arms? 
For a repository collection instrument such as described here, equipoise is not relevant. 
  
 
9.  CONFIDENTIALITY CONSIDERATIONS: EXPLAIN STEPS THAT WILL BE TAKEN TO INSURE THE 
CONFIDENTIALITY OF INFORMATION THAT IS OBTAINED IN THE COURSE OF THIS RESEARCH PROJECT.  
INCLUDE THE FOLLOWING: 
 
a. How will identifiers be used? 
Data and samples of all participants will be barcoded. Samples and data from subjects who did not wish to 
receive genetic test results or to have future contact will be irreversibly de-identified.  
 
All of those participants who want their sample to be anonymous and who do not wish to receive CLIA test 
results will have their samples coded and de-identified. The CLIA labs will have to de-identify any sample 
before they use it for their own research purpose. Similarly, in future outside researchers will only receive an 
anonymous sample with pertinent clinical information, but without any identifiers. 
 
The NIH will not release any information about research involvement without written permission.  However, if 
the participant signs a release of information form, the NIH will give the requestor information from a 
participant’s medical record. As a result of releasing results, genetic information resulting from these studies 
might affect a participant’s ability to obtain insurance coverage or employment. 
 
b. Where will data be stored? 
The application is being housed and run by NIH's Center for Information Technology (CIT).  CIT access to the 
server is limited to those performing setup and maintenance activities on the CIT servers.  Access to the 
database, either via the web application or direct SQL Server connection, is controlled by a User ID and 
password. Password complexity is determined by the HHS Secure One program and implemented in the 
database access programs. Access to the web server is via secure http protocol (https). Support and 
maintenance is either performed locally within the NIH network or by encrypted VPN access. 
 
CIT will implement and report on the NIST 800-53 security controls for a "moderate" security system.  Annual 
review of the security controls will be performed.  The certification will be renewed every 3 years. 
 
c. Besides the UMMS IRB and their representatives, who will have access to the research data? 
Access to participant data is only available as follows: 
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eyeGENE staff access is limited to the eyeGENE Director, the eyeGENE Coordinator, and the NEI Molecular 
Diagnostic Lab Assistant Director. 
eyeGENE support staff with access to all data is limited to the developer and maintenance staff, NEI IT security 
and software maintenance, and eyeGENE security study staff. 
Physicians, or those acting on behalf of a physician, may access their own participant’s data. Genetic testing 
results are “read-only” for such individuals, once the results are marked final by the CLIA lab. They will not 
have access to identifying information for patients they did not personally submit. 
CLIA diagnostic lab personnel will have full read access to data from participants that are referred to their lab 
for molecular diagnosis. Their ability to modify data in the participant file will be limited to inputting mutation 
data on the participant samples analyzed in their laboratory. CLIA lab personnel will able to see the patient 
identification number, their date of birth, their gender, and their other disease-specific phenotypic 
information.  They will NOT be able to view the patient name, referring physician or other contact 
information. 
A strict audit trail is maintained of any access to patient information by any eyeGENE user, which records the 
date and time of access and the name and organization of the user, which is reviewed periodically, which is 
used as a double-check to ensure that no unauthorized access to patient data has ever occurred. 
 
No information will be released to third parties other than the CLIA labs except or as requested by the 
participant in writing. 
 
 
d. When will the data/specimens be destroyed? 
CLIA regulations require holding onto identifiable samples for two years after the sample has been processed 
if molecular test results are given back to the participant. CLIA labs will be required to destroy identifying 
patient information after this period has elapsed.   
 
e. In the future, might other use be made of specimens collected as part of the research?  If yes, please 
describe.  
Samples and data from subjects who wish to receive CLIA genetic test results or to be contacted in the future 
will be linked to identifiable information that is kept in the eyeGENE database is protected by multiple levels 
of security. 
 
10.  ECONOMIC CONSIDERATIONS: 
 
In the course of this research project, might the subjects experience any additional expenses as a result of 
study participation?  This includes both out-of-pocket costs and expenses that might not be covered by 
medical insurance. 
 
  
 
 
If yes, please explain and justify. 
 
No patient or their insurance company, regardless of whether they are enrolled in an UMMHC clinical trial, will 
be responsible for the costs associated with genetic analysis of the blood sample.  
 
Yes x No  
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As a collaborating site, the investigators will adhere to the NEI eyeGENE protocol. The NEI eyeGENE protocol 
does not provide for funding of tasks other than the genotyping of the sample. As with other standards of 
care, patients or their insurance companies will be responsible for certain aspects of the procedure: 
phlebotomy, shipping, eye examinations and genetic counseling. The eyeGENE initiative allows for the funding 
of sample analysis, the cost of which would normally fall on the patient or their insurance company if that 
patient were not enrolled in the eyeGENE study. The cost of phlebotomy and shipping, for the patient is 
estimated to be $87 USD if they elect to pay out of pocket.  
 
If however genotyping must be completed for data collection as part of enrollment in a UMMHC protocol, this 
is no longer “standard of care” because the patient is a subject of research study and the responsibility of cost 
if slightly different. UMMHC protocols that involve the study of genetic information will be able to provide 
funding for all aspects of sample collection and analysis. 
 
b. Please explain potential increase in standard hospital costs if any. 
 
 
N/A 
11.  DESCRIBE THE CHARACTERISTICS OF THE SUBJECT POPULATION. 
 
a. The subject population includes: 
 
  ADULTS         x  CHILDREN           x 
 
b. Is the subject population restricted in respect to any of the following characteristics? 
   
  
Please “x” those that apply Yes No 
Age Range  x 
Health Status x  
Gender  x 
Racial/Ethnic composition  x 
 
 
If you responded YES to any of the above, include a clear rationale for this restriction. 
Severe systemic disease that compromises the ability of the referring clinician to obtain an adequate eye 
examination.  
Any disease or condition that makes it unsafe for a subject to provide a blood sample of at least 5 mL for 
children and at least 15 mL for adults. 
 
 
 
12.  WILL THE STUDY POPULATION SPECIFICALLY INCLUDE A POPULATION OF SUBJECTS CONSIDERED 
“VULNERABLE”?  VULNERABLE POPULATIONS ARE CHILDREN, MENTALLY IMPAIRED, PREGNANT WOMEN, 
PRISONERS, OR FETUSES. 
 
   
 
 
If yes, please explain. 
Yes x No  
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Children will be enrolled in this protocol if they have one of the diseases being studied.  Pregnant women may 
be enrolled if they have one of the diseases being studied. 
 
13.  WHAT IS THE SOURCE OF THE SUBJECT POPULATION? 
 
Participants will be patients of the UMMMC Ophthalmology clinic. 
 
14.  EXPLAIN ANY STEPS TAKEN TO INSURE THAT THE SUBJECT POPULATION IS REPRESENTATIVE. 
 
No restriction on the form or genotype of ocular disease will be instituted and as such it is expected that the 
recruited patients will be representative of all patients. 
 
 
15.  HOW AND WHERE WILL SUBJECTS BE RECRUITED FOR THE STUDY?  CONSULT THE IRB GUIDELINES FOR 
THE RESTRICTIONS ON RECRUITMENT OF EMPLOYEES, STUDENTS, AND INPATIENTS. ATTACH COPIES OF ALL 
RECRUITMENT MATERIALS TO BE USED AS PART OF THIS RESEARCH STUDY.  THESE MATERIALS MUST BE 
APPROVED BY THE IRB BEFORE BEING USED. Recruitment guidance can be found on our website under HSC 
Forms. 
Recruitment will not be performed with the use of advertisements. Potential participants thought to be 
appropriate for genetic testing either for additional data, for clinical trials, or for standard of care will be 
approached by the investigator or co-investigator. Potential participants will be approached in the clinic 
setting at the time that the investigator or co-investigator discovers that participation is possible. Relatives will 
be identified by the potential participant and will be contacted by study personnel with the potential 
participant’s cooperation and permission. 
 
16. WILL PROTECTED HEALTH INFORMATION (PHI) BE USED AS PART OF THIS RESEARCH STUDY?  PLEASE 
VISIT OUR WEBSITE FOR MORE INFORMATION ABOUT PHI OR THE HEALTH INSURANCE PORTABILITY AND 
ACCOUNTABILITY ACT (HIPAA). 
  
Depending on whether the participant chooses to enroll in research that requires the 
storage of protected health information: see section 4e. 
  
 If yes, please answer the following questions. 
 
How and where will the PHI be accessed (i.e. meditech, database,medical records, another site)? 
 
 
 
 
Will a subject’s PHI be accessed before the subject is enrolled in the study? 
 
 
 
 
Please list the PHI to be used as part of this research study (i.e. name, DOB, medical record #). 
 
Yes X (in 
some 
cases) 
No X (in 
some 
cases) 
Database, medical records 
Name, DOB, Contact information (address, phone #) 
NO 
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17.  METHOD FOR OBTAINING INFORMED CONSENT 
 
a. Are you requesting a waiver of the requirement for obtaining consent? 
 
 
   
 
 
Do not complete the following questions if you are requesting a waiver of informed consent. 
 
18.  WILL VERBAL CONSENT BE OBTAINED? 
 
   
If yes, will an unsigned “fact sheet” be given to subjects before verbal consent is obtained? 
 
 
   
 If yes, please provide a copy of the “fact sheet”. 
 
19.  WILL A SIGNED CONSENT FORM BE REQUIRED? 
 
  
 
 
AS A GROUP, ARE THESE SUBJECTS EXPECTED TO BE COMPETENT TO GIVE CONSENT FOR THEMSELVES? 
 
 
 
   
 If no, please explain why and how consent will be obtained. 
 
21. EXPLAIN THE CIRCUMSTANCES UNDER WHICH CONSENT WILL BE OBTAINED.  HOW WILL YOU INSURE 
THAT POTENTIAL SUBJECTS HAVE ADEQUATE TIME TO CONSIDER THEIR OPTIONS, AND THAT POSSIBLE 
COERCION IS MINIMAL? 
All participants will receive a verbal explanation in terms suited to their comprehension of the purposes, 
procedures, and potential risks of the study. The participants must have the ability to understand and sign an 
informed consent form, or have a legally-authorized representative to sign for them. All affected participants 
will receive the standard consent, while unaffected relatives will receive a separate consent. 
 
Yes  No x 
Yes  No x 
Yes  No  
Yes x No  
Yes x No  
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If the participant requires the consent to be in larger font in order to read it well, this will be provided. If 
participants are visually impaired to the point of being unable to read the consent, they can take the consent 
back with them to read it over with a family member or with the use of magnifying devices.  If the participant 
chooses, the investigator can also read the consent verbatim to the participant and answer any questions that 
may arise. We do not anticipate a large percentage of potential participants to be unable to read. Should a 
potential participant be illiterate, the consent will be read verbatim and care will be taken to ensure 
comprehension by the participant of the information presented in the consent as the document is read. 
 
 
 
22.  IF THE SUBJECT POPULATION INCLUDES MINORS, AND SIGNED CONSENT WILL BE OBTAINED, WILL AN 
ASSENT FORM BE USED AS PART OF THE CONSENTING PROCESS?  CONSULT IRB GUIDELINES FOR 
INFORMATION ABOUT CHILDREN IN RESEARCH STUDIES. 
 
 
 
 
NOTE: In general, it is expected that minors from age 8 to 15 will read and sign an assent form.   Older 
adolescents (16 and 17) will usually read and sign the same consent form as the parents signed.  The assent 
form template is available on our website. 
 
 
 
23.  IF YES, PLEASE EXPLAIN WHO WILL APPROACH THE MINORS AND HOW AND WHERE THE  ASSENTING 
PROCUDURE WILL TAKE PLACE.  
 
Children will be enrolled in this protocol if they have one of the diseases being studied.  Phlebotomy will only 
be done on those able to cooperate and can provide a minimum of 5 ml of blood sample.  Consent will be 
obtained from parents or guardians; assent will be sought from minors older than 7. Genetic information will 
be released to the parents or guardians, if requested.   For those reaching age 18 with stored samples in the 
study, if they express an interested in being contacted about research participation, they will sign a new 
consent form. It will be the responsibility of the study coordinator to contact these patients to arrange for 
consent to be obtained. At that time, these now adult patients will again be made aware of their rights 
concerning the study. 
  
Yes x No Minors enrolled  Verbal consent requested  
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SECTION VI 
CERTIFICATION OF APPROVAL 
PI Name:  Shalesh Kaushal, MD PhD 
DELEGATION OF ROLES/RESPONSIBILITIES*:  Checklist/Signature List 
 
Please type 
Name and 
Credentials 
 
Role* 
 
Signature 
 
Department/Campus 
Delegation of responsibilities: Please 
use key** in box below to summarize 
your study activities and place an “x” in 
the appropriate column 
A B C D E F G H I J 
 
Shalesh Kaushal 
MD PhD 
 
PI  Ophthalmology/ 
UMMMC 
* * *   * * * * * 
Christine Clemson 
PhD 
 
Study 
Coordinator 
 Ophthalmology/ 
UMMS 
     * * * * * 
George Asdourian 
MD 
 
Co-I  Ophthalmolgy/ 
UMMMC 
* * *       * 
Judith Colbert RN 
 
Study 
Nurse 
Coordinator 
 Ophthalmolgy/ 
UMMMC 
* *  * *     * 
 
 
             
 
 
             
              
 
 
             
 
 
             
*Roles: (choose appropriate # below) 
1. Sub or Co-Investigator  2. Study Nurse Coordinator 3. Study Coordinator 4. Other: 
Dr Kaushal and Asdourian will provide pre and post genetic counseling, Dr. Clemson will coordinate all communication 
with eyeGENE coordinating center; Judith Colbert will mail blood samples to eyeGENE coordinating center. 
**Delegation of Responsibility Codes: (choose all that apply) 
A. Consent Subjects F.  Maintain Regulatory Documents 
B. Take Medical History G. CRF Completion and Query Resolution 
C. Conduct Physical Exam H. SAE/AE Monitoring/Reporting 
D.  Phlebotomy I.   IRB Communications and Continuing Review 
E. Monitor Vital Signs/Nursing Assessment J. Other (explain): 
Although the Principal Investigator is ultimately responsible for every element of study activity, this form serves to clarify to whom 
the PI has delegated specific study activities and responsibilites 
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3.6.2 GENOTYPING CONSENT FORM 
 
UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL 
COMMITTEE FOR THE PROTECTION OF HUMAN SUBJECTS IN RESEARCH 
 
CONSENT TO PARTICIPATE IN A RESEARCH PROJECT 
 
Title:  National Ophthalmic Genotyping Network, Stage 1 – Creation of Repository for Inherited 
Ophthalmic Diseases.    Study # 06-EI-0236 
 
Principal Investigator:  Shalesh Kaushal, MD, PhD  
    
Sponsor:  National Eye Institute (NEI) at the National Institute of Health (NIH) 
 
Research Subject’s Name:                                                                Date:                              
 
Invitation to Take Part and Introduction 
 
We invite you to take part in a research study here at the University of Massachusetts 
Memorial Medical Center (UMMMC), that is a part of a larger study at the National 
Institutes of Health (NIH). First, we want you to know that:  
 
Taking part in this NIH sponsored research is entirely voluntary.  
 
You may choose not to take part, or you may withdraw from the study at any time. In 
either case, you will not lose any benefits to which you are otherwise entitled.  
 
You may receive no benefit from taking part. The research may give us knowledge 
that may help people in the future.  
 
Second, some people have personal, religious or ethical beliefs that may limit the kinds 
of medical or research treatments they would want to receive. If you have such 
beliefs, please discuss them with your doctor before you agree to the study.  
 
Now we will describe this research study. Before you decide to take part, please take 
as much time as you need to ask any questions and discuss this study with anyone at 
the UMMMC clinic, or with family, friends or your personal physician or other health 
professional.  
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In the remainder of this consent, we will use the word “you” to mean either “you” or 
“your child,” as applicable. 
 
Purpose of Research 
The purpose of this study is to better characterize and understand the genes involved 
in eye disease. A “bank“ of DNA, blood samples, and eye examination information will 
be created for use in future studies on eye diseases. 
 
The main goal of this research is to understand genetic eye conditions and to identify 
the genetic factors responsible for causing such diseases. DNA samples from a large 
number of people with different eye diseases is needed. The eyeGENE network has 
been set up to enroll people with eye disease, to obtain information on their eye 
examinations, and to collect blood from which the genetic material, DNA, will be 
extracted. The information and samples obtained will be used to test for genes that 
might be involved in the eye disease in your family and will also be placed in a 
repository to make it available to other researchers, now and in the future, who are 
studying eye diseases.  
 
If you are planning to take part in this research study, we would also want you to know that:   
 
You or your insurance company will have to pay for the cost of drawing the blood and shipping 
it to NEI, as well as the genetic counseling. However, analysis of the genetics sample will be 
completed at no cost to you. 
 
If you decide that you do not want to participate in this study you should know that there are 
several other genetics testing laboratories you can approach to obtain your genetic test results 
on a fee-for-service basis.  
 
You will be asked to provide a blood sample and information on your eye condition and family 
history, as well as demographic information.  
 
Your sample will be kept at a DNA and blood repository at the NEI.  
 
Your personal and medical information will be kept in a secure database.  
 
You will need to choose whether 1) you wish to receive genetic results back and 2) if you wish 
to be re-contacted for future clinical or research studies and, if additional tests for your 
disease are found, if you wish to receive the results for these new tests.  
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The amount of personal information you need to provide depends on whether you wish to 
receive results or wish to be re-contacted. Your personal information needs to be maintained 
in the secure eyeGENE database if you wish to be re-contacted.  
 
The time period to obtain genetics testing results back may vary from 3 months to one year 
depending on your disease and the genes that are being tested.  
 
To be eligible for this study, you must meet the following criteria:  
 
1. You or your child must have one of the eye diseases we are currently studying.  
Your UMMMC ophthalmologist will make this determination.  
2. You/Your child must be able to provide a blood sample for genetic testing.  
You may not be eligible for this study if:  
1. You have any disease that makes it impossible to obtain the eye examination 
information that we need for the study or to obtain a blood sample.  
2. You are unable to provide consent for yourself and do not have a legally-authorized 
representative to provide consent for you.  
 
Procedures  
The study doctors believe that you/your child qualifies as a potential participant in this 
trial based on your/your child’s clinical data. We will provide information on your 
medical history and about eye conditions in yourself and your family to the NEI 
coordinating center.  You will need to provide a blood sample. For the blood sample, 
about 5 to 6 teaspoons of blood will be drawn from a vein in your arm. Less blood will 
be drawn from those younger than 12 years.  
Your sample along with medical details will be sent to eyeGENE, who will check all the 
information provided and if they agree that you are eligible then they will send your 
sample for testing for specific genes that are known to contribute to your condition. 
The remaining blood will be stored for use in future approved research studies.  
The eyeGENE coordinating center will send your sample for testing in an approved 
clinical laboratory that is a part of their network. If you would like to receive the results 
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of your genetic testing, they will be sent to our clinic and your physician will share the 
results with you. You will be required to sign a second consent form (a DNA 
diagnostics form) and receive genetic counseling from a UMMMC Ophthalmology clinic 
physician. The genetic counseling will help you to understand the implications of 
genetic testing and of the results of your genetic test. You will only receive results 
from yourself and/or your minor children.   
Please indicate whether you would like to receive the results of your initial genetic 
testing by initialing the box next to your choice.  
A1.______ I would like to receive the results of my genetic testing that will be 
performed at this time. I understand that the results will be sent to my doctor, who 
will give them to me. I agree to meet with my doctor who will provide genetic 
counseling and assist me in understanding the results of the testing.  
The time period to obtain genetics testing results back may vary from 3 months to one 
year or more depending on your disease and the genes that are being tested.   
A2. _____ I do not want to receive the results of the genetic testing that will be 
performed at this time.  
The blood that is stored may be tested in the future for genes that are not currently 
known. Please indicate whether you would like to receive the results of future genetic 
testing by initialing the box next to your choice.  
B1.______ I would like to receive the results of any genetic testing on my sample that 
may be performed in the future. I understand that the results will be sent to my 
doctor, who will give them to me, I agree to meet with a genetic counselor who will 
assist me in understanding the results of the testing.  
B2. _____ I do not want to receive the results of any genetic testing that may be 
performed in the future.  
 
The eyeGENE network will maintain medical examination and family history 
information on you as well as your DNA and blood sample. Other researchers may like 
to study the medical information on your eye disease and your sample. Researchers 
who use samples and medical information with approval of eyeGENE in the future will 
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not know your name. Your personally identifying information will not be disclosed to 
any other people without your consent.  
In the future, researchers will be able to see the results of your genetic testing and 
some information about your eye condition. Examples of such information will include 
the nature of your eye disease status, age when you were evaluated, demographic 
information (such as your age, gender, and race/ethnicity). Other information such as 
pictures of your eye or your history of other diseases may also be available. 
Researchers may view this information to study other diseases or conditions, or for 
other purposes. Researchers will NOT be able to view your name, date of birth or 
contact information. Your DNA/ blood sample will ONLY be used for research studies 
related to vision.  
 
Use of Blood and DNA Samples and Results from this Study  
If the results of any genetics study, in which your DNA/blood was included, are 
reported in medical journals or at scientific meetings, your name will not be used, nor 
will you be identified in any other manner. Family trees may be published but they 
would be trimmed and masked to minimize the possibility of patient identification.  
 
Future research participation  
We hope that researchers using samples and information from the eyeGENE repository 
will also develop new clinical studies of eye disease in the future, and we would like to 
be able to offer you information on new studies that might interest you. Participation 
in future studies is completely voluntary. You do not have to participate in any 
additional studies in order to participate in this study.  
Please let us know if you would like eyeGENE to contact you about future studies. If 
you would like us to hold onto your contact information and let you know if such a 
study arises, please indicate so below: 
 
YES, please re-contact me if you become aware of a clinical study that I may 
qualify.  
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Please note, that in order to make our records as accurate as possible, we 
request that you notify us of any contact information changes. Please send 
an email with the updated address to the eyeGENE Coordinator at 
eyeGENEinfo@nei.nih.gov or contact the eyeGENE coordinator at 301-435-
3032  
____NO, please do not re-contact me for further studies.  
 
Risks, Inconveniences and Discomforts  
Risks of Drawing Blood – A needle will be used to draw blood from a vein in your arm. 
You may experience some discomfort at the site of needle entry, and there is a risk of 
bruising. There is a very small risk of fainting or infection.  
Risks of genetic testing - Genetic testing can provide information about how health or 
illness is passed on within your family. This knowledge may affect your emotional 
wellbeing. This information can cause stress, anxiety, or depression. Some genetic 
testing can also determine if people are directly related. These tests sometimes show 
that people were adopted or that their biological parent is someone other than their 
legal parent. If these facts were not known previously, they could be troubling. Genetic 
counseling will be available to help you understand the nature and implications of your 
and your family’s genetic findings. We will not discuss such information with you 
unless it has direct medical implications for you or your family, which is unlikely.  
Genetic information about you will not be revealed to others, including your relatives 
or your insurance company, without your written permission. Similarly, you will not 
receive information about other family members. You may only receive information 
about yourself or your minor children. Parents are entitled to copies of their minor 
child’s medical records without consent of the child.  
Problems, such as with insurance or employment discrimination, may occur if you 
disclose information about yourself or agree to have your research records released. 
We will not release any information about you or your family to any physician, 
insurance company or employer unless you sign a document allowing release of the 
information.  
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Potential Benefits  
You may benefit from participating in this study by learning more about the genetic 
basis of your eye disease. We also hope to gain knowledge that may help you, your 
family members, or others with eye disease in the future.  
Right of Withdrawal  
You have the right to withdraw from the study at any time and for any reason.  
Upon your request, we can remove your sample at the repository or permanently 
remove all identifying information from the repository and the collaborating DNA  
diagnostic lab. Your sample can be destroyed (when possible) on your written request.  
However, we are not able to retrieve portions of your sample that may have been 
already distributed to researchers. If your sample has already had all identifying 
information removed, we would not be able to identify your sample in order to destroy 
it.  
 
Compensation/Cost of Participation  
You will not be paid to participate in this study. Genetic testing will be provided at no cost, 
however, you or your insurance company will be responsible for the costs of drawing blood 
and for shipping the blood sample to NEI, and for the eye examinations and genetic 
counseling.   
 
Alternatives to Participation  
You do not have to participate in this study in order to have genetic testing or genetic 
counseling for your eye disease. These services can be provided through your health 
care provider. This study does not provide treatment and does not replace any therapy 
that you may be receiving from your own physician. You may choose not to participate 
in this study.  
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Confidentiality  
Your samples and medical information will be assigned a unique specimen code. Only 
the specimen code will be used to identify them. The identifiable information that you 
provide is protected in a secure eyeGENE database with multiple levels of security and 
only limited authorized eyeGENE personnel will be granted access to this information. 
No researchers using your samples or medical information will receive any information 
that could personally identify you, unless you have opted to be re-contacted in the 
future and have given us permission to provide your information to the researcher.  
To help protect your privacy, eyeGENE has obtained a Certificate of Confidentiality for 
this research study. With this Certificate, the researchers cannot be forced, for 
example, by court subpoena to disclose information that may identify you, in any 
federal, state, or local civil, criminal, administrative, legislative, or other proceedings. 
However, the Certificate cannot be used to resist a demand from the Department of 
Health and Human Services or other offices in the United States Government for audit 
and evaluation purposes, nor does it preclude voluntary disclosure.  
You should understand that a Certificate of Confidentiality does not prevent you or a 
member of your family or researchers from voluntarily releasing information about 
yourself or your involvement in this research. If an insurer, employer, or other person 
obtains your written consent to receive research information, then the researchers may 
not use the Certificate to withhold that information.  
Although every reasonable effort will be made to protect the confidentiality of your 
medical records, a potential risk for possible breach of confidentiality exists and 
absolute protection cannot be guaranteed.  
Information kept at the University of Massachusetts Medical Center:  You 
have the right to privacy.  All information obtained from this research that can be 
identified with you will remain confidential within the limits of the law. The study 
doctor and other people associated with this research will keep information about your 
participation in locked files. They will restrict access to the information in these files to 
persons directly involved with the research. 
Information available to other people:  Representatives of the Food and Drug 
Administration (FDA) and the Data and Safety Monitoring Board may review your 
medical and research records to assure the quality of the information used in the 
research. The FDA may photocopy your medical and research records to verify 
information submitted to the FDA.  
An Institutional Review Board (IRB) is a group of people who are responsible for 
assuring the community that the rights of participants in research are respected. 
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Members and staff of the IRB at this medical center may review the records of your 
participation in this research. A representative of the Board may contact you for 
information about your experience with this research. If you wish, you may refuse to 
answer any questions the representative of the Board may ask. 
 
YOUR  QUESTIONS:  The study doctor is available to answer your  questions about 
this research. The Chairman of the IRB is available to answer questions about your 
rights as a participant in research or to answer your questions about an injury or other 
complication resulting from participating in this research. You may telephone the 
Chairman of the IRB during regular office hours at (508) 856-4261 
 
YOUR WILL HAVE A COPY OF THIS CONSENT FORM TO KEEP. 
 
Your signature below certifies the following: 
• You have read (or been read) the information provided above. 
• You have received answers to all of your questions. 
• You have freely decided to participate in this research. 
• You understand that you are not giving up any of your legal rights. 
 
 
CONFLICT OF INTEREST DISCLOSURE  
NONE 
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CONSENT TO PARTICIPATE IN THE RESEARCH PROJECT 
 
Title:   National Ophthalmic Genotyping Network, Stage 1 – Creation of Repository for 
Inherited Ophthalmic Diseases.   
 
P.I. Name:      Shalesh Kaushal, MD, PhD                                                     
Subject’s Name:                                                  
I understand the purpose and procedures of this research project and the predictable 
discomfort, risks, and benefits that might result.  I have been told that unforeseen 
events may occur.  I have had an opportunity to discuss the risks and benefits of this 
research with the investigator and all of my questions have been answered.  I agree to 
participate as a volunteer in this research project.  I understand that I may end my 
participation at any time.  I have been given a copy of this consent form. 
 
                                                                                                   Date:                                          
 Subject’s signature 
Subject’s Legal Representative, if appropriate: 
Name:           Relationship to Subject:                                      
  (Print)   
                                                                                           Date:                                            
Legally Authorized Representative or Family Member Signature 
 
 
 
Witness Name:                                                         
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                (Print) 
  
Witness Signature:                                                               Date:                                           
  
STATEMENT OF PERSON OBTAINING CONSENT 
I, the undersigned, have fully explained the details of this clinical study as described in 
the consent form to the subject named above. 
 
______________________________________________ Date: ________________ 
 Signature of person obtaining consent 
 
 INVESTIGATOR’S DECLARATION 
As the principal investigator or co-investigator on this study, I attest to the following: 
 the nature and purpose of the study and study procedures, as well as the 
foreseeable risks, discomforts and benefits have been explained to the above-
named subject 
 this subject has been given the opportunity to ask questions and to have those 
questions answered by knowledgeable research staff 
 this subject meets the inclusion/exclusion criteria for this study 
I have considered and rejected alternative procedures for answering this research 
question.  
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3.6.3 GENOTYPING ASSENT FORM 
 
UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL 
COMMITTEE FOR THE PROTECTION OF HUMAN SUBJECTS IN RESEARCH 
 
ASSENT TO PARTICIPATE IN RESEARCH 
 
Title:  National Ophthalmic Genotyping Network, Stage 1 – Creation of 
Repository for Inherited Ophthalmic Diseases.    Study # 06-EI-0236 
 
Principal Investigator:  Shalesh Kaushal, MD, PhD  
    
Sponsor:  National Eye Institute (NEI) at the National Institute of Health (NIH) 
 
My name is ______________________________________. 
    Name of person obtaining assent 
 
We are asking you to take part in a research study because we are trying to learn 
more about eye diseases that affect people. We are interested in people who may 
have an eye disease, which was passed onto them from their family members or was 
present from the day they were born. 
 
If you agree to be in this study the doctor will look at your eyes. Depending on what 
type of eye disease you have, he will perform different tests, which may include 
shining a bright light, using eye drops, or taking photographs of your eye/back of your 
eye. Your doctor will explain everything to you. 
 
As a part of this research, your doctor will take about one tablespoon of blood from 
your arm and send it to the National Eye Institute for research and tests. He may 
numb the area with some cream first. You still might feel a little pinch or pressure. 
 
You may have a little bleeding from the area where the doctor takes blood and you 
might have a bruise. 
 
You may benefit from participating in this study by learning more about how and why 
people can get your eye disease. We also hope to gain knowledge that may help you, 
your family members, or others with eye disease in the future. 
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Please talk this over with your parents before you decide whether or not to participate. 
We will also ask your parents to give their permission for you to take part in this study.  
But even if your parents say “yes” you can still decide not to do this. 
 
Your participation is entirely voluntary.  If you don’t want to be in this study, you don’t 
have to participate. Remember, being in this study is up to you and no one will be 
upset if you don’t want to participate or even if you change your mind later and want 
to stop. 
 
You can ask any questions that you have about the study. If you have a question later 
that you didn’t think of now, you can call me at 508-334-6855 or ask me next time. 
 
Signing your name at the bottom means that you agree to be in this study. You and 
your parents will be given a copy of this form after you have signed it. 
 
 ASSENT TO PARTICIPATE IN THE RESEARCH PROJECT 
Title:   National Ophthalmic Genotyping Network, Stage 1 – Creation of Repository for 
Inherited Ophthalmic Diseases.   
Subject’s Name:_______________________________                                                  
 
I have had this study explained to me in a way that I understand, and I have had the 
chance to ask questions. I agree to take part in this study. 
                                                                                          Date:                                          
Subject’s signature 
_____________________________________________Date: ________________ 
Signature of person obtaining assent 
____________________________________________Date: ________________ 
Signature of Investigator 
3.6.4 GENOTYPING HIPPA AUTHORIZATION 
    
UMass Memorial Medical Center 
AUTHORIZATION TO DISCLOSE  
PROTECTED HEALTH INFORMATION FOR RESEARCH PURPOSES 
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The privacy law, Health Insurance Portability & Accountability Act (HIPAA), protects my individually identifiable health 
information (protected health information).  The privacy law requires me to sign an authorization (or agreement) in order 
for researchers to be able to use or disclose my protected health information for research purposes in the study entitled:  
National Ophthalmic Genotyping and Phenotyping Network, Stage 1 — Creation of DNA Repository for 
Inherited Ophthalmic Diseases 
 
I authorize UMass Memorial Medical Center to disclose my protected health information to : 
 
 UMass Medical School including the researcher Dr. Shalesh Kaushal and his/her research staff 
 Federal and State authorities that oversee research 
 The eyeGENE National Ophthalmic Disease Genotyping Network 
 
Protected health information (PHI) that may be disclosed includes all “x” boxes, and PHI which is listed in the sections titled “other” 
below. 
[PI, “X” relevant boxes below, double click on box to “X”]: 
     General Records 
  Cardiac Studies (Heart)   Laboratory Reports 
  Consultations   Office/Clinic Notes  
  Discharge Summaries   Operative/Procedure Reports 
  EEG/EMG/Sleep Studies   Pathology Reports 
  Emergency Service Records   Problem List 
  Home Health Records   Pulmonary Studies (Lung/Respiratory) 
  Hospice Records   Radiology (X-ray/CAT/MRI/Ultrasound/Nuclear)  
  Immunization Records   Rehabilitation Notes (PT/OT/Speech) 
Other (Specify):    Name, Date of Birth, Contact information, race, ethnicity, results of genetic testing, family history, medical 
history, information about your eye disease,  results of ophthalmic tests 
    Statutorily Protected Records 
  Abortion   Domestic Violence Counseling 
  Alcohol / Drug Abuse   HIV / AIDS Test Results / Treatment 
  Psychiatric Health   Sexually Transmitted Diseases 
  Sexual Assault Counseling  
Other (specify):  
 
 
My protected health information will be disclosed as listed above for the following reasons: 
 
The purpose of this study is to better characterize and understand the genes involved in eye disease. 
A “bank“ of DNA, blood samples, and eye examination information will be created for use in future 
studies on eye diseases.  
 
 
 
I do not have to sign this Authorization.  If I decide not to sign the Authorization: 
 It will not affect my treatment, payment or enrollment in any health plans, or affect my 
eligibility for benefits.   
 I will not be allowed to participate in the research study. 
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If I sign the Authorization, I understand that: 
 
 I have the right to withdraw, or revoke, the Authorization. 
 If I revoke the Authorization, I will send a written letter to: Dr. Shalesh Kaushal, Dept of 
Ophthalmology, Rm S6-410; UMMS, 55 Lake Ave. N, Worcester, MA 01605 to inform him or 
her of my decision. 
 If I revoke this Authorization, researchers may only use the protected health information 
already collected for this research study. 
 If I revoke this Authorization my protected health information may still be used and disclosed 
should I have an adverse event (a bad effect). 
 If I change my mind and withdraw the authorization, I will not be allowed to continue to 
participate in the study. 
 Any disclosure carries the potential for re-disclosure. Once UMass Memorial Medical Center 
releases my protected health information, it may no longer be protected by the HIPAA privacy 
rule.  
 The entities receiving my protected health information will use it as described in the Consent 
Document for this study.  
 I may not be allowed to review some of the research-related information in my medical record 
until after the study is completed.  When the study is over, I will have the right to access the 
information again. 
 I will receive a signed copy of this authorization for my personal records. 
 
 
This Authorization does not have an expiration date. 
 
If I have questions about the research study, I should contact: Dr. Shalesh Kaushal, at Ph: 508 
334-0687 
 
If I have not already received a copy of the Privacy Notice, I may request one.  If I have any 
questions or concerns about my privacy rights, I should contact the UMass Memorial Medical Center 
Privacy Officer at Ph: 508-334-5551. 
 
I HAVE READ AND UNDERSTAND THE ABOVE STATEMENTS AND AUTHORIZE THE 
DISCLOSURE OF THE INFORMATION REQUESTED ABOVE. 
 
 
Signature of Subject Date 
Subjects Name Printed DOB SS# 
 
Use boxes below if parent or legal representative is signing for research subject 
 
Subject’s Legal Representative Signature Relationship Date 
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Print Name of Research 
Subject DOB SS# 
 
 
 
Please explain Representative’s Relationship to Patient and include a description of Representative’s 
Authority to act on behalf of Patient: 
__________________________________________________________________________________
__________________________________________________________________________________
______________________________________________ 
 
 
 
Person obtaining HIPAA authorization  Date 
 
NOTE TO PI: 
 
Forward the original signed authorization to: 
 
Health Information Management – Room HB 354 
UMass Memorial Medical Center 
55 Lake Avenue North 
Worcester, MA. 01655 
 
Give a copy of the signed authorization to the research subject, and keep a copy for your study files. 
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3.6.5 CLINICAL TRIAL APPLICATION 
 
PROTOCOL SUMMARY SHEET 
Today's Date: 5/22/09  
P.I. Name: Shalesh Kaushal Degree: MD PhD  
(PI Must be UMMS Faculty Member) Faculty Title: Chair and Assoc. Professor 
Department: Ophthalmology 
Division Name:  Duration of the Study: 60 weeks 
Phone # 508 334-0687  Total # of subjects at UMMMC: 45 
Beeper/Pager#:   Total # of subjects at off-site locations : 
45 
 
Email Address: Shalesh.kaushal@umassmemorial.org 
Title of Study: (type 
right) 
Phase II Clinical Trial of Valproic Acid for Retinitis Pigmentosa 
 
 
( Protocol # and version) 
 
 
 
 
 "X" below which sites will participate 
Contact Person Name Christine Clemson, PhD Phone # 508 856-4808 University:   
Pager 
# 
  Memorial : X 
Identify Condition being studied: Retinitis Pigmentosa Marlborough:  
 Shriver Center:  
Source of Funding: Departmental Others:  
 
DEVICE INFORMATION                              DRUG INFORMATION 
Please provide IDE# if not approved by FDA   In the table below, list all drugs being used.  If the drug  
considered investigational by the FDA you must include th  
IND# assigned by the FDA.  Please "X” approved o  
investigational. 
Device Name Approved Investigational IDE# 
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USE SPACE BELOW FOR COMMENTS OR ADDITIONAL DRUG 
INFORMATION 
 
Drug Name: Approved Inves. IND# 
 Valproic Acid  X Pending 
    
    
    
    
    
 
DECRIBE THE RESEARCH BY CHECKING ALL THE ITEMS “YES” OR “NO” 
 
Yes No  Yes No  Yes No  
x  On Site at UMMS/UMMMC x  Adults x  Questionnaires (please provide) 
x  Multicenter Study  x Pregnant Women  x Filming/video/audio 
 x Cooperating Institutions  x Minors (under 18) x  Marketed drugs 
 x Research Currently Funded  x Teenagers ( 12-17)  x Diagnostic Radiation  
 x Financial interest involved  x Prisoners  x Therapeutic Radiation 
x  Funding applied for  x Fetuses / Abortuses  x MRI 
 x UMMMC inpatients x  Randomization  x Ultrasound 
x  UMMMC outpatients x  Placebo  x Radioisotopes 
 x Normal volunteers x  Investigational drugs/device  x Radiation involved? 
 x Other  x Increased hospital costs  x Would receive radiation regardless 
x  Males  x Mental Impairment  x Radiation Safety Approval Needed? 
x  Females  x Data bank  x Biosafety Review Needed? 
 x Phase I Study x  Phase II Study  x Phase III Study 
 
 
SECTION V 
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 DESCRIPTION OF RESEARCH PROJECT 
 
 
PERSONNEL ENGAGED IN THE RESEARCH STUDY.  List all personnel engaged in the study.  This list 
must agree with that in Section VI (Delegation of roles/responsibilities). 
 
Shalesh Kaushal, M.D. PhD. will serve as a Principal Investigator of this study providing oversight for all aspects of the 
design and performance of the clinical treatment. He will oversee and participate extensively in the screening of 
participants, and will make the ultimate determination of whether a recruit is a suitable subject.  Dr. Kaushal will be 
involved in the baseline and ongoing follow up assessments of all participants, and will interact closely with the creation 
of and communication with the DSMB.  Dr. Kaushal will be responsible for assessing and reporting adverse events, as 
well as closing monitoring the clinical and serum profiles of the second cohort on escalating dosages. Dr. Kaushal will 
provide pre and post test genetic counseling to participants who choose to be genotyped.  
 
 
Christine Clemson, PhD. will serve as the Study Coordinator of this trial, providing oversight for all aspects of the design and 
performance of this project. In particular, Dr. Clemson is responsible for the pre-clinical analysis, clinical trial development and 
details, and all regulatory applications and reporting.   Dr. Clemson is completing an intensive 2 year Masters Program in Clinical 
Investigation.  Dr. Clemson is combining this professional development with her 15 years of experience as a cell biologist to 
implement a “translational” approach to this clinical trial.  Her unique and broad set of skills is instrumental in the unique multi-
layered study design which will allow a wealth of information on efficacy in RP patients in general and within specific mutation 
populations, as well as dose response and therapeutic dosing windows all within a relatively short period of time.  
 
George Asdourian, M.D. will serve as a co-investigator. He will aid in the screening and baseline measurements of all 
participants, as well as help perform clinical diagnostic follow up of  participants during the study. Dr. Asdourian  will 
help provide pre and post test genetic counseling to participants who choose to be genotyped.    
 
Judith Colbert, R.N. will serve as the study nurse coordinator for the UMMMC site, performing and overseeing many 
diagnostic procedures.  She will perform the visual acuity and color contrast sensitivity testing of all participants, and she 
will supervise the technicians performing the extensive ocular imaging. 
 
Elena Filippova, MD will serve as the clinician/research technician responsible for genotyping and drug dosing analysis.  
She will be responsible for registering subjects with the NIH eyeGENE clinical coordinating center, collecting and 
coordinating NEI required participant documentation for all recruited patients; she will oversee the collection, storage 
and shipment of all blood samples for genotyping.  Dr. Filippova will also be responsible for collecting and collating data 
on serum VPA levels for all patients, and for the escalating dosing in cohort 2; she will be responsible for reporting 
results back to principal investigators.  Dr. Filippova is skilled at and will be responsible for administering many of the 
ophthalmic diagnostic measures. 
 
Julie Wilson (UMMMC) will serve as one of the ophthalmic imagers and technician.  Julie is highly trained on the imaging 
equipment that will be used during this study including static and kinetic perimetry, fundus photography, optical 
coherence tomography and submicrovolt ERG.   
 
Heather Hudson (UMMMC) will serve as one of the ophthalmic imagers and technician.  Julie is highly trained on the 
imaging equipment that will be used during this study including static and kinetic perimetry, fundus photography, optical 
coherence tomography and submicrovolt ERG. 
 
Biostatistician (UMMMC) A senior biostatistician to be named later will be hired from the University of Massachusetts 
Medical School Quantitative Health Sciences Core Facility to consult with Dr. Clemson. 
 
2.  GENERAL STATEMENT OF PROBLEM 
 Purpose: Include concise hypothesis to be tested by proposed research. 
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Figure 1 Valproic Acid allows mutant P23H rhodopsin to properly fold to 
the level of wild type. HEK293 cells stably expressing an inducible mutant 
P23H rhodopsin expression vector were grown to confluence and tetracycline 
was added to induce opsin expression. 3mM VPA was added for 48h. 
Rhodopsin was purified by immunoaffinity methods.  Yields of folded p23H 
opsin were quantified by spectrophotometry .  In the presence of 11-cis 
retinal, folded mutant rhodopsin levels (red) increase from baseline (blue) to 
that of wild type (green).   
 
 
 
 
 
 
Figure 2  VPA Rescues Retinal Pigmented Epithelium 
Cells from Hydroquinone (HQ) induced apoptosis.  
ARPE-19 cells are protected from HQ mediated apoptosis 
by the presence of VPA.  
 
 
 
 
Purpose: To investigate the safety and efficacy of valproic acid in treating retinitis pigmentosa (rod-cone dystrophy).  
 
Hypothesis:  Valproic acid (VPA) can reduce the rate of vision loss from RP.   
 
 
3.   BACKGROUND AND SIGNIFICANCE: 
a. Provide a summary of the facts which led to 
selection of the problem.  
RP is a severe neurodegenerative disease of the retina 
characterized initially by night blindness with progression 
to tunnel vision and eventual loss of central vision and total 
blindness.  Targeted therapies for RP are complicated by 
the identification of more than 30 genes linked to the 
dominant and recessive forms of the disease.  Further 
compounding this complexity is the rarity of this disorder: 
although RP is one of the most common inherited eye 
diseases with an incidence of ~1:3000, its prevalence is 
relatively rare.  RP affects approximately 100,000 
individuals in the U.S. which qualifies it as an orphan 
disease.  Given the huge costs associated with the 
preclinical and clinical phases of drug development, 
pharmaceutical companies are generally reluctant to invest 
in developing new therapeutics for RP.  While a few new 
approaches for RP treatment have recently been 
investigated including nutritional supplementation, light reduction and gene therapy (Delyfer et al., 2004; Gaby, 2008; 
Hartong et al., 2006), of these, vitamin A supplementation is the most 
promising, but its benefits are modest and side effects are 
problematic.  Therefore, currently there is no therapy to substantially 
alter or reverse the progression of RP.   
 
 
b. Please describe the Investigator’s previous work on the 
problem.  
Scientific Rationale: 
Recently, we have demonstrated the use of retinoids and other small 
molecules as pharmacological chaperones to increase the yield of 
properly folded RP mutant rhodopsins in heterologous cell culture 
(Noorwez et al., 2008).   We have tested whether other known small 
molecules can provide similar effects.  We identified valproic acid 
(VPA) through this screen. In vitro data supports that VPA has multiple 
biologic properties that make it an ideal candidate for a retinal 
therapeutic.  First, our in vitro assay shows that VPA effectively 
increases yields of properly folded mutant rhodopsin (Figure 1).  
Second, VPA protects cells from oxidative stress induced apoptosis 
(Figure 2), most likely through upregulation of the heat shock 
response (not shown).  Other work demonstrates that VPA is a potent 
inhibitor of histone deacetylase (HDAC) (Gottlicher et al., 2001) and the inflammatory response pathway via apoptosis of 
microglial cells (Chen et al., 2007; Dragunow et al., 2006; Kim et al., 2007). 
 
Pilot Clinical Analysis: 
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Figure 3  Perimetry Tracing of a Patient treated 
with VPA Goldmann Kinetic Perimetry tracings 
(using V4e isopter) of Patient One before and after 
treatment with VPA 250 mg twice daily. 
Six RP patients were treated off-label with oral VPA (250 mg BID) for 
2 to 6 months.  Visual fields were measured using kinetic perimetry 
(Figure 3).  Results varied from patient to patient, 2 of 6 patients 
experienced progression of their disease while on VPA. However, 4 
of 6 patients showed no progression of their disease on VPA (Figure 
4), moreover, these 4 patients experienced an increase in their 
visual field (e.g. Figure 3)- which no other therapeutic has previously 
shown.  Overall, we detected an average increase in visual field of 
6%/month.  These results suggest that VPA has the potential to not 
only stop the progression but may also reverse loss of visual field 
 
 
 
 
 
 
 
 
 
 
 
 
 
c. What are the aspects that justify the use of human subjects, human data, or specimens as part of 
this research? 
It is critical to emphasize that the extensive history and well established safety and tolerability profile of VPA makes it an 
ideal candidate for a Phase II study, which streamlines the time to treatment in humans considerably relative to new 
drug design.  VPA was approved by the FDA for use as a broad spectrum anticonvulsant in 1978 and is also used for 
acute and maintenance therapy of bipolar disease, for migraine prophylaxis, and occasionally for chronic pain 
syndromes (Henry, 2003).  
 
Prevention of disease progression and restoration of vision are the ultimate goals of this trial. RP is an incurable and 
untreatable group of heterogeneous retinal degenerative diseases that cause severe visual loss. While individual rates of 
vision loss can vary greatly even among siblings with the exact same mutation (Berson et al., 2002), projections from the 
 
Figure 4  Visual Field Areas of Patients Treated off-label with VPA. 
Goldmann Kinetic Perimetry tracings (isopter V4e) from each eye (e.g. 
Figure 3) were digitized and areas were automatically calculated.  The 
6 patients were treated with VPA for varying lengths of time so the 
percent change per month from baseline was calculated for each eye 
and average values are presented.    
 
 148 
 
literature suggest that RP patients will lose an average of 15-17% of their visual field (VF) annually (Massof et al., 1990; 
Zeger and Liang, 1986) and 25% of RP patients will lose 20% of their VF in one year (Merin et al., 2008). There is 
currently no significant therapeutic that effectively slows the progression of this disease, and certainly none that can 
restore vision in RP patients.  Our preliminary studies indicate that VPA is a remarkable retinal therapeutic that may not 
only stop the progression of this disease, but also reverse loss of visual field.  An investigator initiated clinical trial as we 
propose is an important if not the only way for new therapeutics to be investigated for rare disorders such as RP. 
 
d. Attach references as appropriate. 
1.Delyfer, M.N., T. Leveillard, S. Mohand-Said, D. Hicks, S. Picaud, and J.A. Sahel. 2004. Inherited retinal degenerations: therapeutic 
prospects. Biol Cell 96:261-269. 
2.Gaby, A.R. 2008. Nutritional therapies for ocular disorders: Part Three. Altern Med Rev 13:191-204. 
3.Hartong, D.T., E.L. Berson, and T.P. Dryja. 2006. Retinitis pigmentosa. Lancet 368:1795-1809. 
4.Noorwez, S.M., D.A. Ostrov, J.H. McDowell, M.P. Krebs, and S. Kaushal. 2008. A high-throughput screening method for small-
molecule pharmacologic chaperones of misfolded rhodopsin. Invest Ophthalmol Vis Sci 49:3224-3230. 
5.Gottlicher, M., S. Minucci, P. Zhu, O.H. Kramer, A. Schimpf, S. Giavara, J.P. Sleeman, F. Lo Coco, et al. 2001. Valproic acid defines 
a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20:6969-6978. 
6.Dragunow, M., J.M. Greenwood, R.E. Cameron, P.J. Narayan, S.J. O'Carroll, A.G. Pearson, and H.M. Gibbons. 2006. Valproic acid 
induces caspase 3-mediated apoptosis in microglial cells. Neuroscience 140:1149-1156. 
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deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity. 
Neuroscience 149:203-212. 
8.Kim, H.J., M. Rowe, M. Ren, J.S. Hong, P.S. Chen, and D.M. Chuang. 2007. Histone deacetylase inhibitors exhibit anti-
inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J Pharmacol 
Exp Ther 321:892-901. 
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4.  DETAILED DESCRIPTION OF RESEARCH PLAN (especially as it affects the subject) 
 
Include a schematic representation of what the research will entail (e.g. a table with the number of 
visits and what will happen at each visit or flow diagram of subject’s involvement over time). 
 
This is a two- site, interventional, prospective, placebo-controlled, blinded study of 90 subjects undergoing therapywith oral VPA.  
The second site will be the Retina Foundation of the Southwest (RFSW).  David G. Birch, Ph.D. will serve as the Principal Investigator 
at the RFSW. Dr. Birch is the Chief Scientific and Operating Officer of the RFSW and an adjunct Professor at the University of Texas 
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Southwestern Medical School.  He is a highly regarded clinical trialist and his clinical team has been involved in many RP clinical trials 
both current and ongoing.  He will be responsible for all aspects of oversight and reporting for the RFSW site. He is also highly 
involved in the study design and statistical analysis. 
 
Patients will undergo clinical examinations and evaluations of retinal function and structure prior to consideration of the subject as a 
candidate for clinical trials. Clinical examinations will include refraction, static and kinetic perimetry, fundus photography and visual 
acuity. Measures of visual function will include full-field electroretinography.  Optical coherence tomography will be used to 
measure retinal structure. Methods of these measures are detailed below. During these evaluations, medical and ophthalmic 
histories will be elicited from subjects and their families to ensure that there are no comorbid medical or ocular genetic conditions 
that may prevent study participation. While the equipment proposed for use in this trial is state of the art and as such will provide 
the highest level of quantitation available, the quasi-subjective nature inherent in many standard ocular tests make day-to-day 
variation an important confounder to our analysis. All diagnostic measures will be calibrated and standardized such that intervisit 
and interocular variances for each outcome measure will be quantified and included in our analysis.  This will involve sequential 
repeated measures for the same and different patients on these machines.   
 
 
 
 
 
Figure 5:  Study visit schedule 
 Cells outlined in red represent clinic visits with full battery of outcome measures.  
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TABLE 1:  SCHEDULED STUDY EVALUATIONS  
 
          
Time relevant to start of Oral VPA  
Screening 
Visit  
1 
Visit  
2 
Visit 
3 
Visit 
4 
Visit     
5 
Early 
term.
d 
b 
Month 0 2 6 12 15  
Week -12 to -4 0 8 24 48 60  
Informed Consent x x      
Inclusion/exclusion Criteria x x      
Medical/surgical history x       
Physical examination x       
Ophthalmic history x       
Safety Labs x x x x x x x 
Demographic data x       
Molecular Genotyping
a
 x x      
Ophthalmic  Exam
b 
 x x x x x x x 
Urine pregnancy test x x      
Visual Acuity (BCVA) x x x x x x x 
Perimetry x x   x  x 
Color Contrast Sensitivity  x   x  x 
Electoretinography  x   x  x 
Optical coherence tomography (OCT)  x   x  x 
Fundus photography (FP) x    x  x 
Quality of Life Questionnaire
 c
  x   x  x 
Remaining pill count for med. monitoring   x x x   
Provide Study Meds  x x x    
VPA level (labs)   x x x x x 
Concomitant medications x x x x x  x 
Adverse events assessment   x x x x x x 
e. If enrolled 
f. Ophthalmic examinations include:  slit lamp examination; tonometry, indirect ophthalmoscopy and retinal biomicroscopy.  
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Dose Rationale 
Treatment dosages were selected based on our proof of concept preliminary studies described above and known safety and 
tolerability profiles of VPA. For the intervention, VPA dosage will vary by weight (Table 2) and will be ½ to ⅓ the dosage 
recommended for anticonvulsant therapy (Table 3). 
 
  
 
 
 
 
 
The Screening visit consists of the following examinations and  
procedures:  
 Explanation of study and a copy of the trial Consent form (if not mailed ahead of the visit) and the genotyping 
consent form.  (Note:   eyeGENE is a separate protocol submitted to  the Umass IRB – but it overlaps with this 
study) 
 Signing of the Informed Consent for the trial  
 Signing of the Informed consent for genotyping  (not necessary for enrollment in study)    
 Complete medical and ocular history  
 Urine test for pregnancy (if of child bearing potential) 
 Blood draw for hepatic and pancreatic function screen (and genotyping if enrolled). 
 Visual acuity examination  
 Ocular examination  
 Semi-Automated Kinetic Perimetry,  with static measurements in the 30: central field (in Duplicate) 
 Fundus photographs  
 
 
Baseline Visit    
Qualified participants will be asked to return to the clinic within 30 to 120 days after the Screening Visit. Randomization 
will occur only after the participant is confirmed to be eligible. Participants are considered eligible if they meet all the 
inclusion criteria, and do not meet one or more exclusion criteria and return to the clinic within 120 days following the 
Screening Visit, and sign the consent form.  
 
Participants must be re-qualified if randomization does not occur within 120 days of the Screening Visit.  Re-qualification 
requires that the responses to each of the eligibility questions be verified and ocular exams and fundus photographs re-
performed.  
 
Table 3:  Recommended Starting VPA Dosage Schedule for anti-
convulsant therapy .(DEPAKENE(R) oral capsules, oral syrup, 
2006)  
Pounds ( bs) Kilograms (Kg) Total Daily 
Dose (mg) 
22 -54.9 10 - 24  250  
55 - 87.9 25 - 39.9 500 
88 - 131.9 40 - 59.9 750 
132 -164.9 60 -74.9 1000 
165-197.9 75-89.9 1250 
 
 
 
 
 
TABLE 2:  VPA DOSAGE SCHEDULE BY 
WEIGHT   
 
Pounds ( bs) Kilograms (Kg) Total Daily 
Dose (mg) 
22 -87.9 10 – 39.9 Excluded from 
study 
88 – 164.9 40 – 74.9 500 
165-197.9 75-89.9 750 
198-349.9 90-158.9 1000 
350+ 159+ Excluded from 
study 
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The UMMMC  coordinating center will assign bottle numbers. The master randomization list for both centers will be 
maintained at the UMMMC Coordinating Center.    
  
The Baseline Visit consists of the following examinations and procedures:  
 
Signing of the eyeGENE genotyping consent form (if not signed at the Screening  Visit)- not a prerequisite for study   
(Note:   eyeGENE is a separate protocol approved by the Umass IRB) 
  
1. Urine test for pregnancy (if of child bearing potential)  
2. Semi-Automated Kinetic Perimetry,  with static measurements in the 30: central field (in Duplicate) 
3. Optical Coherance Tomography (OCT) 
4. Color-Contrast Sensitivity Analysis (Chroma Test) in duplicate 
5. Full-field Electroretinogram (Spectralis) in duplicate 
6. Visual acuity examination  
7. Ocular Examination  
8. Quality of Life Questionaire(QOL)  
9. Concomittant Medications 
10. Distribution of Study Medication (or placebo) and administration directions.  
11. Assignment of Bottle Numbers  
 
Participants who consent to participate will be contacted by telephone within 24 hours to answer questions and assure 
full understanding of dosing instructions and procedures.   
  
Follow-up Visits  
In-clinic follow-up visits will occur at 60, 180, and 360 days after initiating VPA treatment for evaluation of their clinical 
status and to assess adverse events.  Participants will be asked to provide information on any side effects they are 
experiencing.  Subjects will be followed up with phone calls after the baseline, week 1 and at month 1, 3, 4, 5, 7, 8, 9, 10, 
11. The purpose of these phone calls is to assess adherence to study medication, assess adverse events, schedule 
additional clinic visits if needed, and clarify study procedures.   In all cases, participants will be followed for a period of 3 
months after the study ends.   
 
The in-clinic follow-up visits will consist of the following examinations and  
procedures:  
 
1. Safety Labs 
2. Concomitant Medications 
3. Visual acuity examination  
4. Ocular examination  
5. Adverse Event assessment  
6. Collection and re-issuance of study medication bottles  
7. Assessment of study drug adherence via self-report, VPA blood levels, and pill counting 
8. Semi-Automated Kinetic Perimetry,  with static measurements in the 30: central field -in Duplicate (at month 12 
follow-up visits.) 
9. Optical Coherance Tomography (OCT) in duplicate (at month 12 follow-up visit.) 
10. Color-Contrast Sensitivity Analysis (Chroma Test) in duplicate (at month 12 follow-up visit.) 
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11. Full-field Electroretinogram in duplicate (at month 12 follow-up visit.) 
12. Quality of Life Questionaire(QOL)  (at 12 month follow up visit). 
   
b. Inclusion/Exclusion Criteria - As appropriate, explain what steps will be taken to insure that subjects meet the 
criteria (e.g. healthy, not pregnant, etc). 
Inclusion Criteria  
1. To be eligible for the study, subjects must fulfill all of the following criteria: 
2. Understand and sign the IRB-approved informed consent document for the study. 
3. Age  18 years. 
4. Weight  40 Kg and ≤158.9 Kg 
5. Diagnosis of Retinitis Pigmentosa including photoreceptor degeneration established by visual field constriction, 
night blindness, marked reduction of ERG responses, and the clinical signs of RP including waxy pallor of the 
optic nerve, vascular attenuation and/or the presence of intraretinal pigment on clinical examination. 
6. Female adults of child bearing potential who have attained menarche must have a negative pregnancy test at 
study entry and commit to using an acceptable method of barrier or hormonal contraception. 
7. Willingness to comply with the protocol. 
8. Exclusion Criteria   
9. Potential participants meeting any of the following criteria will be excluded from the study: 
10. Medical problems that make consistent follow-up over the treatment period unlikely (e.g. stroke, severe MI, end 
stage malignancy), or in general a poor medical risk because of other systemic diseases or active uncontrolled 
infections. 
11. Other retinal diseases: Glaucoma, retinal inflammatory disease, (Note:  CME is allowable), cataract worse than 
+2 NS or herpes simplex virus of the eye.  
12. Intact visual field of 5: or less.  
13. Diabetes or cancer.  
14. A hemoglobin concentration of less than 8 gm/dL a platelet count of less than 75K/mm3 or an absolute 
neutrophil count of less than 500/mm3 at study entry.  
15. Liver disease determined by an alanine aminotransferase (ALT) aspartate aminotransferase (AST) or bilirubin 2.5 
times greater than the upper limit of normal.  
16. History of pancreatitis by clinical features and/or laboratory abnormalities in the last 12 months.  
17. Renal dysfunction based on serum creatinine using the MDRD equation.   
18. Patients suffering from urea cycle disorders will be excluded. 
19. Patients with history of seizure disorders and/or those already receiving valproic acid or other anti-convulsants 
will be excluded 
20. Sensitive to or have ever had an allergic reaction to Valproic Acid.   
21. Pregnant or Lactating mothers who are breast feeding their babies will not be eligible. 
22. RP patients involved in other clinical trials within the last 3 months are ineligible for this study.  
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c. Discuss the number of experimental and control subjects, and explain the statistical basis for the 
numbers. 
Attainable recruitment goals and functional outcome data from our preliminary analysis were both used to estimate 
sample size for the Phase II trial.  Our pilot analysis demonstrated a potential annual change of +72% in VF annually in 
VPA treated RP patients (Figure 4). Reports in the literature allow us to conservatively estimate a 5% reduction in VF 
annually in untreated RP patients (Berson et al., 2002). If we reduce our estimate of delta to boost the statistical 
validity of the trial, and assume a 60% difference in the rate of visual field change in Phase II, statistical significance for a 
two-sided test using a significance level of 0.05 and 80% power would require around 40 patients per group.   
 
In general, RP patients are highly motivated to comply as evidenced in the similarly designed RFSW based Phase I trial of 
DHA where drop-out rates were 0% at year 3 and 7% at year 4. Because we will likely enroll sibling pairs into the trial, 
the total number of “active” participants has been increased from 80 to 90 to permit statistical compensation of these 
sibling pairs. 
 
 
d. Does the study involve randomization?  
  
 
 If yes, please describe process. 
Two codes will be used for the two types of capsules (placebo and VPA) provided to patients.  The 250 mg VPA capsule 
and lactose containing placebos will be over-encapsulated (ie. put into an identical empty shell) by the research 
pharmacy, so their appearance is similar. All patients will be assigned to receive capsules following a computer-
generated randomization performed by the UMMMC research pharmacy. 
 
The capsule code information will be kept on a password-protected computer with the password known only to the 
capsule coordinator. 
 
The randomization code for the groups will consist of 2 single-letter identifiers for the two capsule types (A or B). The 
capsule codes are a temporary identifier of capsule bottles as the capsule coordinator (research pharmacist at UMMMC) 
will place a label with each individual’s ID number over the capsule code. This will prevent laboratory personnel from 
associating the patient ID with capsule code assignment. 
 
UMMMC will be the coordinating center and the research pharmacy will randomly assign the study intervention.  
Participants and investigators will be masked to the treatments. Participants will be unmasked if deemed clinically 
necessary by the examining physician and if the Study Chair and Data Safety and Monitoring Board (DSMB) Chair are in 
agreement. A written request for unmasking, after approval by the Study Chair and DSMB Chair, will be made to the 
Coordinating Center, who will inform the site Principal Investigator of the treatment assignment. All instances of 
unmasking must be reported to the IRB, the DSMB and the FDA.  
 
e. How long will each subject be enrolled in the study? 
15 months 
 
f. Provide a brief overview of what participation in the study will mean to each participant in terms of 
what he/she will experience.  Describe in order, each procedure, how long each procedure will take and 
Yes    
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how often each procedure will be performed.  Include doses & route of administration of any drugs and 
whether the procedure or drugs would always, sometimes or never be required as part of the subject’s 
standard of care.  
Please note, all of these procedures are being performed at the Department of Ophthalmology Clinical Trial 
Suite at Memorial Hospital and will be billed to the clinical trial.  No tests, procedures or visits will be billed to 
the participant or their insurance company.  
Visual Field (perimetry):   30 minutes, performed 3 times in the 15 months:  at screening, baseline, and month 12. 
 This test is sometimes administered as standard of care once a year, however these tests will be for research 
purposes only. 
The visual field test will take about 30 minutes and will involve the participant sitting comfortably at machine that will 
shine lights in their eyes to determine which part of their eyes are affected by RP. 
 
Visual Acuity: 5 minutes, performed 6 times, at screening, baseline, month 2, 6, 12 and 15. 
This test would be administered as standard of care once a year, but is being performed here for research purposes. 
This will take about 5 minutes and involves the subject sitting comfortably at a computer and answering questions about 
the letters that appear. 
 
Color Contrast Sensitivity: 10 minutes, performed 2 times at Baseline, month 12. 
This test would not be administered as standard of care 
Color vision will be tested by the Chroma Test program, this involves sitting comfortably at a computer and answering 
questions about the colors that appear. 
 
Optical Coherence Tomography (OCT) : 10 minutes, performed 2 times. 
This test would sometimes be administered as standard of care every 2-3 years, this test is being performed for 
research purposes. 
The thickness of the retina will be examined by Optical Coherance Tomography (OCT). This procedure will take about 10 
minutes and involves the participant sitting comfortably at a machine and looking straight ahead. 
 
Fundus Photography: 10 minutes, performed 2 times, at screening and 12 month visit. 
This test would sometimes be administered as standard of care every 5 years. 
Photography (performed to minimize excess visible light exposure) will be performed at the screening visit and at the 12 
month visit.  
 
Full-field Electroretinogram (ERG) 45 minutes, performed 2 times at baseline, and month 12. 
This test would sometimes be administered as standard of care every 5 years, and is being performed here for 
research purposes. 
An ERG will be performed to determine how well the rod and cone receptors respond to light.  This test takes about 45 
minutes and involves having anesthetic drops placed in the eyes, causing them to become numb. The eyelids are then 
propped open with a speculum and an electrode is gently placed on each eye with a device very similar to a contact lens. 
Readings will be taken first in normal room light, then with the lights dimmed and finally readings are taken as a bright 
flash is directed toward the eyes. 
 
Quality of Life (QOL) 15 minutes, administered 2 times at Baseline and month 12. 
This test would not be administered as standard of care. 
QOL will be assessed using the 25-Item National Eye Institute Visual Function Questionnaire (Mangione et al., 2001).  
The questionnaire will be administered in an interview format at the baseline visit and at the 12 month visit. 
 
Genotyping Analysis: blood draw – one time – at Baseline. 
This test is sometimes administered as standard of care. 
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The genotyping test will be done as a part of the eyeGene clinical research study at the National Institutes of Health 
(NIH).  EyeGENE informed consent for genotyping and DNA diagnostics will be included in the trial consent form and will 
be approved by the University of Massachusetts Institutional Review Board.  These completed consent forms will be 
sent to the eyeGENE coordinating center and clinical criteria for each participant will be entered into the eyeGENE 
online database prior to shipment of blood samples.  5–10 ml of whole blood will be obtained by routine phlebotomy 
using plastic vacutainers containing K2 EDTA. Dr. Kaushal or Dr. Asdourian will provide pre and post-test genetic 
counseling to all participants. 
 
Safety labs: blood draw –six times – at Screening, Baseline, month 2, 6, 12 and 15 months. 
This test is sometimes administered as standard of care. 
 
 
Serum VPA Assay: blood draw 4 times at month 2, 6, 12 and 15. 
This test would not be administered as standard of care. 
Compliance is an issue in self administered study drug clinical trials.  Medication monitoring will occur at every follow up 
visit.  Patients will be instructed to bring prescription bottles to every visit for counting.  Additionally, serum VPA levels 
will be assayed at regular intervals for bioavailability determination as well as validation of participant compliance to 
protocol.  Serum concentrations will be assayed by a fluorescence polarization immunoassay system (Ax-Sym analyzer; 
Abbott Diagnostic Division, Irving, TX). 
   Since the results of this test would obviously unblind any research staff, the VPA blood levels will be held by the clinical 
lab facility until the end of the study.  Given that the VPA serum level is being used primarily for a research question, and 
likely does not afford useable safety information, we feel this will not compromise subject safety.  If however, serious 
adverse events occurred, then this information would be available if a particular subject is unblinded. 
 
 
g. Is any aspect of this research study being conducted in the Medical School or a non-UMMMC 
facility?  If yes, please explain. 
Yes, this is a two-site study performed at the Umass Memorial Campus and at the Retina Foundation of the Southwest in 
Dallas, Texas. 
 
h. Will hospitalization be required as part of this research study? 
 
 
If yes, how long will subjects be hospitalized? 
i.   Will there be any material inducements or recruitment incentives given to research staff or research 
subjects as part of this research study?  (e.g., direct payments, free hospitalization, care) 
  
   
If yes, explain how much, the pay schedule, or any partial payments that will be given. 
$250 per participant for completing the 6 visit schedule.  If the subject drops out before the final visit, the 
compensation will be prorated at $50 per visit. 
  No  
Yes    
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DISCLOSURE OF CONFLICT OF INTEREST  
Investigators should disclose any financial arrangement they may have with a company whose product figures 
prominently in their research or financial arrangements they may have with company making a competing 
product.  The relationship should also be described in the informed consent documents.  In the case 
where the only relationship is that a company is sponsoring the research study, it is sufficient to prominently 
identify the sponsor on the front page of the consent form and to simply state “NONE” in the consent form 
under Conflict of Interest. 
Is there a conflict of interest?    
NO 
 
6.  RELATIONSHIP TO STANDARD THERAPY. 
Describe the standard therapy that patients would receive if not in the research study.  Explain how 
this research intervention deviates from or replaces generally accepted standard therapy and justify 
the deviation. 
While there is no known treatment to substantially alter or reverse the progression of RP, supplementation with vitamin 
A is currently the standard of care.    The diagnostic tests proposed are state of the art optical evaluations that would be 
included in an advanced Ophthalmologic clinic environment. 
 
7.  DESCRIBE THE POTENTIAL BENEFITS OF THIS PROJECT. 
Include hoped-for benefit to society, to the group of subjects or to individual subjects.   
Based on the preclinical and preliminary clinical efficacy data, there is potential that oral VPA may provide some degree 
of improvement in visual function in some of the individuals participating in this study.  However, the likelihood of 
achieving any benefit, and the degree of any benefit that may occur, is unknown.  
 
Address the risk/benefit ratio of the study.  If there are no direct subject benefits, this should be stated. 
The potential benefits of this study far outweigh the potential risks. RP is a serious disorder that leads to complete 
blindness with no effective pharmacotherapy. Patients accepted into the study will receive close medical monitoring as 
well as treatment with valproic acid that has a well-documented safety profile. Patients will be screened prior to 
admission into the study and those at risk for adverse reactions will be excluded. The subjects selected for participation 
will be monitored closely for adverse effects. 
 
 
 
 
8.  DESCRIBE THE POTENTIAL RISKS TO SUBJECTS INCLUDE PSYCHOLOGICAL, ECONOMIC, 
LEGAL OR SOCIAL RISKS AS WELL AS PHYSICAL RISKS. 
Include the following information: 
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a. Estimate likelihood of occurrence, severity, and duration.  If generally accepted quantitative 
estimates are available based on previous data, these should be stated.  Otherwise, qualitative 
estimates such as “rare”, “occasionally", or “frequently” may be used.  The committee needs scientific 
information about drug/device side effects so as to best judge the pros and cons of the study.  Do not 
simply cut and paste the consent form “Risk” section into this part of the protocol. 
VPA is well tolerated in most patients and adverse events are rare (reviewed in Peterson and Naunton, 2005).  The 
primary concern is hepatoxicity which is rare in low risk patients occurring in fewer than .29 in 10,000 patients (Bryant 
and Dreifuss, 1996). Subjects will be carefully screened for comorbid conditions and concomitant medications to ensure 
that only patients at the lowest risk for serious adverse events are enrolled (see Exclusion Criteria above).   
 
In the pilot study, RP patients on similar amounts of VPA experienced minor side effects, the most common of which 
were stomach irritation and tiredness. 
 
Potential risks to study subjects include the well known and characterized risks associated with administration of the 
therapeutic agent and with study procedures. Valproic acid can cause serious and fatal hepatoxicity especially in 
individuals with liver disease, organic brain disease, serious seizure disorders, congenital metabolic disorders, those on 
multiple anticonvulsants and children under the age of 2.  Therefore individuals with contraindicating diseases and 
concomitant medications as well as children under 18 will be excluded from this study. The risk of hepatoxicity usually 
occurs within the first 6 months of treatment and decreases considerably in older age groups. Serious or fatal 
hepatotoxicity may be preceded by non-specific symptoms such as malaise, weakness, lethargy, facial edema, anorexia, 
and vomiting. 
 
Valproic acid can cause serious and fatal pancreatitis. Some of the cases have been described as hemorrhagic with a 
rapid progression from initial symptoms such as abdominal pain, nausea, vomiting, and/or anorexia to death. Cases have 
been reported shortly after initial use as well as after several years of use. 
 
Valproate can produce teratogenic effects such as Spina Bifida, therefore woman of child bearing potential will be 
screened for pregnancy prior to administration of the study agent and must maintain use of contraception during the 
study period.   
 
The risks associated with ophthalmic procedures include redness, discomfort or allergic reaction to topical medications 
used to dilate the pupil prior to visual function tests. High blood pressure, cardiac dysrhythmias and closed angle 
glaucoma may be exacerbated by some of these medications and light sensitivity may be experienced when the pupil is 
dilated.  Corneal abrasions may result from the contact lenses used in performing electroretinography testing. The risks 
of drawing blood from a vein include discomfort at the site of puncture; possible bruising and swelling around the 
puncture site; rarely an infection; and, uncommonly, faintness from the procedure.  
 
 
Explain what steps will be taken to protect against its occurrence, minimizing the harm, methods for 
early detection of harm, and what procedures will be followed to avoid serious injury (e.g. withdraw 
from study or dose reduction).   
In-clinic follow-up visits will occur at 60, 180, and 360 days after initiating VPA treatment for evaluation of their clinical 
status and to assess adverse events.  Participants will be asked to provide information on any side effects they are 
experiencing.  Subjects will be followed up with phone calls after the baseline, week 1 and at month 1, 3, 4, 5, 7, 8, 9, 10 
and 11. The purpose of these phone calls is to assess adherence to study medication, assess adverse events, schedule 
additional clinic visits if needed, and clarify study procedures.   In all cases, participants will be followed for a period of 3 
months after the study ends.   
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In the event of a non-serious adverse effect, the drug dose may be lowered, or the participant may be counseled to take 
the medication with food (in the event of gastric disturbance).  If that does not resolve the issue, or the adverse event is 
more serious, then the participant will be withdrawn from the study. 
 
The subjects will be informed of possible consequences of the study from one of the investigators in language they can 
understand.  They will be informed that they may withdraw from the study at any time and for any reason without 
jeopardizing their future treatment.  They will be asked to follow-up with necessary safety evaluations if they have 
received study agent prior to their desire to withdraw.  They will be given full information regarding potential side 
effects of VPA and the procedures involved.  The medical history and physical examination performed prior to study 
agent administration will identify patients with medical conditions that would increase the risks associated with study 
procedures and those subjects will be excluded from participation.  The administration of the study agent and all 
procedures related to the study will be performed by trained and licensed medical and health professionals.  They will 
be provided with contact numbers for any questions or concerns arising regarding the possible effects of the VPA and 
encouraged to call if they feel that an adverse event is occurring.  In the event of an adverse event associated with the 
clinical trial, immediate medical care will be provided.  
  
Patients will be followed closely, especially in the first 6 months for known adverse reactions to VPA.  Safety labs 
regarding liver and pancreas toxicity will be drawn prior to and periodically during dosing with VPA.  Results of all 
laboratory and safety exams performed to ensure subject eligibility and safety will be reviewed by an investigator during 
the study.  Subjects with known risk factors such as liver disease, pancreatic conditions, metabolic disorders, organic 
brain diseases, seizure disorders and those on anti-convulsants will be excluded from the study. Female subjects of child 
bearing potential must have a negative pregnancy test at the baseline visit and prior to study agent administration.  
Female subjects of reproductive ability must be willing to use effective contraception for the duration of the study, one 
year.  Lactating mothers will not be included in this study.  We will not include children under 18 in this study. 
 
The Data Safety Monitoring Board (DSMB) will be established with members who have an understanding of the disease, 
ethics, and biostatistics.  They will review the study results and notify the PI of their findings and recommendations for 
study continuation or modification.  The DSMB will be charged with monitoring the conduct of the trial and assessing 
patient safety on an ongoing basis.  This group will review all safety data, including serious adverse events, adverse 
events, and laboratory data.  Confidentiality of the subjects will be maintained in the process of review by the DSMB. 
The DSMB will provide committee recommendations after each review.  Adverse events will be reported to the IRB, NIH, 
and FDA as regulated to insure the safety of subjects. 
 
Data and Safety Monitoring Plan  
The study will be monitored in compliance with the relevant parts of 21 CFR and according to the ICH GCP Guidelines. 
 
The procedures outlined in the protocol and case report forms will be carefully reviewed by the Principle Investigators 
and staff prior to Study initiation to ensure appropriate interpretation and implementation.  No deviations from the 
protocol shall be made except in emergency situations where alternative treatment is necessary for the protection, 
proper care and well being of subjects. 
 
Amendments will be submitted to the IRB for their review and approval prior to implementation.  When an amendment 
to a protocol substantially alters the study design or increases potential risk to the study subject, the Informed Consent 
form will be revised and if applicable, subject’s consent to continue participation will again be obtained. 
To ensure safety of human subjects and integrity of data in this trial, a data and safety monitoring plan will be 
established.  
 The levels of monitoring will include: 
 Dr. Shalesh Kaushal, MD, PhD as Principal Investigator, will continuously monitor patient safety and be 
responsible for reporting serious and unexpected adverse reactions as regulated to the FDA, DSMB and IRB. 
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 The DSMB will provide safety oversight of the trial, to monitor the progress of the study, and to recommend 
modification of the trial, as appropriate.  The DMSB will review safety data after  two and  6 months of oral 
dosing.  Serious and unexpected adverse reactions will be reviewed by the DSMB or subcommittee. 
 Approval of the IRB will be obtained before enrolling subjects in this clinical trial.  Following the beginning of 
enrollment, the IRB will conduct continuing reviews of the trial at intervals appropriate to the degree of risk to 
human subjects. 
 
The degree of certainty with which an adverse event is attributed to drug treatment (or alternative causes, e.g. natural 
history of the underlying diseases, concomitant therapy, etc.) will be determined by how well the experience can be 
understood in terms of one or more of the following: 
 
 Known pharmacology of the drug 
 Reaction of similar nature being previously observed with this drug or class of drug 
 The experience having often been reported in literature for similar drugs as drug related 
 
 
A detailed Data and Safety Monitoring Plan will be submitted to the IRB prior to the accrual of human subjects. 
 
 
c. Explain whether or not these risks are from a procedure performed with the intent and reasonable 
prospect of yielding direct health related benefit to the subject. 
 
Procedures and interventions used in this trial are performed with the intent to at the very least stop the 
progression of this blinding disease. The pilot study strongly suggests that VPA has the potential to reverse 
vision loss in RP patients who currently have no treatment options. 
 
d. Do you, as the PI, have equipoise regarding the study?  That is, are you comfortable with the risks in 
relationship to the knowledge gained?  If the study involves randomization, do you believe in the 
equality of the treatment arms? 
Yes.  It is possible to treat patients off-label with this medication, however an investigator initiated clinical trial, 
such as proposed here, is the robust way to examine the efficacy of this medication for RP. 
  
 
9.  CONFIDENTIALITY CONSIDERATIONS: EXPLAIN STEPS THAT WILL BE TAKEN TO INSURE THE 
CONFIDENTIALITY OF INFORMATION THAT IS OBTAINED IN THE COURSE OF THIS RESEARCH 
PROJECT.  INCLUDE THE FOLLOWING: 
a. How will identifiers be used? 
Research material obtained from identifiable living human subjects includes reports of:  history and physical 
assessments, blood, urine, pregnancy tests, perimetry, optical coherence tomography, visual acuity measurements, 
color contrast sensitivity and electroretinography measurements, clinical assessments, adverse events, and autopsies.  
Copies of case report forms, original test results, subject medical records, signed subject informed consent, 
correspondence, and any other documents of the subjects, relevant to the conduct of the study will be kept on file by 
the principal investigator.  All material or data collected as part of the study will be obtained specifically for research 
purposes.  
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The patients will be de-identified by the creation of a master list assigning a study number to each patient.  The 
database will be protected and will include the study number with a reference to the medical record number and name 
during data collection phase. Then it will be de-identified by removing the name and medical record for a final analysis.   
 
 
 
b. Where will data be stored? 
Electronic sources of data will only be stored on the hospital secure server and will be deleted from storage.  Any paper 
containing identifying data will be shredded and placed in secured disposal bins available throughout the hospital. 
 
c. Besides the UMMS IRB and their representatives, who will have access to the research data? 
Only those personnel participating in the research study from UMMMC and RFSW described above will have access to 
the research data. The subjects will be informed of the information stored and the review of that information by the 
DSMB, U Mass and RFSW IRB, and U Mass and RFSW clinical facility personnel, Data Management and Statistical 
personnel, research staff, and personnel performing the procedures.   
d. When will the data/specimens be destroyed? 
The identifiers collected during the study will be destroyed upon completion of the statistical analysis of the study data.   
 
e. In the future, might other use be made of specimens collected as part of the research?  If yes, 
please describe.  
NO 
10.  ECONOMIC CONSIDERATIONS: 
In the course of this research project, might the subjects experience any additional expenses as a 
result of study participation?  This includes both out-of-pocket costs and expenses that might not be 
covered by medical insurance. 
If yes, please explain and justify. 
 
 
Patients may incur travel expenses.  Many RP patients seek out clinical trials and may travel a great distance 
to both the UMMMC and RFSW clinics.  Given the limited funding of this trial, travel expenses will not be 
covered.  
 
 
b. Please explain potential increase in standard hospital costs if any. 
N/A 
11.  DESCRIBE THE CHARACTERISTICS OF THE SUBJECT POPULATION. 
Yes   
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a. The subject population includes: 
  ADULTS   90        CHILDREN     0      
 
b. Is the subject population restricted in respect to any of the following characteristics?  
  
Please “x” those that apply Yes No 
Age Range x  
Health Status x  
Gender  x 
Racial/Ethnic composition  x 
 
If you responded YES to any of the above, include a clear rationale for this restriction. 
Retinitis Pigmentosa is a disease caused by a variety of mutations.  This is a rare disorder that tends to run in families, so 
recruitment efforts will likely result in a homogenous population. Because of X-linked forms, men are affected at a 
slightly higher rate than woman.  Women will not be excluded from this study. While most ethnic groups are affected by 
RP, in the United States, RP cases are predominantly Caucasian. We would not refuse anyone admission with another 
ethnic or racial group.   
 
The age range for the onset of vision loss in most individuals with RP is over 18 years of age. Additionally, the risk of the 
study medication is significantly greater in children. Thus no children younger than 18 will be included in this study.  
 
 
12.  WILL THE STUDY POPULATION SPECIFICALLY INCLUDE A POPULATION OF SUBJECTS 
CONSIDERED “VULNERABLE”?  VULNERABLE POPULATIONS ARE CHILDREN, MENTALLY 
IMPAIRED, PREGNANT WOMEN, PRISONERS, OR FETUSES. 
   
 
If yes, please explain. 
 
13.  WHAT IS THE SOURCE OF THE SUBJECT POPULATION? 
Retinitis Pigmentosa patients from the Greater Worcester and Dallas area and throughout the US. 
 
14.  EXPLAIN ANY STEPS TAKEN TO INSURE THAT THE SUBJECT POPULATION IS 
REPRESENTATIVE. 
  No  
 163 
 
No restriction on the form or genotype of RP patients will be instituted and as such it is expected that the 
recruited patients will be representative of all RP patients. 
15.  HOW AND WHERE WILL SUBJECTS BE RECRUITED FOR THE STUDY?  CONSULT THE IRB 
GUIDELINES FOR THE RESTRICTIONS ON RECRUITMENT OF EMPLOYEES, STUDENTS, AND 
INPATIENTS. ATTACH COPIES OF ALL RECRUITMENT MATERIALS TO BE USED AS PART OF THIS 
RESEARCH STUDY.  THESE MATERIALS MUST BE APPROVED BY THE IRB BEFORE BEING USED. 
Recruitment guidance can be found on our website under HSC Forms. 
Patients will be recruited from the Ophthalmology clinics at the University of Massachusetts Medical Center and the 
Retina Foundation of the Southwest  as well as through the Foundation Fighting Blindness disease specific web site and 
email blast.  This protocol will be listed in the Clinical Trials Data Bank of the NIH.  The copy for all advertisements will be 
submitted to the IRB as an amendment for approval prior to any posting. 
16. WILL PROTECTED HEALTH INFORMATION (PHI) BE USED AS PART OF THIS RESEARCH STUDY?  
PLEASE VISIT OUR WEBSITE FOR MORE INFORMATION ABOUT PHI OR THE HEALTH INSURANCE 
PORTABILITY AND ACCOUNTABILITY ACT (HIPAA). 
 
 If yes, please answer the following questions. 
 
How and where will the PHI be accessed (i.e. meditech, database,medical records, another site)? 
Meditech, database and Medical Records 
Will a subject’s PHI be accessed before the subject is enrolled in the study? 
NO 
Please list the PHI to be used as part of this research study (i.e. name, DOB, medical record #). 
Name, DOB, address, medical record# 
 
17.  METHOD FOR OBTAINING INFORMED CONSENT 
a. Are you requesting a waiver of the requirement for obtaining consent? 
 
 
 
Do not complete the following questions if you are requesting a waiver of informed consent. 
18.  WILL VERBAL CONSENT BE OBTAINED? 
 
Yes    
  No  
Yes  No x 
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If yes, will an unsigned “fact sheet” be given to subjects before verbal consent is obtained? 
 
   
 If yes, please provide a copy of the “fact sheet”. 
 
19.  WILL A SIGNED CONSENT FORM BE REQUIRED? 
  
 
AS A GROUP, ARE THESE SUBJECTS EXPECTED TO BE COMPETENT TO GIVE CONSENT FOR 
THEMSELVES? 
 
 
 If no, please explain why and how consent will be obtained. 
21. EXPLAIN THE CIRCUMSTANCES UNDER WHICH CONSENT WILL BE OBTAINED.  HOW WILL YOU 
INSURE THAT POTENTIAL SUBJECTS HAVE ADEQUATE TIME TO CONSIDER THEIR OPTIONS, AND 
THAT POSSIBLE COERCION IS MINIMAL? 
Consent forms will be distributed in written format which will be mailed in advance of the screening visit.  
Potential study patients who demonstrate an interest in participating in the study will receive an explanation of 
the terms, procedures, and requirements of the study from an investigator of the research team in language 
they can understand. They will receive a copy of the written version of the Informed Consent Form to read (or 
be read to) and share with family or friends.  Subsequently, an investigator will answer questions and request 
the patient's permission to participate in the study. Volunteer participants who sign a study-specific patient 
informed consent form approved by the Institutional Review Board will then be scheduled for a screening 
evaluation to determine their eligibility.   
 
22.  IF THE SUBJECT POPULATION INCLUDES MINORS, AND SIGNED CONSENT WILL BE OBTAINED, 
WILL AN ASSENT FORM BE USED AS PART OF THE CONSENTING PROCESS?  CONSULT IRB 
GUIDELINES FOR INFORMATION ABOUT CHILDREN IN RESEARCH STUDIES. 
 
 
NOTE: In general, it is expected that minors from age 8 to 15 will read and sign an assent form.   Older 
adolescents (16 and 17) will usually read and sign the same consent form as the parents signed.  The 
assent form template is available on our website. 
Yes  No  
Yes    
Yes    
  No Minors enrolled    
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23.  IF YES, PLEASE EXPLAIN WHO WILL APPROACH THE MINORS AND HOW AND WHERE THE  
ASSENTING PROCUDURE WILL TAKE PLACE.  
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 SECTION VI 
CERTIFICATION OF APPROVAL 
PI Name:  Kaushal, Shalesh 
DELEGATION OF ROLES/RESPONSIBILITIES*:  Checklist/Signature List 
 
Please type 
Name and 
Credentials 
 
Role* 
 
Signature 
 
Department/Campus 
Delegation of responsibilities: 
Please use key** in box below to 
summarize your study activities and 
place an “x” in the appropriate column 
A B C D E F G H I J 
 
Shalesh 
Kaushal MD 
PhD 
PI  Ophthalmology/ 
UMMMC 
* * *   * * * * * 
              
Christine 
Clemson 
PhD 
 
Study 
Coordinator 
 Ophthalmology/ 
UMMS 
     * * * * * 
George 
Asdourian 
MD 
Co-I  Ophthalmolgy/ 
UMMMC 
* * *       * 
Judith 
Colbert RN 
 
Study 
Nurse 
Coordinator 
 Ophthalmolgy/ 
UMMMC 
*   * * *    * 
Julie Wilson 
 
Other  Ophthalmolgy/ 
UMMMC 
         * 
Heather 
Hudson 
Other  Ophthalmology/           
 
Elena 
Filippova, 
MD 
 
Other 
 UMMMC 
Opthalmology/ 
UMMC 
         * 
* 
*Roles: (choose appropriate # below) 
1. Sub or Co-
Investigator  
2. Study Nurse 
Coordinator 
3. Study Coordinator 4. Other: Ophthalmic 
Imager 
PLEASE SEE SECTION 1 – PERSONNEL ENGAGED IN THIS RESEARCH STUDY FOR A DETAILED 
DESCRIPTION OF THE “OTHER” ROLES AND RESPONSIBILITIES 
**Delegation of Responsibility Codes: (choose all that apply) 
A. Consent Subjects F.  Maintain Regulatory Documents 
B. Take Medical History G. CRF Completion and Query Resolution 
C. Conduct Physical Exam H. SAE/AE Monitoring/Reporting 
D.  Phlebotomy I.   IRB Communications and Continuing Review 
E. Monitor Vital Signs/Nursing Assessment J. Other (explain): 
Although the Principal Investigator is ultimately responsible for every element of study activity, this form serves 
to clarify to whom the PI has delegated specific study activities and responsibilities. 
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3.6.6 CLINICAL TRIAL CONSENT FORMS 
 
 CONSENT TO PARTICIPATE IN A RESEARCH PROJECT 
 
Title:  Phase II Clinical Trial of Valproic Acid for Retinitis Pigmentosa 
 
Principal Investigator:  Shalesh Kaushal, MD, PhD  
Contact Information:  (508) 334-0687 
    
Research Subject’s Name:                                                                    Date:                              
 
Invitation to Take Part and Introduction 
 
You are invited to volunteer for a research study.  You are asked to take part because you have 
been diagnosed with Retinitis Pigmentosa (RP). The 45 human subjects who will be included in 
the proposed clinical trial will be males and females who have been diagnosed with Retinitis 
Pigmentosa, 18 years of age and older, who do not have any diseases or conditions 
inconsistent with treatment using valproic acid. 
 
Purpose of Research 
 
The goal of this research is to determine if valproic acid (VPA) can reduce the rate of vision loss 
from RP.   
 
 
Your Rights 
It is important for you to know that: 
 
Your participation is entirely voluntary. 
 
You may decide not to take part or decide to quit the study at any time, without any changes 
in the quality of the health care you receive. 
 
You will be told about any new information or changes in the study that might affect your 
willingness to participate. 
 
Description of the Investigational Drug:   
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VPA is already approved by the U.S. Food and Drug Administration (FDA) for sale by 
prescription to treat seizure disorders.  VPA is not approved by the FDA for RP but approval is 
currently being pursued for treatment of patients with  RP.   
 
Randomization: Since no one knows yet whether Valproic Acid will be effective or not, not 
everyone in the research study will be treated with VPA.  Each volunteer in the study will get 
either VPA or a placebo.  A placebo is an inactive substance which looks exactly like the 
experimental drug, but which is not expected to have any medical effects.  This means you 
may not receive the drug being tested.  The decision as to whether you receive the drug or 
placebo will be made by chance, like the flip of a coin, not by your doctor or based on your 
medical condition.  Neither you nor the doctors will know whether you are getting the 
experimental drug or a placebo. You have 1 chance in 2 of getting the experimental drug.  This 
way of studying medicines provides more objective information about the drugs and allows 
better comparisons to be made.   In an emergency, a doctor can find out what you are taking 
by calling (508) 334-1000 and have the operator page the on-call Investigational Pharmacist.  
   
PROCEDURES 
 
Screening :  You will be screened to determine if you are suitable for this study.  The screening 
visit will take about 3 hours. We will go over this consent form with you and once all of your 
questions are answered, and you wish to be considered for this trial, you can sign it.  
 
At the Screening visit these procedures will be performed: 
 
1. Signing of consent forms.   
 
2. A small sample of blood (about 5 tablespoons) will be collected from the arm vein to be 
sure it is safe for you to take the study medication. 
 
3. Signing of genotyping consent forms if you wish to have genetic testing performed.  This 
is blood test that may be able to determine which gene is causing your RP.  (You do not 
need to be genotyped to be in this study).  
 
4. A small sample of blood (about 1 tablespoon) will be collected from your arm if you wish 
to have genetic testing performed. 
 
5. If you are capable of having children, urine will be collected to be sure you are not 
pregnant. 
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6. You will have a physical exam by a study doctor. 
 
7. You will be asked about your medical history. 
 
8. An eye exam will be performed by one of the study doctors and your eyesight will be 
tested.  This involves sitting at a computer and answering questions about the letters 
that appear.  
 
9. Your visual field will be measured.  The visual field test will take about 30 minutes and 
will involve you sitting at machine that will shine lights in your eyes to determine which 
part of your eyes are affected by RP. 
 
10. Fundus photography will be performed that will take about 10 minutes and involves 
having your eyes photographed.   
 
11. You will be asked about any other medications you take. 
 
12. If the study doctors determine that you are suitable for this trial, you will be contacted 
in a few weeks to participate in this research. 
            
Evaluations during the research:  
If you choose to be part of this trial, the research will last for about 15 months and you will be 
asked to return to the clinic 4 more times.   
 
The First visit (also called the Baseline visit) will occur within 120 days of the Screening visit.  
At this visit you will be given a supply of either the valproic acid or the placebo, depending on 
which you were randomly assigned to take.  This will be a pill to be taken up to 4 times a day 
(depending on your weight).  You will be advised to take this pill with food and to slowly 
increase the amount you take over the course of seven days until you reach the prescribed 
dose.  
 
The Baseline clinic visit will take about three hours and these procedures will be performed: 
 
1. A small sample of blood (about 5 tablespoons) will be collected from the arm vein to be 
sure it is safe for you to take the study medication. 
 
2. If you are capable of having children, urine will be collected to be sure you are not 
pregnant. 
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3. An eye exam will be performed by one of the study doctors and your eyesight will be 
tested.  This involves sitting at a computer and answering questions about the letters 
that appear.  
 
4. Your visual field will be measured.  The visual field test will take about 30 minutes and 
will involve you sitting at machine that will shine lights in your eyes to determine which 
part of your eyes are affected by RP. 
 
5. The thickness of your retina will be examined by Optical Coherance Tomography (OCT).  
This procedure will take about 10 minutes and will involve you sitting comfortably at a 
machine and looking straight ahead. 
 
6. Your color vision will be tested by the Chroma Test program, this involves sitting 
comfortably at a computer and answering questions about the colors you see.   
 
7. An important test called an Electroretinogram will be performed to determine how well 
your eye cells respond to light.  This test takes about 45 minutes and involves having 
anesthetic drops placed in your eyes, causing them to become numb. The eyelids are 
then propped open with a speculum and an electrode is gently placed on each eye with 
a device very similar to a contact lens. Readings will be taken first in normal room light, 
then with the lights dimmed and finally readings are taken as a bright flash is directed 
toward the eyes. 
 
8. You will be asked to fill out a 25 question survey about how your vision affects your 
quality of life. 
 
9. You will be asked about any other medications you take. 
 
The 2 month follow up visit will occur approximately 60 days after the Baseline visit. It will 
take approximately 90 minutes and these procedures will be performed: 
 
 A small sample of blood (about 5 tablespoons) will be collected from the arm vein to 
check for safety and levels of the study medication. 
 
 An eye exam will be performed by one of the study doctors and your eyesight will be 
tested.  This involves sitting at a computer and answering questions about the letters 
that appear.  
 
 You will be asked about any other medications you take. 
 You will be asked about any side effects you are feeling. 
 Your remaining study capsules will be counted. 
 
 You will be provided more study drug if needed. 
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The 6 month follow up visit will occur approximately 180 days after the Baseline visit. It will 
take approximately 90 minutes and these procedures will be performed: 
 
1. A small sample of blood (about 5 tablespoons) will be collected from the arm vein to 
check for safety and levels of the study medication. 
 
2. An eye exam will be performed by one of the study doctors and your eyesight will be 
tested.  This involves sitting at a computer and answering questions about the letters 
that appear.  
 
3. You will be asked about any other medications you take. 
 
4. You will be asked about any side effects you are feeling. 
 
5. Your remaining study capsules will be counted. 
 
6. You will be provided more study drug if needed. 
 
The 12 month visit will occur approximately one year after the baseline visit.  It will take about 
three hours and these procedures will be performed: 
 
1. A small sample of blood (about 5 tablespoons) will be collected from the arm vein to 
check for safety and levels of the study medication. 
 
2. An eye exam will be performed by one of the study doctors and your eyesight will be 
tested.  This involves sitting at a computer and answering questions about the letters 
that appear.  
 
3. Your visual field will be measured.  The visual field test will take about 30 minutes and 
will involve you sitting at machine that will shine lights in your eyes to determine which 
part of your eyes are affected by RP. 
 
4. The thickness of your retina will be examined by Optical Coherance Tomography (OCT). 
This procedure will take about 10 minutes and will involve you sitting comfortably at a 
machine and looking straight ahead. 
 
5. Your color vision will be tested by the Chroma Test program, this involves sitting 
comfortably at a computer and answering questions about the colors you see.   
 
6. An important test called an Electroretinogram will be performed to determine how well 
your eye cells respond to light.  This test takes about 45 minutes and involves having 
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anesthetic drops placed in your eyes, causing them to become numb. The eyelids are 
then propped open with a speculum and an electrode is gently placed on each eye with 
a device very similar to a contact lens. Readings will be taken first in normal room light, 
then with the lights dimmed and finally readings are taken as a bright flash is directed 
toward the eyes. 
 
 
7. Fundus photography will be performed that will take about 10 minutes and involves 
having your eyes photographed.   
 
8. You will be asked to fill out a 25 question survey about how your vision affects your 
quality of life. 
 
9. You will be asked about any other medications you take. 
 
10. You will be asked about any side effects you are feeling. 
 
11. Your remaining study capsules will be counted. 
 
 
The 15 month follow up visit will occur approximately 90 days after the 12 month visit.  It will 
take approximately 45 minutes and these procedures will be performed: 
 
1. A small sample of blood (about 5 tablespoons) will be collected from the arm vein to 
check for safety and levels of the study medication. 
 
2. An eye exam will be performed by one of the study doctors and your eyesight will be 
tested.  This involves sitting at a computer and answering questions about the letters 
that appear.  
 
3. You will be asked about any other medications you take. 
 
4. You will be asked about any side effects you are feeling. 
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Follow up phone calls 
You will be followed closely during this research for your safety.  During the months that you 
do not have clinic visits scheduled (month 1, 3, 4, 5, 7, 8, 9, 10 and 11) a research nurse will 
call you at a time that is convenient for you.  She will ask you about any side effects you are 
feeling and if you are taking the medication as prescribed.  If necessary, she will arrange for 
you to come into the clinic for an additional visit. 
 
 
CONFLICT OF INTEREST DISCLOSURE  
 
NONE 
 
 
POSSIBLE RISKS:   
 
In patients with RP who have taken similar amounts of VPA to this study, the most common 
side effects were not serious and included stomach irritation and tiredness.  These symptoms 
may be alleviated by taking the medication on a full stomach and slowly ramping up the 
dosage over the course of 7 days. 
 
The risks associated with this study involve blood collection, the visual function tests and 
taking VPA.  During the blood draw your may experience discomfort, bleeding, and/or 
bruising. Your may feel dizzy or faint. On a rare occasion, an infection could develop at the site 
where the blood was collected. Blood will be drawn by personnel experienced in blood 
collection. 
 
The risks associated with ophthalmic procedures include redness, discomfort or allergic 
reaction to topical medications used to dilate the pupil prior to visual function tests. High 
blood pressure, cardiac dysrhythmias and closed angle glaucoma may be exacerbated by some 
of these medications and light sensitivity may be experienced when the pupil is dilated.  
Corneal abrasions may result from the contact lenses used in performing electroretinography 
testing. 
 
The most common side effects from VPA are stomach irritation, drowsiness or dizziness, 
restlessness or irritability, diarrhea or constipation, trembling of hands or arms.  In addition 
you may experience other unforeseen side effects that have not been reported before. 
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More serious side effects are rare (less than 1% of patients who take this medication 
experience these), but include:  Severe weakness or dizziness, severe vomiting that doesn't go 
away, unusual bleeding or bruising and yellowing of the skin or eyes.  If any of these symptoms 
occur, contact your study doctor immediately or seek emergency care. 
 
As with any study agent, there may be a risk of allergic reaction that could include rash, hives, 
itching skin, difficulty breathing, lowered blood pressure, swelling and even death.  If any of 
these symptoms occur, contact your study doctor immediately or seek emergency care.  You 
will be immediately treated with standard medicines used to treat such reactions. 
 
Your condition will be watched closely during the study.  If you have any serious reactions or 
problems, the treatment will be changed or stopped to protect your health. 
 
How you can help reduce some of the risks:  During your participation in this research, the 
study doctor will watch closely to determine whether there are problems that need medical 
care.  It is your responsibility to do the following:     
 Ask questions about anything you do not understand. 
 
 Keep appointments. 
 
 Let the investigators know if your telephone number, address or e-mail address 
changes. 
 
 Follow the study doctor’s instructions. 
 
 Take the medication with meals and slowly increase the dosage over 7 days until the 
prescribed dosage is reached. 
 
 Store study capsules in a cool, secure place at home away from anyone who is unable to 
read and understand labels, especially children. 
 
 Tell the study doctor before you take any new medication even if it is prescribed by 
another doctor for a different medical problem. 
 
Tell your regular doctor about participating in this research.       
What to do if you have problems:  If you have problems, such as unusual symptoms or pain, at 
any time while participating in the research, the study doctor can recommend treatment.  
Please report the problem to Dr. Kaushal immediately at (508) 334-0687. 
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PREGNANCY and REPRODUCTION 
 
VPA is known to be unsafe to the fetus during pregnancy and the infant during breast feeding, 
so women who are pregnant or nursing may not take part in this study.  VPA is known to have 
negative effects on sperm and hormones involved in reproduction.  The long term effects of 
VPA on reproduction are not known.  If you are a woman who is able to have children, you 
must have a negative pregnancy test before you begin the study and you must agree to use an 
effective birth control, such as oral contraceptive pills, contraceptive patch (if less than 198 
lbs), Depo Provera injection, or IUD during the study and up to 3 months after stopping the 
study drug.  If you become pregnant during the study, you should inform the doctors.  You and 
your child will need to be followed closely until the baby is born.  Men involved in this study 
must agree to use a barrier method of birth control during the study and up to 3 months after 
stopping the study drug. 
 
 
POSSIBLE BENEFITS:   
 
You may not benefit directly from being in this research study, either because you are 
assigned to take the placebo, or because VPA does not prove effective for RP.  However, your 
participation may help others with this condition in the future as a result of knowledge gained 
from the research. 
 
 
REASONS YOU MIGHT BE WITHDRAWN FROM THE STUDY WITHOUT YOUR CONSENT    
 
You may be taken out of the research study if: 
1. The investigator decides that continuing in the study would be harmful to you. 
2. You need treatment not allowed on this study. 
3. You fail to keep your appointments or take the medications as instructed. 
4. You become pregnant. 
5. The study is canceled by the company making the drug, the FDA, or the University of 
Massachusetts Medical School Institutional Review Board. 
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ALTERNATIVES    
You do not have to participate in this research to receive care for your medical problem. 
Although VPA is not approved for RP, it is possible to receive this medication without being 
involved in this study.  Alternative care includes nutritional supplementation with vitamin A 
that may slow progression of the disease.  No other treatment for RP is available.  
 
COSTS    
 
There will be no additional cost to you or your insurance company from being in this research 
study.  All the clinic visits, medicine and tests are done for research purposes and will be free.  
 
COMPENSATION 
 
You will be paid $250 for completing the six visits required to reimburse you for your time, 
travel and other expenses associated with this research study.  If you do not complete the 
entire study you will be reimbursed $50 per visit completed.   
 
CONFIDENTIALITY  
 
Your privacy is important to us.  Your research records will be confidential to the extent 
possible. In all records, you will be identified by a code number and your name will be known 
only to the researchers.  Your name will not be used in any reports or publications of this 
study.  However, the U.S. Food and Drug Administration (FDA), and the UMMS Institutional 
Review Board and/or their representatives may inspect your medical records that pertain to 
this research study.  We will not allow them to copy down any parts of your identifiable 
information (e.g. your name) or take any of your identifiable information from our offices. 
 
 
YOUR PARTICIPATION IN THIS PROJECT IS ENTIRELY VOLUNTARY.  YOU MAY WITHDRAW 
FROM THE STUDY AT ANY TIME. 
 
THE QUALITY OF CARE YOU RECEIVE AT THIS HOSPITAL WILL NOT BE AFFECTED IN ANY WAY 
IF YOU DECIDE NOT TO PARTICIPATE OR IF YOU WITHDRAW FROM THE STUDY. 
 
 
CONSEQUENCES OF WITHDRAWAL  
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If you, the study doctor, or the Monitoring Board stops your participation in the research it is 
your responsibility to do the following: 
•  Let the study doctor know immediately that your wish is to withdraw from the 
research. 
•  Return to the research center for tests that may be needed for your safety. 
•  Return any unused study materials, including empty containers. 
•  Discuss your future medical care with the study doctor and your regular doctor. 
 
RESEARCH INJURY COMPENSATION    
 
If you are injured or have any harmful effects as a direct result of your being in this research, 
treatment will be made available to you at UMass Memorial Medical Center (UMMMC).  You 
will not have to pay any charges resulting from the harmful effect or injury of a study drug (or 
device) or procedure that would not have otherwise been done as part of your regular care. 
 
QUESTIONS 
 
Before you sign this consent form, please feel free to ask any questions you may have about 
the study or about your rights as a research subject.  If other questions occur to you later, you 
may ask Dr. Kaushal at (508) 334-0687, the Principal Investigator. You may take as much time 
as needed to think this over.  If at any time during or after the study, you would like to discuss 
the study or your research rights with someone who is not associated with the research study, 
you may contact the Administrative Coordinator for the Committee for the Protection of 
Human Subjects in Research at UMMS.  The telephone number is (508) 856-4261.
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CONSENT TO PARTICIPATE IN THE RESEARCH PROJECT 
 
Title:  Phase II Clinical Trial of Valproic Acid for Retinitis Pigmentosa 
 
P.I. Name:   Shalesh Kaushal, MD PhD                                                         
 
Subject’s Name:                                                  
 
I understand the purpose and procedures of this research project and the predictable discomfort, risks, and 
benefits that might result.  I have been told that unforeseen events may occur.  I have had an opportunity to 
discuss the risks and benefits of this research with the investigator and all of my questions have been answered.  
I agree to participate as a volunteer in this research project.  I understand that I may end my participation at any 
time.  I have been given a copy of this consent form. 
 
                                                                                          Date:                                          
  Subject’s signature 
 
STATEMENT OF PERSON OBTAINING CONSENT 
I, the undersigned, have fully explained the details of this clinical study as described in the consent form to the 
subject named above. 
 
______________________________________________ Date: ________________ 
 Signature of person obtaining consent 
 
 INVESTIGATOR’S DECLARATION 
 
As the principal investigator or co-investigator on this study, I attest to the following: 
 the nature and purpose of the study and study procedures, as well as the foreseeable risks, 
discomforts and benefits have been explained to the above-named subject 
 this subject has been given the opportunity to ask questions and to have those questions answered by 
knowledgeable research staff 
 this subject meets the inclusion/exclusion criteria for this study 
 
I have considered and rejected alternative procedures for answering this research question. 
_______________________      ________________ 
PI Signature                                               Date 
 
3.6.7 CLINICAL TRIAL HIPPA RELEASE 
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UMass Memorial Medical Center 
AUTHORIZATION TO DISCLOSE  
PROTECTED HEALTH INFORMATION FOR RESEARCH PURPOSES 
 
The privacy law, Health Insurance Portability & Accountability Act (HIPAA), protects my individually identifiable health 
information (protected health information).  The privacy law requires me to sign an authorization (or agreement) in order 
for researchers to be able to use or disclose my protected health information for research purposes in the study entitled:  
Phase II Clinical Trial of Valproic Acid for Retinitis Pigmentosa 
 
I authorize UMass Memorial Medical Center to disclose my protected health information to : 
 
UMass Medical School including the researcher Dr. Shalesh Kaushal and his/her research staff 
Federal and State authorities that oversee research 
 
Protected health information (PHI) that may be disclosed includes all “x” boxes, and PHI which is listed in the sections 
titled “other” below. 
     General Records 
  Cardiac Studies (Heart)   Laboratory Reports 
  Consultations   Office/Clinic Notes  
  Discharge Summaries   Operative/Procedure Reports 
  EEG/EMG/Sleep Studies    Pathology Reports 
 Emergency Service Records   Problem List 
  Home Health Records   Pulmonary Studies (Lung/Respiratory) 
  Hospice Records   Radiology (X-ray/CAT/MRI/Ultrasound/Nuclear)  
  Immunization Records   Rehabilitation Notes (PT/OT/Speech) 
Other (Specify):    Name, Date of Birth, Contact information, race, ethnicity, results of genetic testing, family history, medical 
history, results of ophthalmic tests 
    Statutorily Protected Records 
  Abortion   Domestic Violence Counseling 
  Alcohol / Drug Abuse   HIV / AIDS Test Results / Treatment 
  Psychiatric Health   Sexually Transmitted Diseases 
  Sexual Assault Counseling  
Other (specify):  
 
 
My protected health information will be disclosed as listed above for the following reasons: 
 
The purpose of this research is to investigate whether valproic acid is safe and effective for treating retinitis 
pigmentosa (rod-cone dystrophy). 
 
I do not have to sign this Authorization.  If I decide not to sign the Authorization: 
 It will not affect my treatment, payment or enrollment in any health plans, or affect my eligibility for 
benefits.   
 I will not be allowed to participate in the research study. 
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If I sign the Authorization, I understand that: 
 I have the right to withdraw, or revoke, the Authorization. 
 If I revoke the Authorization, I will send a written letter to: Dr. Shalesh Kaushal, Dept of 
Ophthalmology, Rm S6-410; UMMS, 55 Lake Ave. N, Worcester, MA 01605 to inform him of my 
decision. 
 
 If I revoke this Authorization, researchers may only use the protected health information already 
collected for this research study. 
 If I revoke this Authorization my protected health information may still be used and disclosed should I 
have an adverse event (a bad effect). 
 If I change my mind and withdraw the authorization, I will not be allowed to continue to participate in 
the study. 
 Any disclosure carries the potential for re-disclosure. Once UMass Memorial Medical Center releases 
my protected health information, it may no longer be protected by the HIPAA privacy rule.  
 The entities receiving my protected health information will use it as described in the Consent 
Document for this study.  
 I may not be allowed to review some of the research-related information in my medical record until 
after the study is completed.  When the study is over, I will have the right to access the information 
again. 
 I will receive a signed copy of this authorization for my personal records. 
 
 
This Authorization does not have an expiration date. 
 
If I have questions about the research study, I should contact: Dr. Shalesh Kaushal, at Ph: 508 334-0687 
 
If I have not already received a copy of the Privacy Notice, I may request one.  If I have any questions or 
concerns about my privacy rights, I should contact the UMass Memorial Medical Center Privacy Officer at Ph: 
508-334-5551. 
 
I HAVE READ AND UNDERSTAND THE ABOVE STATEMENTS AND AUTHORIZE THE DISCLOSURE OF THE 
INFORMATION REQUESTED ABOVE. 
 
 
 
Signature of Subject Date 
Subjects Name Printed DOB SS# 
 
Use boxes below if parent or legal representative is signing for research subject 
 
Subject’s Legal Representative Signature Relationship Date 
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Print Name of Research 
Subject DOB SS# 
 
 
 
Please explain Representative’s Relationship to Patient and include a description of Representative’s Authority 
to act on behalf of Patient: 
__________________________________________________________________________________________
__________________________________________________________________________________________
______________________________ 
 
 
 
Person obtaining HIPAA authorization  Date 
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3.6.8 RESEARCH PHARMACY  
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CHAPTER 4:  APPLICATIONS FOR FUNDING 
4.1 INTRODUCTION 
Funding mechanisms for investigator initiated clinical trials are limited at best.  NIH initiatives tend to 
be for large, collaborative, extremely expensive studies or small proof of concept studies.  The NEI is 
one of the smaller NIH institutes and their funding opportunities for clinical trials appear to be limited 
to one large U-type grant opportunity.  In fact, many of their RFPs specifically exclude clinical trials.  
The primary pathway we initially pursued for funding this trial was through private foundations.  We 
were in early discussions with the Foundation Fighting Blindness (FFB) when the stimulus funding 
was announced and I discovered a potential challenge grant opportunity (15-OD(ORDR)-101* Pilot 
Projects for prevention, early detection and treatment of rare diseases.)  While the description of 
this RFA only mentioned clinical trials briefly, we felt that the contained nature of the trial would make 
it ideal for the 2 year Challenge grant mechanism.  Dr. Kaushal and I spoke directly to the contact at 
NEI who administered this specific RFA and he informed us that it was likely written specifically for an 
existing consortium, but our proposal sounded promising so we should submit an application. 
We tandemly pursued funding through Dr. Kaushal‟s contacts with the FFB.  The lack of formalized 
process by the FFB is reflected in the fact that the only document they officially requested is the 
budget I produced.  This does not accurately reflect the major amount of time on the phone, in email 
correspondence and meetings that was spent pursuing this opportunity.   
4.2 THE PROCESS 
4.2.1 CHALLENGE GRANT APPLICATION 
Although I had been involved in many NIH submissions before, I had never independently written and 
submitted a grant. Fortunately, there are a host of UMMMC resources to aid in submission of funding 
applications.  The Research Office helped me to set up the ERA Commons (the NIH electronic 
submission tool) and Cayuse accounts and I quickly taught myself to use these systems to prepare 
and assemble the application.   The Research Office was always available, even in the midst of an 
overwhelming number of Challenge grant submissions, and their help was invaluable. 
Writing the research plan for the Challenge grant while designing the study was very helpful as I was 
able to more thoroughly define the processes and procedures proposed in the trial.  Additionally, the  
sections required for NIH proposals proposing human subjects testing (page 201) served as the 
framework for many aspects of the protocol.  Preparing the NIH budget was perhaps the most 
daunting aspect of the Challenge grant proposal. Clinical trials are not typically included in NIH 
research proposals from the UMMMC community. Complicating this was the newness of Dr. 
Kaushal‟s clinical trial facility at the Memorial campus and the uncertainty of how to bill the 
procedures.  I ended up preparing two budgets – one procedure-based and a more professional 
services-based budget.  Ultimately, the professional services-based budget was used as the template 
for the final NIH budget  (page 210).  
4.2.2 FOUNDATION FIGHTING BLINDNESS  
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To begin discussions regarding the funding of the trial by the FFB, Dr. Kaushal hosted a meeting at 
our campus with the director of the FFB and another board member.  Dr. Noorwez from Dr. Kaushal‟s 
lab presented the in vitro studies on VPA and I presented some early data from the few subjects I had 
access to as well as my current study design.  We were extremely encouraged by the positive 
feedback from the FFB and pointed requests by the director for us to pursue funding with the FFB. 
There was no real formal process for applying for funding from the FFB, and the process was 
punctuated by periodic phone calls from the director making assertions such as “I can write you a 
check for the trial right now” and other conflicting communiqués suggesting the FFB was in a funding 
crisis.  The lack of FFB process was a huge disadvantage as I had no visibility into what was 
required, and despite my attempts to annotate the process, it can be described summarily as – 
whenever anyone at the FFB, from the director to a board member, thought up something new they 
wanted to see- we were required to produce it immediately.  On one occasion they requested the 
protocol before it was completed, another time they asked for a complete literature review on the 
safety of VPA on long term reproduction, another time they requested all the raw visual fields we had 
collected to date on patients. Compounding the frustrating nature of the interactions was the very real 
lack of confidentiality maintained by everyone at the FFB.   
The culmination of our funding request was a meeting of the FFB board to decide whether to commit 
the funds for this trial.  In addition to responding to the many whims of the board member weeks 
before this meeting, I prepared an entirely procedure-based budget for this proposal (page 213). It 
was in the process of sending materials in anticipation of this meeting that Dr. Kaushal learned of 
several egregious instances whereby the director of the FFB and board members violated 
confidentiality agreements with us and we summarily severed ties with the FFB.   
4.3 ISSUES AND RECOMMENDATIONS 
The Research Office and Sheila Noone were incredibly helpful in guiding me through the budget 
process for both the NIH and FFB proposals.  It is clear that the UMMMC infrastructure in this area is 
established and expertly staffed.  One area of clinical trial budgeting that could be improved upon is in 
defining the procedure and drug costs that the investigator will incur during the trial.  There is no 
online standardized list of costs for services like CBCs; this information can be obtained by calling the 
laboratory directly or consulting the clinical research office to determine the negotiated costs.  
Additionally, the costs for more complicated diagnostics are not well defined.  Working with the 
Ophthalmology clinic billing staff I was able to estimate various costs, but a formalized system of 
relating clinic procedures to actual investigator costs would allow more accurate accounting for these 
kinds of budgets. 
Additionally, it will be important to centralize all the resources for clinical trial budgeting and sponsor 
negotiations through the UMCCTS website.  Currently these documents are buried and difficult to 
locate among the Office of Research portal. 
4.4 OUTCOMES 
The Challenge grant application was reviewed but not given a priority score.  The reviewer feedback 
was quite variable with one reviewer scoring it high in every aspect, and one reviewer giving it poor 
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scores for each area.  The other two reviewers scored the application in the mid-range over all.  The 
critiques ranged from my newness as a clinical researcher (which is actually supposed to be 
considered positively since we submitted under the “New Investigator” initiative), to the lack of 
evidence supporting VPA as a retinal therapeutic. Ultimately the comments will be used to strengthen 
the application as we plan to submit an R01 to NINDS in the spring.   
Needless to say, after almost an entire year of pursuing funding of this trial by the FFB, we are no 
longer in contact with this organization. Nevertheless, I learned quite a bit about sponsored trials from 
this process. 
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4.5 NIH CHALLENGE GRANT SUBMISSION 
Project Summary/Abstract 
 
This application addresses broad Challenge Area (15) Translational Science, and the specific challenge area 15-
OD(ORDR)-101* Pilot Projects for prevention, early detection and treatment of rare diseases.  
 
Retinitis Pigmentosa (RP) is a rare (orphan) disease affecting approximately 100,000 people in US, with an incidence of 
about 1 in 3000 in the general population. This catastrophic disease is characterized by progressive loss of visual field 
(VF) until complete blindness.  There is no treatment currently available.  Investigator initiated clinical trials are an 
important avenue for efficacy studies in orphan diseases such as RP given the perceived lack of financial return on 
investment by industry.  We have recently focused our efforts to couple our in-depth knowledge of the cellular basis of RP 
with the biological action of already approved drugs. The significantly shortened time to treatment inherent in new 
indications for existing medications allows for more rapid introduction of new treatments.  This is appealing to independent 
investigators, which means more rapid translation of basic science discoveries to the clinic.  We initially identified valproic 
acid (VPA) as a potential target for RP therapy utilizing a screen to examine small molecules for enhanced mutant 
rhodopsin folding.   Other work by our lab has shown that this small molecule is a potent inhibitor of retinal cell 
apoptosis which is also important in the pathogenesis of RP.  We performed a preliminary clinical analysis by treating 
6 RP patients off label with oral VPA. This preliminary clinical data suggests that VPA has the potential to not 
only stop the progressive loss of VF in RP patients, but can also restore VF.   Here, we propose to conduct a 12 
month Phase II clinical trial to test the efficacy of VPA for treatment of RP.  Using the pilot data, we have designed a 
unique one-armed self-controlled study. We propose to assess primary outcomes during a defined period just prior to 
start of study medication; in this manner we can predict personalized rates of vision loss that would have occurred 
during the 12 months of treatment. The study protocol includes screening, baseline and monthly ophthalmologic 
measures including perimetry, color contrast sensitivity (CCS) and visual acuity (VA).  Furthermore, we propose to 
correlate genotyping information with efficacy to investigate whether VPA is selective for a sub-population of RP patients.  
Finally, we propose to perform an initial therapeutic dosing analysis in a standardized subgroup of subjects.  
This clinical trial is appropriate for the 2 year timeline for the following reasons:  1) VPA‟s prior FDA approval 
allows for an expedited approval process; 2) we have been in close contact with FDA and are in the process of 
submitting both the IND and the IRB application supporting our ability to begin recruitment in September 2009; 3) an 
established population of RP patients in our clinic combines with the absence of any standard therapy to allow for an 
efficient and curtailed recruitment period; 4) our new, state-of-the art clinic is already equipped with all the necessary 
diagnostic equipment and  5) the study design and proposed recruitment and follow up fit within the 24 month 
timeline. 
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Specific Aims  
 
Phase II Clinical Trial of Valproic Acid for Retinitis Pigmentosa  
We present here a unique combination of preclinical data combined with preliminary clinical evidence suggesting that 
valproic acid (VPA) is an effective therapeutic agent for Retinitis Pigmentosa (RP), a devastating and serious orphan 
disease that currently has no effective treatment.  VPA is already approved by the FDA for other indications, allowing for 
an expedited human study. VPA is off patent protection, and is widely used off-label for a variety of indications, making 
this initial efficacy study an unattractive candidate for pharmaceutical companies.  Investigator initiated clinical trials, such 
as we propose here, are often the primary source of new therapeutics for rare diseases.   
This proposal for phase II clinical trial of oral (VPA) administration to subjects with RP associated retinal disease stems 
from both the lack of treatment for this severe blinding disease and our proof-of-concept studies. Preliminary clinical data 
suggests that VPA, at doses that have not shown toxicity in humans, results in improvement in visual fields. The primary 
endpoints in this trial will be visual function as assessed by perimetry, standard acuity assessments, color contrast 
sensitivity, optical coherence tomography and electroretinograms.  Safety will also be assessed by systemic clinical 
examinations and measurements of hepatic and pancreatic function as assessed by hematology and serum chemistries 
and reported subject history of any symptoms and adverse events. 
 
Specific Aim 1: Perform a phase II clinical trial of 12 month treatment with oral VPA, 250 mg BID, in subjects 18 
years and older with Retinitis Pigmentosa. 
To assess the efficacy of oral administration of VPA in RP patients, we will perform an open-label, standard-dose per 
patient, phase II clinical trial in a cohort of 45 patients. The planned dose of VPA that will be administered to human 
subjects is approximately half of the recommended dose for anti-convulsant therapy and has been well demonstrated to 
be safe in humans.  Patients will provide their own historical control as primary outcome measures will be determined 
from one to 3 months prior to the start of the study and again at baseline.  These control measurements will provide 
estimated rates of vision loss that would occur during the course of the study. 
 
Specific Aim 2:  Perform a genotype analysis of enrolled subjects in order to determine both the generalizability 
of this medication to all RP mutant types and to collect data on the possible mechanistic action of VPA. 
Preliminary studies in vitro and in vivo suggest that VPA may work at multiple levels as a retinal therapeutic.  We have in 
vitro data to suggest that it works at the level of rhodopsin folding, which would indicate that only those patients with 
protein folding associated RP would benefit from this medication.  However, other evidence suggests that VPA may work 
at the level of cell death protection or inflammatory mediation to exact its affect.  Our other preliminary clinical data 
suggests that VPA may be beneficial to other ocular diseases that aren‟t known to have protein folding pathway 
deficiencies, also supporting that VPA is working either on multiple pathways or in a protein folding independent pathway.  
To examine this in more detail, we propose to genotype the mutations associated with enrolled subjects.  We will correlate 
primary and secondary outcome measures with each known mutation to determine if VPA has a general benefit to all 
patients with RP or if its effect is specific for sub populations of patients.  
 
Specific Aim 3: In a cohort of selected patients with similar disease progression and/or mutation profile (e.g. RHO 
p23H), perform an escalating dose trial. 
Our preliminary clinical analysis suggests that RP patients receive an almost immediate therapeutic benefit to VPA.  A 
critical question will be the effective dose range for RP patients.  Utilizing the genotyping information from Aim 2, and/or 
the projected rate of vision loss from the screening period coupled with outcome measures from the initial intervention 
phase (the first 6 months), we can identify a standardized cohort of patients.  In this cohort (cohort 2), we will escalate the 
dose of VPA from 250 mg BID to 250 mg QID over the course of 6 months (this is still well within the known safety and 
tolerability profile of this medication). Primary outcome measures will be assessed to determine therapeutic dosing 
windows and dose response relationships.   
 
This data from the above Specific Aims will be used, in collaboration with the NIH and potential pharmaceutical 
companies, for planning the Phase III clinical trial. 
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Research Design and Methods 
Phase II Clinical Trial of Valproic Acid for Retinitis Pigmentosa 
Challenge Area and Specific Challenge Topic 
This application addresses broad Challenge Area (15) Translational Science, and the specific challenge area 15-
OD(ORDR)-101* Pilot Projects for prevention, early detection and treatment of rare diseases.  
 
 
The Challenge and Potential Impact: 
The Challenge 
RP is a severe neurodegenerative disease of the retina 
characterized initially by night blindness with 
progression to tunnel vision and eventual loss of central 
vision and total blindness.  Targeted therapies for RP 
are complicated by the identification of more than 30 
genes linked to the dominant and recessive forms of the 
disease.  Further compounding this complexity is the 
rarity of this disorder: although RP is one of the most 
common inherited eye diseases with an incidence of 
~1:3000, its prevalence is relatively rare.  RP affects 
approximately 100,000 individuals in the U.S. which 
qualifies it as an orphan disease.  Given the huge costs 
associated with the preclinical and clinical phases of 
drug development, pharmaceutical companies are 
generally reluctant to invest in developing new 
therapeutics for RP.  While a few new approaches for 
RP treatment have recently been investigated including 
nutritional supplementation, light reduction and gene 
therapy (Delyfer et al., 2004; Gaby, 2008; Hartong et al., 
2006), of these, vitamin A supplementation is the most 
promising, but its benefits are modest and side effects 
are problematic.  Therefore, currently there is no 
significant cure for RP.     
 
We present here a new treatment for RP which is based upon our strategic initiative to combine understanding of the 
pathophysiology of the disease with the known biological properties of existing therapeutics.  There are several major 
advantages to this approach.  First, since the bulk of the pre-clinical, pharmacokinetic, manufacturing, safety and 
tolerability analysis is complete, clinical trials can generally begin along the Phase II spectrum.  In this manner, the huge 
costs associated with discovering and testing new medications is avoided, effectively allowing translation of basic science 
discovery via investigator initiated studies.  Second, the time to treatment in humans is expedited, fostering delivery of 
effective medications in a shortened time frame. Third, the relatively inexpensive cost of “relabeling” existing formulations 
for new indications may motivate pharmaceutical companies to invest in therapies for less common diseases.  
Recently, we have demonstrated the use of retinoids and other small molecules as pharmacological chaperones to 
increase the yield of properly folded RP mutant rhodopsins in heterologous cell culture (Noorwez et al., 2008).   We have 
tested whether other known small molecules can provide similar effects.  We identified valproic acid (VPA) through this 
screen. In vitro data supports that VPA has multiple biologic properties that make it an ideal candidate for a retinal 
therapeutic.  First, our in vitro assay shows that VPA effectively increases yields of properly folded mutant rhodopsin 
(Figure 1); such a dramatic impact on mutant rhodopsin folding has never been demonstrated in a potential 
therapeutic.  Second, VPA protects cells from oxidative stress induced apoptosis (Figure 2), most likely through 
upregulation of the heat shock response (not shown).  This result has implications for RP but also for many other 
ocular disorders which are mediated through cell death. Other work demonstrates that VPA is a potent inhibitor of 
histone deacetylase (HDAC) (Gottlicher et al., 2001) and the inflammatory response pathway via apoptosis of microglial 
cells (Chen et al., 2007; Dragunow et al., 2006; Kim et al., 2007). Collectively, this body of evidence suggests that VPA is 
an appropriate therapeutic for patients with retinal dystrophies.  
 
Figure 1 Valproic Acid allows mutant P23H rhodopsin to properly fold to 
the level of wild type. HEK293 cells stably expressing an inducible mutant 
P23H rhodopsin expression vector were grown to confluence and tetracycline 
was added to induce opsin expression. 3mM VPA was added for 48h. 
Rhodopsin was purified by immunoaffinity methods.  Yields of folded p23H 
opsin were quantified by spectrophotometry .  In the presence of 11-cis 
retinal, folded mutant rhodopsin levels (red) increase from baseline (blue) to 
that of wild type (green).   
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It is critical to emphasize that the extensive history and well 
established safety and tolerability profile of VPA makes it an ideal 
candidate for a Phase II study, which streamlines the time to 
treatment in humans considerably relative to new drug design.  VPA 
was approved by the FDA for use as a broad spectrum anticonvulsant 
in 1978 and is also used for acute and maintenance therapy of bipolar 
disease, for migraine prophylaxis, and occasionally for chronic pain 
syndromes (Henry, 2003).  
The unusual and dramatic set of pre-clinical and pilot human 
data that we present here with a FDA approved drug uniquely 
positions us to complete the clinical trial outlined in the  Specific 
Aims in the NIH Challenge Grant funding window of 2 years.  
 
 Potential Impact 
Prevention of disease progression and restoration of vision are the 
ultimate goals of this proposal. RP is an incurable and untreatable 
group of heterogeneous retinal degenerative diseases that cause 
severe visual loss. While 
individual rates of vision loss can 
vary greatly even among siblings with the exact same mutation (Berson et al., 2002), 
projections from the literature suggest that RP patients will lose an average of 15-
17% of their visual field (VF) annually (Massof et al., 1990; Zeger and Liang, 1986) 
and 25% of RP patients will lose 20% of their VF in one year (Merin et al., 2008). 
There is currently no significant therapeutic that effectively slows the progression of 
this disease, and certainly none that can restore vision in RP patients.  Our 
preliminary studies indicate that VPA is a remarkable retinal therapeutic that may not 
only stop the progression of this disease, but also reverse loss of visual field.  An 
investigator initiated clinical trial as we propose is an important if not the only way for 
new therapeutics to be investigated for rare disorders such as RP. 
 
Our comprehensive study design includes novel methodologies that address several 
issues inherent in diseases with wide ranging progression patterns. The individual 
projected rates of vision loss determined from the baseline and screening analysis 
described in Specific Aim 1 and the genotyping and therapeutic dosing studies 
proposed in Specific Aims 2 and 3 provide mechanisms to relate therapeutic benefit 
to specific rates of disease progression, mutations and broad groups of disease 
classification.  Dr. Robert Brown, an internationally lauded clinical trialist in the field of 
amyotrophic lateral sclerosis (ALS), has reviewed and endorsed this trial, and feels 
that it provides methodology that can advance the science of investigating neuro-degenerative disorders in general (see 
Letter of Support). 
 
The Approach: 
Aim 1: Perform a phase II clinical trial of 12 month treatment 
with oral VPA, 250 mg BID in subjects with retinopathy due 
to Retinitis Pigmentosa. 
To assess the efficacy of oral administration of VPA in RP 
patients, we will perform an open-label, phase II clinical trial in a 
cohort of 45 patients. The planned dose of VPA that will be 
administered to human subjects is approximately 1/2 of the 
recommended dose for anti-convulsant therapy (see Table 2) 
and has been well demonstrated to be safe in humans.  Patients 
will provide their own historical control as primary outcome 
measures will be determined from one to 3 months prior to the 
start of the study and again at baseline.  These control 
measurements will provide estimated rates of vision loss that 
would occur during the course of the study. 
 
Pilot Clinical Analysis 
A unique and robust aspect to our proposal is the inclusion of 
preliminary clinical data which informed our trial design. Six RP 
 
Figure 4  Visual Field Areas of Patients Treated off-label 
with VPA. Goldmann Kinetic Perimetry tracings (isopter V4e) 
from each eye (e.g. Figure 3) were digitized and areas were 
automatically calculated.  The 6 patients were treated with VPA 
for varying lengths of time so the percent change per month 
from baseline was calculated for each eye and average values 
are presented.    
 
Figure 2  VPA Rescues Retinal Pigmented Epithelium 
Cells from Hydroquinone (HQ) induced apoptosis.  
ARPE-19 cells are protected from HQ mediated apoptosis 
by the presence of VPA.  
 
 
 
 
Figure 3  Perimetry Tracing of a 
Patient treated with VPA Goldmann 
Kinetic Perimetry tracings (using V4e 
isopter) of Patient One before and after 
treatment with VPA 250 mg twice daily. 
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patients were treated off-label with oral VPA (250 mg BID) for 2 to 6 months.  Visual fields were measured using kinetic 
perimetry (Figure 3).  Results varied from patient to patient, 2 of 6 patients experienced progression of their disease while 
on VPA. However, 4 of 6 patients showed no progression of their disease on VPA (Figure 4), moreover, these 4 patients 
experienced an increase in their visual field (e.g. Figure 3)- which no other therapeutic has previously shown.   
 
Overall, we detected an average increase in visual field of 6%/month. These results suggest that VPA has the 
potential to not only stop the progression but may also reverse loss of visual field.  No adverse affect of VPA was 
seen in these patients as assessed by clinical analysis, hematology and serum chemistry or by patient reports. 
 
While this preliminary clinical analysis combines with the in vitro data above to suggest that VPA may be an effective 
retinal therapeutic, the number of patients and length of treatment was short.  Moreover, several factors likely contributed 
to the within-patient variability.  Individual historical information was not available to calculate expected rates of vision 
loss. Secondly, the rigorous standardization of ophthalmologic diagnostic measures that we propose here were not 
instituted in the off label treatment of these few patients.  We propose to address these issues carefully in our study 
design below. Additionally, the between-patient variability potentially suggests that certain patient populations may 
preferentially benefit from this medication (this will be examined in detail in Specific Aim 2).    
 
Clinical Trial Design 
A variety of factors were considered for the overall study design.  While crossover, futility and delayed start type studies 
were initially considered, the length of time needed to detect a change in outcome combined with the potential for short 
term symptomatic versus therapeutic benefit suggested that these designs were not appropriate.  A randomized placebo 
controlled trial was considered, but for the RP population with 
drastically different presentation and progression, it is difficult if not 
impossible to ensure that controls represent the treated subjects.  
The additional costs and difficulty in recruiting twice the number of 
patients in an orphan disease population were also significant 
concerns.  A novel aspect to our trial design is that it is self 
controlled; individual patients provide current rates of vision loss.  
We designed the trial and protocol in close communication and 
consultation with Wiley Chambers, M.D., deputy director of the 
FDA's Division of Anti-Inflammatory, Analgesic and Ophthalmologic 
Drug Product and multiple experts in the field of neurovision 
research including (see letters of support): Stephen Rose, Ph.D,  
the Research Director for the Foundation Fighting Blindness (FFB); 
Robert Brown, MD, PhD, the Chair and Professor of Neurology at 
the University of Massachusetts Medical Center (UMMMC), a 
renowned and experienced clinical trialist in neurodegenerative 
disorders similar to RP; and Gerald Cagle, PhD; a trustee for the 
National Neurovision Research Institute (NNRI) who recently 
retired as the senior vice president of Research and Development 
and Chief Scientific Officer for Alcon.  Additionally, we have 
consulted colleagues at Ora, a retinal clinical trial contract research 
organization, and institutional biostatisticians.  
 
 Using a one sample t-test calculation, informed by our pilot analysis and historical control data, we estimate a 
treatment effect (delta) of 50% change in VF annually in untreated versus VPA treated RP patients. This estimate of 
delta assumes that participants would lose no VF in a year if left untreated (a conservative assumption given the 
natural course of this disease (Berson et al., 2002; Massof et al., 1990; Merin et al., 2008)).  An enrollment of about 40 
patients provides 90% power for a significance level of p<.05 (Figure 5). Due to the fact that related family members 
will likely co-enroll in our study (see Recruitment section), the relatively short nature of this trial and the motivation 
associated with this devastating disease, we conservatively estimate attrition of about 10%, leading to a projected 
recruitment target of 45 participants.  In our novel design, assessments of primary outcomes will be performed from 1 to 
3 months and immediately prior to the start of the study agent to calculate individualized (linked) loss of vision rates for 
each subject (Figure 6).  This contemporary historical information will be used to predict the loss of vision that would have 
occurred in the 12 months of the study.   
 
Study Medication, Route of Administration and Dosage 
Figure 5 Sample Size and Power calculations. 
Sample size estimates using pilot data (Figure 4).  A 
one sample t-test calculation assuming no loss of VF 
in untreated RP patients (U0=0%) and an estimated 
VF yearly gain of UA= 50%, (SD=96%) on VPA 
provides an estimate of around 40 patients with 90% 
power and statistical significance of p<.05. 
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VPA is well tolerated in most patients and adverse events are rare (reviewed in Peterson and Naunton, 2005).  The 
primary concern is hepatoxicity which is rare in low risk patients occurring in fewer than .29 in 10,000 patients (Bryant and 
Dreifuss, 1996). Subjects will be carefully screened for comorbid conditions and concomitant medications to ensure that 
only patients at the lowest risk for serious 
adverse events are enrolled (see Exclusion 
Criteria in Protection of Human Subjects 
Section).   
VPA will be administered orally by ingestion of 
250 mg capsules. Cohort 1 will receive 250 mg 
BID (for a total daily dose of 500 mg) for the 
entire 12 months of the study, while subjects in 
cohort 2 will receive a dose of 250 mg BID for the 
first six months and receive a dose of 250 mg 
TID (for a total daily dose of 750 mg) from month 
6-9 and 250 mg QID (for a total daily dose of 
1000 mg) from month 9-12 – see Specific Aim 3.  
In order to avoid gastrointestinal side-effects all 
patients will be instructed to take the medication 
with food and to gradually increase the dosage of 
VPA to achieve targeted dosing in 7 days. 
 
Study Design and Execution 
Patients will undergo clinical examinations and 
evaluations of retinal function and structure prior 
to consideration of the subject as a candidate for clinical trials. Clinical examinations will include refraction, static and 
kinetic perimetry, fundus photography and visual acuity. Measures of visual function will include full-field 
electroretinography. Optical coherence tomography will be used to measure retinal structure. Methods of these measures 
are detailed below. During these evaluations, medical and ophthalmic histories will be elicited from subjects and their 
families to ensure that there are no comorbid medical or ocular genetic conditions that may prevent study participation. 
While the equipment proposed for use in this trial is state of the art and as such will provide the highest level of 
quantitation available, the quasi-subjective nature inherent in many standard ocular tests make day-to-day variation an 
important confounder to our analysis. All diagnostic measures will be calibrated and standardized such that intervisit and 
interocular variances for each outcome measure will be quantified and included in our analysis.  This will involve 
sequential repeated measures for the same and different patients on these machines from a representative sample of our 
recruited patients.   
  
Recruitment 
Primary recruitment would be from the greater Worcester area from the UMMMC Department of Ophthalmology. 
Additional recruitment support will be provided by the Foundation Fighting Blindness (see letter of support). Given the 
debilitating nature of this disease, established number of clinically well characterized RP patients and family groups and 
lack of any available treatment combined with the overwhelming expressed interest of our established patients, 
recruitment will be swift.  At present, 20 patients in Dr. Kaushal‟s rapidly growing practice are likely recruitments.  We 
anticipate that we can begin screening the first patients in September 2009, with baseline screening of the last patient in 
by June, 2010 (see Timeline and Milestones).  Given our access to the extensive histories of most of those recruited, we 
anticipate that most screened participants will be suitable for enrollment, hence an estimate of 50 screened subjects to 
achieve the target of 45 enrolled patients.  
 
Study Visit Schedule (see Table 1) 
All screening determinations will be performed between 4 and 12 weeks prior to the baseline visit.  Baseline determination 
will be considered time 0 and study medication will commence on that day.  Screening and baseline determinations will be 
used as individual control information for each patient.   Most participants will take oral VPA 250 mg BID for the entire 
study period, while a small cohort in the second half of the study will take escalating doses as described below.  All 
participants will return to the clinic 7, 21, 60, 120, 180, 270 and 360 days after initiating VPA treatment for evaluation of 
their clinical status and to assess adverse events.  Participants will be asked to provide information on any side effects 
they are experiencing.  Subjects will be followed up with phone calls after the baseline, week 1 and 6 and 9 month visit.  In 
all cases, participants will be followed for a period of 3 months after the study ends.  In the latter 6 month phase of the 
trial, cohort 2 patients will be followed closely during the escalation phase of their dosing.  Additional visits may be 
scheduled as clinically required. 
 
 
Figure 6 Study Design. Blocks outlined in red represent 
comprehensive testing visits where the most extensive battery of 
diagnostics will performed. Other follow up visits entail less extensive 
diagnostics.  (See Table 1 for  full schedule of study visit procedures). 
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Evaluation of Primary Endpoint- Visual Function and Retinal Anatomy Changes 
Visual function will be quantified for the months prior to and after start of study medication in order to determine whether 
VPA administration affects visual/retinal function. The main measure of visual function will be visual fields as measured by 
kinetic and static perimetry. Other measures of visual function will include best corrected ETDRS visual acuity; color 
contrast sensitivity as measured by the Chroma Test; retinal anatomy as measured by Optical Coherance Tomography 
(OCT) and  rod and cone responses as analyzed by electroretinography (ERG).  Primary outcomes for efficacy for both 
eyes will be determined.   
 
Secondary outcomes will include: fundus photography; the 25 item National Eye Institute Visual Function questionnaire to 
assess quality of life (QOL); efficacy as predicted by specific mutation; the dose response profile of VPA as measured by 
serum VPA levels and the toxicity and safety profile of VPA in RP patients.   
 
Follow-Up 
We have been in close contact with Wiley Chambers, M.D., deputy director of the FDA's Division of Anti-Inflammatory, 
Analgesic and Ophthalmologic Drug Products throughout the development of this protocol.  Although we were advised 
that no additional follow up of these subjects after the 12 month treatment is necessary, we intend to follow these patients 
for an additional 3 months after the end of the study.  Additionally, if the VPA treatment appears to be efficacious and the 
DSMB concurs, interested participants will continue to be provided prescriptions for VPA and standard follow up care, at 
their own incurred expense.  
 
 
Statistical Methods 
Table 1:  Schedule of Study Evaluations. 
                      
  Screening Baseline Treatment  
Time relevant to start of Oral VPA  Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 7 Visit 8 Visit 9 Visit     10 
Early 
term.
d 
b Month 0 1 2 4 6 9 12 15 
Week -8 to -4 0 1 3 8 16 24 36 48  
Informed Consent x x                   
Inclusion/exclusion Criteria x x                   
Medical/surgical history x                    
Physical examination x                  x 
Ophthalmic history x                    
Safety Labs x  x   x  x x x  x  x x 
Demographic data x                    
Molecular Genotyping
a
  x          
Ophthalmic  Exam
b 
 x x x  x x  x x x   x  x 
Urine pregnancy test x  x          x        
Visual Acuity (BCVA) x x x x  x  x x  x  x  x 
Perimetry x x      x     x  x x  x x   x 
Color Contrast Sensitivity x x  x  x  x x  x   x  x 
Electoretinography x x      x    x  x 
Optical coherence tomography (OCT) x  x         x   x   x 
Fundus photography (FP) x               x  x 
Quality of Life Questionnaire
 c
  x       x  x 
Remaining pill count for med. monitoring   x x x x x x x   
VPA prescribed  x x x x x x x x x  
VPA level (labs)    x x x x x x x x 
Increase VPA dose (cohort 2)       x x    
Concomitant medications x  x  x  x  x  x x x  x  x  x 
Adverse events assessment    x x x x x x x x x x 
24 hours follow-up phone call   x x    x x    
i. If enrolled 
j. Ophthalmic examinations include:  slit lamp examination; tonometry, indirect ophthalmoscopy and retinal biomicroscopy.  
k. Quality of Life Assessed using the 25-Item NEI Visual Function Questionnaire 
l. For subjects that withdraw from the study at any time before visit 9. 
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Sample size calculations were based on the pilot study as described in detail above and in Figure 5.  Briefly, the null 
hypothesis being tested in this trial is that there will be no change in measures of visual field upon treatment.  An effect of 
50% positive increase in VF annually will provide 90% power for a significance level of p<.05.  Data will be analyzed using 
student t tests (paired and unpaired).  Multiple predictor regression models will be created using exponential change (to 
better approximate normality) in VF area, visual acuity, color contrast sensitivity, ERG amplitude and central foveal 
thickness as outcomes.  Predictor covariates will be age, age at presentation, VF area at baseline, genotype, inheritance 
pattern, current rate of annual VF loss (predicted from baseline and screening visits), average serum VPA value and dose 
of VPA.  Analysis will be performed based on an intention to treat analysis.   
The relationship between VPA dosing and efficacy as measured by change in VF from baseline will be assessed in cohort 
2 at total daily dose levels of 500 mg; 750 mg and 1000 mg via AUC analysis.  A secondary objective will be to investigate 
the relationship between serum VPA concentrations and efficacy in the entire study group. 
 
Premature Discontinuation 
Subjects who do not complete the full schedule of evaluations will be considered to have prematurely 
discontinued the clinical trial. The reasons for premature discontinuation will be documented. Subjects who 
elect to prematurely discontinue participation may be considered for re-entry into the study at their request. 
Potential reasons for premature discontinuation include: grade 3 or 4 toxicity judged to be possibly or probably 
related to study therapy, or the development of other unexpected, life-threatening complication not described; 
patient noncompliance with study procedures; voluntary withdrawal; termination of the study by a Principal 
Investigator, the Data Safety Monitoring Board, or the Food and Drug Administration. Subjects may voluntarily 
discontinue their participation prematurely without prejudice. Subjects who withdraw from the study will be asked to return 
to the study center to complete an early withdrawal visit. 
 
Detailed Methods for Visual Function: 
 
Visual Field 
Visual field measurements will be made as described for patients with severe vision loss (Nowomiejska et al., 2005; 
Nowomiejska et al., 2008) using the Octopus 101 (Haag-Streit International) with the semiautomatic kinetic perimetry 
(SKP) module.  Stimuli of selected size and luminance according to the Goldmann classification are moved along user-
defined vectors having a constant angular velocity of 3° per second. Vectors are drawn manually using an electronic pen. 
The stimulus is moved almost perpendicularly towards the presumed scotoma border from nonseeing towards seeing 
areas of the VF. Fixation is monitored by a digital infrared camera, which provides a highly magnified image of the tested 
eye. The stimulus movement along each vector is terminated by the response of the patient, who is instructed to look 
straight ahead at the fixation point (green cross) and press a button as soon as the stimulus is perceived. The respective 
stimulus location is marked on the screen automatically by the software with a size- and intensity-specific symbol, and 
after several repetitions with different vectors, the symbols are connected, and enabling isopters are drawn in selectable 
color. The area enclosed by an isopter is automatically quantified by the software using triangulation in square degrees of 
eccentricity. 
 
Visual Acuity 
Although patients in this clinical trial may have severe loss of visual function, an attempt will nevertheless be made at 
measuring a best-corrected visual acuity. Testing in each eye will use standard Early Treatment Diabetic Retinopathy 
Study (ETDRS) protocol.  If the patient cannot read at least three of the letters of the first line correctly, the chart distance 
will be progressively halved from the standard 4 m until either the first line is correctly read or the shortest distance of 0.5 
m is reached. The measurable range of visual acuity will be 20/20 or better to 20/1600. Patients who are unable to read 
any letters on the chart will be tested for light perception and if they can perceive light they will be assigned the acuity 
score equivalent of 20/3200. 
 
Color Contrast Sensitivity 
The ChromaTest psychophysical vision testing system (CH Electronics) will be used to measure color contrast sensitivity. 
For this test the subject is seated at a fixed distance from a large format standardized and calibrated NEC Spectraview 
LCD monitor.  Alphabetical letters displayed on a background of equiluminance at a constant angle and size create an 
image that tests the central 6.5 degrees of the retina. The computer finds the endpoint of the test by a Modified Binary 
Search method; if response is correct, on the next presentation the color difference between letter and background is 
halved. If response is incorrect, the color -contrast is doubled. Incorrect responses prolong the test, but do not influence 
the final threshold. This method of determining thresholds leads to finite steps which reach a plateau at the color contrast 
sensitivity threshold at a test sensitivity of 1% (Wong et al., 2008). 
 
Optical Coherence Tomography (OCT)  
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Spectral –domain OCT (Spectralis – Heidelberg Engineering) will be used to estimate the existence and the extent of 
retained photoreceptors. In patients with stable fixation, the OCT studies will involve groups of raster scans to sample the 
retinal region of interest. The distance between the parallel scans (and thus the lateral resolution) will be 0.3 mm (~1 
degree) and will cover a 18x12 mm2  region of the retina centered on the fovea. 
 
Fundus Photography 
Photography (performed to minimize excess visible light exposure) will be performed at the screening visit and at the 12 
month visit.  
 
Full-field Electroretinogram (ERG) 
Multi-focal full field ERGs (Veris, Electro-diagnostics Imaging Co.) will be performed. Special protocols for the recording of 
„submicrovolt‟ ERGs have already been used in two clinical trials that included patients with relatively severe forms of 
retinitis pigmentosa (RP). For this proposal, methods of recording submicrovolt ERGs will be similar to those previously 
used in very severe retinal degenerative diseases (Jacobson et al., 1998). Full-field 29 Hz flicker will be presented with 
the standard stimulus on the 7 cd.m-2 white background and 100 sets of flicker trains consisting of three consecutive 
responses will be recorded. These sets will be repeated five times to obtain a measure of reproducibility. 
 
Quality of Life (QOL) 
QOL will be assessed using the 25-Item National Eye Institute Visual Function Questionnaire (Mangione et al., 2001).  
The questionnaire will be administered in an interview format at the baseline visit and at the 12 month visit. 
 
Genotyping Analysis 
The genotyping test will be done as a part of the eyeGene clinical research study at the National Institutes of Health (NIH).  
EyeGENE informed consent for genotyping and DNA diagnostics will be included in the trial consent form and will be 
approved by the University of Massachusetts Institutional Review Board.  These completed consent forms will be sent to 
the eyeGENE coordinating center and clinical criteria for each participant will be entered into the eyeGENE online 
database prior to shipment of blood samples.  5–10 ml of whole blood will be obtained by routine phlebotomy using plastic 
vacutainers containing K2 EDTA. All samples will be stored exclusively at room temperature with overnight shipping.  
Participants will be screened for the most common RP mutations including:  ABCA4, RHO, RDS, IMPDH1, PRPF31, 
PRPF3, RP1, PRPF8, NR2E3, TOPORS, RPGR, RP2, CNGA1, CRB1, C1QTNF5/ CTRP5, MERTK, PDE6A, PDE6B, 
RGR, RLBP1, RPE65, TULP1, CA4.  Dr. Kaushal or Dr. Asdourian will provide pre and post-test genetic counseling to all 
participants. 
 
Serum VPA Assay 
Compliance is an issue in self administered study drug clinical trials.  Medication monitoring will occur at every follow up 
visit.  Patients will be instructed to bring prescription bottles to every visit for counting.  Additionally, serum VPA levels will 
be assayed at regular intervals for bioavailability determination as well as validation of participant compliance to protocol.  
Serum concentrations will be assayed by a fluorescence polarization immunoassay system (Ax-Sym analyzer; Abbott 
Diagnostic Division, Irving, TX). 
  
Specific Aim 2:  Perform a genotype analysis of enrolled subjects in order to determine both the generalizability 
of this medication to all RP mutant types and to collect data on the possible mechanistic action of VPA  
Retinitis Pigmentosa is technically a group of retinal dystrophic disorders characterized by multiple mutations in proteins 
such as rhodopsin, retinal pigment epithelium protein, GTPase regulater; ATP binding cassettes; carbonic anhydrase, an 
oxygen-regulated photoreceptor protein.  The mutations are inherited in either an autosomal dominant, autosomal 
recessive or X-linked recessive fashion. The heterogeneic nature of RP mutations makes correlating progression of 
disease with therapeutic benefit difficult.  Recent clinical trials for RP generally classify patients according to gross class of 
disease without identifying or correlating treatment benefit with specific mutations involved (e.g. Bahrami et al., 2006; 
Merin et al., 2008; Radtke et al., 2008; Vingolo et al., 2008).  It is likely given the vastly different nature of the proteins 
involved in this disorder, that certain therapies will have varying beneficial effects on patients with different mutations. 
Indeed our preliminary clinical analysis suggests a varied response to VPA among the 6 RP patients treated (Figure 4), 
and indicates that certain individual or patient populations may preferentially respond to this medication.   
 
Our preliminary studies in vitro and in vivo also suggest that VPA may work at multiple levels as a retinal therapeutic.  We 
have in vitro data to suggest that it works at the level of rhodopsin folding (Figure 1), which would indicate that only those 
patients with protein folding associated RP would benefit from this medication.  However, other preclinical evidence 
suggests that VPA may work at the level of cell death protection (Figure 2) or inflammatory mediation (Chen et al., 2007; 
Dragunow et al., 2006; Kim et al., 2007) to exact its affect.  Preliminary clinical data on patients with age related macular 
degeneration suggests that VPA may be beneficial to other ocular diseases that aren‟t known to have protein folding 
pathway deficiencies (not shown), also supporting that VPA can work either on multiple pathways or in a protein folding 
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independent pathway.  Patients included in our preliminary clinical analysis described above (Figure 4), were not well 
characterized in regards to their RP genotype. To examine this in more detail, we propose to perform molecular genotype 
analysis on each enrolled patient.  Performing stepwise regression analysis adjusting for each mutation, we will correlate 
primary and secondary outcome measures with genotype to determine if VPA has a general benefit to all patients or if it 
effect is specific for certain populations of RP patients.  
 
The genotyping test will be done as a part of the eyeGene clinical research study at the National Institutes of Health (NIH).  
After informed consent, blood samples will be collected from enrolled patients and mailed to the eyeGENE coordinating 
center where it will be screened for the most common RP mutations (see Detailed Methods). Due to the rarity and 
sporadic nature of the many mutations associate with RP, it is likely that specific mutation information will not be identified 
for over half of our enrolled patients, (Daiger et al., 2007; Daiger et al., 2008; Sullivan et al., 2006); however, the additional 
information gained from the patients that can be genotyped will be valuable in understanding the potential mode of VPA 
action and targeted effectiveness of therapy.  Additionally, this information will be used to inform our escalating dose study 
in Aim 3. 
 
 
Specific Aim 3: Perform an escalating dose trial in a sub cohort of selected patients with similar rates of vision 
loss and/or mutation profile. 
If VPA proves to be an effective medication for ocular therapy, it will be important to establish effective therapeutic dosing 
windows.  The myriad of proteins and mutations that give rise to RP lead to an inherent heterogeneity in patients in both 
presentation and progression, which can compound attempts to narrowly define therapeutic dosing windows.  Utilizing the 
genotyping information from Aim 2, and/or the rate of vision function 
loss determined in the baseline screening, we can identify a 
standardized cohort of patients.  In this cohort (cohort 2 – see Figure 
7), we propose to perform a pilot analysis to define both dose 
response relationships and to identify effective dosing windows.    
 
While over 25 genes have been associated with RP, by far the most 
studied is rhodopsin (RHO). Over 120 point mutations in RHO have 
now been identified.  Although some of these mutations cause 
recessive RP and congenital stationary night blindness (CSNB), the 
vast majority cause autosomal-dominant RP (ADRP). ADRP is 
estimated to account for between 20 and 40% of all RP cases in the 
US. The most common ADRP mutations (about 26%), are 
characterized by mutations in the intradiscal, transmembrane and 
cytoplasmic domains of RHO, which result in misfolding of the protein, 
defined by the inability to form a functional chromophore with 11-cis-
retinal.  Published estimates (Daiger et al., 2007), and  patient profiles 
from the primary recruiting site (UMMMC Ophthalmology clinic), 
coupled with the tendency for family groups to co-enroll in these kinds 
of trials, we estimate that we will enroll approximately 10 patients with 
RHO associated ADRP.  Since these patients are likely to define the largest majority of patients enrolled in our study, we 
project that patients with RHO associated ADRP mutations will be enrolled in the escalating dose phase as cohort 2.   
 
However, there are several scenarios that could occur that 
may make it unlikely for us to form the second cohort based 
on mutational analysis alone.  We may not get adequate 
genotyping information on enough of the enrolled 
participants (if for example many of our enrolled patients 
have rare or as of yet unidentified mutations), alternatively 
and additionally, the enrolled patient population that can be 
genotyped may have a wide mix of mutations.  Finally, it has 
been shown previously the rates of vision function loss for 
RP patients with similar or even identical mutations may vary 
considerably (Berson et al., 2002).  If initial results disallow a 
second cohort to be formed based on common mutations, 
then we will form the second cohort based on similar disease 
progression as determined by the linked historical control analysis performed prior to the start of study medication.  In this 
manner, we hope to assure a standard population of participants in which to perform the dosing analysis.   
 
Figure 7 Escalating Dose Cohort 2 
 
 
 
 
Table 2:  Recommended Starting VPA Dosage Schedule for 
anti-convulsant therapy . 
(DEPAKENE(R) oral capsules, oral syrup, 2006)  
 
Pounds (lbs) Kilograms (Kg) Total Daily 
Dose (mg) 
22 -54.9 10 - 24  250  
55 - 87.9 25 - 39.9 500 
88 - 131.9 40 - 59.9 750 
132 -164.9 60 -74.9 1000 
165-197.9 75-89.9 1250 
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Providing there were no serious adverse events at the initial dose and DSMB approval, cohort 2 will receive a dose of 250 
mg VPA TID during month 6-9 of the study; if the safety and tolerability profile at this dose remains favorable and DSMB 
approves, this dose will then be escalated to 250 mg QID for months 6-9 (Figure 7).  This is still within and likely below the 
drug dosing guidelines for this medication (Table 2).  Serum VPA and safety measures in our standardized population of 
cohort 2 will be monitored closely (see Table 1).  
 
While there is no established relationship between mean VPA plasma concentration and clinical response for 
anticonvulsant therapy (Gram et al., 1979), it is possible that for this indication of retinal therapy, such a relationship can 
be established. Serum VPA levels will be collected from all enrolled patients (cohort 1 and 2) at all visits starting at week 
3.  These levels will be correlated with primary outcome measures to determine therapeutic dosing windows and dose 
response relationships.  
 
 
Timeline and Milestones: 
We have been extremely rigorous in our estimation of the timeline for this study.  This estimated timeline is based on 
Dr. Kaushal‟s extensive prior experience in vision based clinical trials and our consultation with relevant and 
appropriate officials and researchers as described above. Dr. Robert Brown in particular has scrutinized this study in 
regards to the proposed timeline and feels that it fits well within this funding window (see Letter of Support).  However, 
in the event that the timeline for this proposed study extends beyond the 2 year funding window, we have already 
lined up the FFB as a source of funds to complete the trial (see Letter of Support). If, as we fully expect, this trial is 
completed by September 2011, then the FFB has expressed interest in funding a new protocol for continued long term 
follow up of these participants. 
 
Timeline – Current and Projected Ongoing Milestones 
Pre-Clinical and Preliminary Clinical Evaluation  
Pre-clinical assessment of VPA‟s effect on cellular rhodopsin 
folding 
January 2008- January, 2009 
Pre-clinical assessment of VPA‟s protection of cells from 
apoptotis 
February, 2008 – January, 2009 
Dr. Kaushal treats several  RP patients off label with VPA at the 
University of Florida 
January 2008-December 2009 
University of Massachusetts IRB approval for retrospective 
chart review of RP patients treated with VPA 
February, 2009 
Abstraction of pilot data on Visual Field measures and statistical 
analysis for study design 
February -April, 2009 
Institutional Regulatory Requirements  
Dr. Clemson communicates with Brian O‟Sullivan, MD chair of 
University of Massachusetts Medical Center IRB to discuss 
specifics of clinical trial 
February, 2009 
Drs. Kaushal and Clemson submit full proposal to UMMMC IRB June,  2009 
IRB Approval of Phase II Clinical Trial August, 2009 
Data, Safety and Monitoring Board Convened December, 2009 
CDER/FDA Interactions  
Pre-IND teleconferences with Wiley Chambers, M.D., deputy January, February, March and April, May, June, 2009 
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director of the FDA's Division of Anti-Inflammatory, Analgesic and 
Ophthalmologic Drug Products 
Drs. Kaushal and Clemson submit expedited IRB proposal to 
the FDA 
July, 2009 
FDA approval for Phase II Clinical Trial August, 2009 
Subject Recruitment   
Dr.  Kaushal currently has about 20 RP patients who would be 
appropriate for this trial, and receives weekly calls from RP 
patients seeking new treatment options. 
Ongoing 
Meeting with Steve Rose, PhD  Chief Research Officer,  
Foundation For Fighting Blindness to discuss recruitment 
support (see Letter of Support) 
March 30, 2009 
Advertise at UMMMC, and the Foundation for Fighting 
Blindness website and email list and the Research to Prevent 
Blindness website  
September, 2009 
List trial in Clinicaltrials.gov September, 2009 
Begin Screening of potential subjects  September, 2009 
Enroll first patients October, 2009 
Screening of potential Subjects (we estimate need to screen 
total of 50 patients) 
September, 2009 -  April, 2010 
Final Patient Enrolled (enroll 45 patients assuming 10% loss to 
follow up ) 
May , 2010 
Baseline Evaluation  
Enrolled patients receive baseline evaluations  October, 2009 –June, 2010 
Last patient in receives baseline evaluation June, 2010 
Therapeutic Intervention/Outcome Measures  
First Enrolled patients begin oral VPA January, 2010 
Last Enrolled patients begin oral VPA May , 2010 
Patients return for periodic follow up/clinical assessments 
according to schedule (see Table 1) 
January  2010 – May, 2011 
Genotype Profiling and Analysis  
Serum samples sent to EyeGene for mutational analysis  October, 2009 – May, 2010 
Expected results returned from genotyping  February 2010 – November 2010 
Dose Escalation Analysis  
A standardized cohort of already enrolled subjects with 
similar mutation profiles and/or progression patterns is 
July – Nov 2010 
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defined as cohort 2 
Cohort 2 dosing increased to 250 mg TID July – Nov, 2010 
Cohort 2 dosing increased to 250 mg QID Sep, 2010 – Feb, 2011 
Safety Assessments  
Patients routinely screened for adverse events with follow 
up phone calls, safety labs and clinical assessment (see 
Table I) 
January 2010 – May, 2011 
DSMB reviews patient records and clinical outcomes  March, June, August, December, 2010 and Feb, April 2011 
DSMB reviews patient records and clinical outcomes for 
first dose escalation proposed cohort 2 
June - Nov, 2010 
DSMB reviews patient records and clinical outcomes for 
second dose escalation cohort 2 
Sep, 2010 – Feb, 2011 
Statistical and Data Analysis  
Dr. Clemson consults with institutional biostatisticians; Dr. 
Gerald Cagle at the National Neurovision Research 
Institute and Dr. David Birch of the Retinal Foundation of 
the Southeast on study design 
January – April, 2009 
Dr. Clemson utilizes preliminary clinical data to finalize 
clinical trial design 
April, 2009 
Baseline and Screening Control Data assessed for cohort 
2 definition 
October, 2009 – July, 2010 
Analysis of 6 month primary outcome measures as 
predicted by RP mutation for definition of cohort 2 
June, 2010 – Nov 2010 
15 month follow up visit and safety assessment  March, 2011 – August, 2011 
Data analysis September, 2009 - September 2011 
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Protection of Human Subjects 
 
Human Subjects Research Yes  
Exemption   No  
Clinical Trial Yes  
NIH-Defined Phase III Clinical Trial No  
 
Protection of Human Subjects 
This Human Subjects Research meets the definition of a clinical trial. 
 
Inclusion of Women and Minorities 
Retinitis Pigmentosa is a disease caused by a variety of mutations.  This is a rare disorder that tends to run in 
families, so recruitment efforts will likely result in a homogenous population. Because of X-linked forms, men 
are affected at a slightly higher rate than woman.  Women will not be excluded from this study. We anticipate 
enrolling women who are not pregnant or lactating, and will agree to contraception if of childbearing capacity.  
While most ethnic groups are affected by RP, in the United States, RP cases are predominantly Caucasian. We 
would not refuse anyone admission with another ethnic or racial group.   
 
Targeted/Planned Enrollment Table 
 
TARGETED/PLANNED ENROLLMENT: 45 
Ethnic Category 
Sex/Gender 
Females Males Total 
 Hispanic or Latino 0 0 0 
 Not Hispanic or Latino 22 23 45 
 Ethnic Category Total of All Subjects* 22 23 45 
Racial Categories 
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 American Indian/Alaska Native 0 0 0 
 Asian 0 0 0 
 Native Hawaiian or Other Pacific Islander  0 0 0 
 Black or African American  0 0 0 
 White 22 23 45 
 Racial Categories: Total of All Subjects * 22 23 45 
 
Participation of Children 
The age range for the onset of vision loss in most individuals with RP is over 18 years of age. Additionally, the 
risk of the study medication is significantly greater in children. Thus no attempt will be made to include 
children younger than 18 in this study.  
 
Protection of Human Subjects  
 
Risks to Human Subjects  
a. Human Subjects Involvement and Characteristics  
The proposed clinical trial is open-label, single and escalating dose oral VPA treatment. The Phase II clinical 
trial using VPA will assess efficacy and safety measures.  VPA has a well documented and established safety 
profile given that it has been used for other indications for over 30 years. The 45 human subjects who will be 
included in the proposed clinical trial will be males and females who have been diagnosed with RP, 18 years of 
age and older, who do not have any diseases or conditions contraindicated for VPA administration. 
 
Inclusion Criteria: 
 Understand and sign the IRB-approved informed consent document for the study. 
 Age  18 years. 
 Diagnosis of Retinitis Pigmentosa including  photoreceptor degeneration established by reduced visual 
acuity, visual field constriction, night blindness, marked reduction of rod and cone ERG responses, and 
presence of intraretinal “bone-spicule” pigment on clinical examination. 
 Willingness to comply with the protocol. 
 
Exclusion Criteria: 
 Medical problems that make consistent follow-up over the treatment period unlikely (e.g. stroke, 
severe MI, end stage malignancy), or in general a poor medical risk because of other systemic diseases 
or active uncontrolled infections. 
 Other retinal diseases: Glaucoma, retinal inflammatory disease, macular edema, cataract or herpes 
simplex virus of the eye.  
 Diabetes or cancer.  
 A hemoglobin concentration of less than 8 gm/dL a platelet count of less than 75K/mm(3) or an 
absolute neutrophil count of less than 500/mm(3) at study entry.  
 Liver disease determined by an alanine aminotransferase (ALT) aspartate aminotransferase (AST) or 
bilirubin 2.5 times greater than the upper limit of normal.  
 History of pancreatitis by clinical features and/or laboratory abnormalities in the last 12 months.  
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 Renal dysfunction determined by a calculated urine creatinine clearance of less than 60 mL/min in 
adults or using the Schwartz formula or Levy formula based on serum creatinine.   
 Patients clinically suspected of suffering from urea cycle disorders will be excluded. 
 Patients with history of seizure disorders and/or those already receiving valproic acid or other anti-
convulsants will be excluded 
 Sensitive to or have ever had an allergic reaction to Valproic Acid.  
 Female adults who have attained menarche must have a negative pregnancy test at study entry and 
commit to using an acceptable method of barrier or hormonal contraception  
 Lactating mothers who are breast feeding their babies will not be eligible. 
 RP patients involved in other clinical trials within the last 3 months are ineligible for this study.  
 
 
Adequacy of Protection Against Risks  
a. Recruitment and Informed Consent  
Patients will be recruited from the Department of Ophthalmology at the University of Massachusetts Medical 
Center and through the Foundation Fighting Blindness disease specific web site and email blast.  This protocol 
will be listed in the Clinical Trials Data Bank of the NIH.  Potential study patients who demonstrate an interest 
in participating in the study will receive an explanation of the terms, procedures, and requirements of the 
study from an investigator of the research team in language they can understand. They will receive a copy of 
the Informed Consent Form to read and share with family or friends.  Subsequently, an investigator will 
answer questions and request the patient's permission to participate in the study. Volunteer participants who 
sign a study-specific patient informed consent form approved by the Institutional Review Board will then be 
scheduled for a screening evaluation to determine their eligibility.  Children under 18 are not included in this 
study. 
 
b. Protections Against Risk  
 
The subjects will be informed of possible consequences of the study from one of the investigators in language 
they can understand.  They will be informed that they may withdraw from the study at any time and for any 
reason without jeopardizing their future treatment.  They will be asked to follow-up with necessary safety 
evaluations if they have received study agent prior to their desire to withdraw.  They will be given full 
information regarding potential side effects of VPA and the procedures involved.  The medical history and 
physical examination performed prior to study agent administration will identify patients with medical 
conditions that would increase the risks associated with study procedures and those subjects will be excluded 
from participation.  The administration of the study agent and all procedures related to the study will be 
performed by trained and licensed medical and health professionals.  They will be provided with contact 
numbers for any questions or concerns arising regarding the possible effects of the VPA and encouraged to 
call if they feel that an adverse event is occurring.  In the event of an adverse event associated with the clinical 
trial, immediate medical care will be provided.   
 
Patients will be followed closely, especially in the first 6 months for known adverse reactions to VPA.  Safety 
labs regarding liver and pancreas toxicity will be drawn prior to and periodically during dosing with VPA.  
Results of all laboratory and safety exams performed to ensure subject eligibility and safety will be reviewed 
by an investigator during the study.  Subjects with known risk factors such as liver disease, pancreatic 
conditions, metabolic disorders, organic brain diseases, seizure disorders and those on anti-convulsants will be 
excluded from the study. Female subjects of child bearing potential must have a negative pregnancy test at 
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the baseline visit and prior to study agent administration.  Female subjects of reproductive ability must be 
willing to use effective contraception for the duration of the study, one year.  Lactating mothers will not be 
included in this study.  We will not include children under 18 in this study. 
 
Confidentiality will be assured by limiting access to the subject database to key research personnel.  Individual 
identifiers will be stored in the computerized database and will also be the only identifier on analyzed and 
stored subject specimens.  Access to the database will be controlled by a user code.  The log identifying the 
subject names with the subject numbers, as well as Case Report Forms, Informed Consent Forms, laboratory 
study reports, and demographic profiles will be kept locked in an investigator’s office.  The subjects will be 
informed of the information stored and the review of that information by the DSMB, U Mass IRB, and U Mass 
clinical facility personnel, Data Management and Statistical personnel, research staff, and personnel 
performing the procedures.   
 
The Data Safety Monitoring Board (DSMB) will be established with members who have an understanding of 
the disease, ethics, and biostatistics.  They will review the study results and notify the PI of their findings and 
recommendations for study continuation or modification.  The DSMB will be charged with monitoring the 
conduct of the trial and assessing patient safety on an ongoing basis.  This group will review all safety data, 
including serious adverse events, adverse events, and laboratory data.  Confidentiality of the subjects will be 
maintained in the process of review by the DSMB. The DSMB will provide committee recommendations after 
each review.  Adverse events will be reported to the IRB, NIH, and FDA as regulated to insure the safety of 
subjects. 
 
The study will be monitored in compliance with the relevant parts of 21 CFR and according to the ICH GCP 
Guidelines. 
 
Potential Benefits of the Proposed Research to Human Subjects and Others  
There is no currently available treatment for RP.  Based on the preclinical and preliminary clinical efficacy data, 
there is potential that oral VPA may provide some degree of improvement in visual function in some of the 
individuals participating in this study.  However, the likelihood of achieving any benefit, and the degree of any 
benefit that may occur, is unknown.  
 
Importance of the Knowledge to be Gained  
Currently there is no cure for the retinal degeneration that occurs in RP.  Determining the efficacy of oral VPA 
has the potential for improving vision in RP patients who are most certainly going blind.  
 
Data and Safety Monitoring Plan  
The study will be monitored in compliance with the relevant parts of 21 CFR and according to the ICH GCP 
Guidelines. 
 
The procedures outlined in the protocol and case report forms will be carefully reviewed by the Principle 
Investigators and staff prior to Study initiation to ensure appropriate interpretation and implementation.  No 
deviations from the protocol shall be made except in emergency situations where alternative treatment is 
necessary for the protection, proper care and well being of subjects. 
 
Amendments will be submitted to the IRB for their review and approval prior to implementation.  When an 
amendment to a protocol substantially alters the study design or increases potential risk to the study subject, 
 205 
 
the Informed Consent form will be revised and if applicable, subject’s consent to continue participation will 
again be obtained. 
 
To ensure safety of human subjects and integrity of data in this trial, a data and safety monitoring plan will be 
established.  The levels of monitoring will include: 
 
Dr. Shalesh Kaushal, MD, PhD as Principal Investigator, will continuously monitor patient safety and be 
responsible for reporting serious and unexpected adverse reactions as regulated to the FDA, DSMB and IRB. 
The DSMB will provide safety oversight of the trial, to monitor the progress of the study, and to recommend 
modification of the trial, as appropriate.  The DMSB will review safety data after the first month of oral dosing 
and at regular intervals.  Serious and unexpected adverse reactions will be reviewed by the DSMB or 
subcommittee. 
 
Approval of the IRB will be obtained before enrolling subjects in this clinical trial.  Following the beginning of 
enrollment, the IRB will conduct continuing reviews of the trial at intervals appropriate to the degree of risk to 
human subjects. 
 
The degree of certainty with which an adverse event is attributed to drug treatment (or alternative causes, 
e.g. natural history of the underlying diseases, concomitant therapy, etc.) will be determined by how well the 
experience can be understood in terms of one or more of the following: 
 
 Known pharmacology of the drug 
 Reaction of similar nature being previously observed with this drug or class of drug 
 The experience having often been reported in literature for similar drugs as drug related 
 
 
A detailed Data and Safety Monitoring Plan will be submitted to the IRB prior to the accrual of human 
subjects. 
 
ClinicalTrials.gov Requirements  
The application includes a trial which requires registration in ClinicalTrials.gov.   The clinical trial will be 
registered in ClinicalTrials.gov when IRB approval has been received.  
 
Inclusion of Women and Minorities  
A section heading entitled "Inclusion of Women and Minorities" has been placed immediately following the 
“Protection of Human Subjects" section.  
 
b. Sources of Materials  
Research material obtained from identifiable living human subjects includes reports of:  history and physical 
assessments, blood, urine, pregnancy tests, perimetry, optical coherence tomography, visual acuity 
measurements, color contrast sensitivity and electroretinography measurements, clinical assessments, 
adverse events, and autopsies.  Copies of case report forms, original test results, subject medical records, 
signed subject informed consent, correspondence, and any other documents of the subjects, relevant to the 
conduct of the study will be kept on file by the principal investigator.  All material or data collected as part of 
the study will be obtained specifically for research purposes.  
 
c. Potential Risks  
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Potential risks to study subjects include the well known and characterized risks associated with administration 
of the therapeutic agent and with study procedures.  
 
Valproic acid can cause serious and fatal hepatoxicity especially in individuals with liver disease, organic brain 
disease, serious seizure disorders, congenital metabolic disorders, those on multiple anticonvulsants and 
children under the age of 2.  Therefore individuals with contraindicating diseases and concomitant 
medications as well as children under 18 will be excluded from this study. The risk of hepatoxicity usually 
occurs within the first 6 months of treatment and decreases considerably in older age groups. Serious or fatal 
hepatotoxicity may be preceded by non-specific symptoms such as malaise, weakness, lethargy, facial edema, 
anorexia, and vomiting.  
 
Valproic acid can cause serious and fatal pancreatitis. Some of the cases have been described as hemorrhagic 
with a rapid progression from initial symptoms such as abdominal pain, nausea, vomiting, and/or anorexia to 
death. Cases have been reported shortly after initial use as well as after several years of use. 
 
Valproate can produce teratogenic effects such as Spina Bifida, therefore woman of child bearing potential will 
be screened for pregnancy prior to administration of the study agent and must maintain use of contraception 
during the study period.   
 
The risks associated with ophthalmic procedures include redness, discomfort or allergic reaction to topical 
medications used to dilate the pupil prior to visual function tests. High blood pressure, cardiac dysrhythmias 
and closed angle glaucoma may be exacerbated by some of these medications and light sensitivity may be 
experienced when the pupil is dilated.  Corneal abrasions may result from the contact lenses used in 
performing electroretinography testing. The risks of drawing blood from a vein include discomfort at the site 
of puncture; possible bruising and swelling around the puncture site; rarely an infection; and, uncommonly, 
faintness from the procedure.  
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Multiple PI Leadership Plan 
 
Shalesh Kaushal, MD/PhD is the surgeon in the currently NIH funded (National Eye Institute) study entitled “Clinical Trials 
of Gene Therapy for Leber Congenital Amaurosis", and is the first investigator to use complement inhibitor molecules to 
treat patients. He is an internationally known clinician and researcher and will be responsible for all clinical aspects of this 
project.  He will oversee the screening, treatment and follow up of the subjects. Dr. Kaushal will be responsible for 
supervision of clinical personnel. Dr. Kaushal will be responsible for adverse event assessment and reporting.  He will 
form and report to the Data, Safety and Monitoring Board (DSMB). Dr. Kaushal will serve as the contact PI. 
 
Christine Clemson, PhD is also uniquely poised to be a new investigator with PI responsibilities.  She is an established 
and highly regarded Cell Biologist.  She is currently part of an elite group of professionals being trained to run clinical 
studies in the Master of Science in Clinical Investigation Program at the University of Massachusetts Medical School. The 
purpose of this program is to train promising researchers to translate basic science findings to the clinic.  This program is 
a direct result of the NIH‟s strategic direction towards this goal.  This application is an important benchmark in Dr. 
Clemson‟s transition to an independent investigator.  Dr. Clemson will be responsible for all aspects of experimental 
design, data analysis, and all project management and administrative responsibilities. Dr. Clemson will be responsible for 
supervision of personnel related to these roles. She will be responsible for overseeing recruitment outreach and milestone 
monitoring.  Dr. Clemson will be responsible for submission of progress reports and all communication with the NIH, FDA, 
and IRB. 
 
Dr‟s. Clemson and Kaushal will be jointly responsible for project direction and progress, and they will communicate daily 
by phone, email or in person. They will work together on any proposed changes in research direction and redirection of 
funds necessary.  They will each share their results with each other and key personnel. They will jointly publish results 
from this study.  
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Budget Justification  
 
Personnel 
 
Shalesh Kaushal, M.D. PhD. (30% effort, 3.6 cal. mos.) will serve as a Principal Investigator of this study 
providing oversight for all aspects of the design and performance of the clinical treatment. He will oversee and 
participate extensively in the screening of participants, and will make the ultimate determination of whether a 
recruit is a suitable subject.  Dr. Kaushal will be involved in the baseline and ongoing follow up assessments of 
all participants, and will interact closely with the creation of and communication with the DSMB.  Dr. Kaushal 
will be responsible for assessing and reporting adverse events, as well as closing monitoring the clinical and 
serum profiles of the second cohort on escalating dosages. Dr. Kaushal will provide pre and post test genetic 
counseling to participants who choose to be genotyped. Dr. Kaushal has had extensive experience in ocular 
clinical research and treated the patients in the preliminary clinical phase.   Dr. Kaushal is the surgeon in the 
currently NIH funded (National Eye Institute) study entitled “Clinical Trials of Gene Therapy for Leber 
Congenital Amaurosis", and is the first investigator to use complement inhibitor molecules to treat patients.   
*The actual institutional base salary for Dr. Shalesh Kaushal exceeds the current NIH rate allowed, however 
the salary requested is within the rate authorized by the NIH. 
 
Christine Clemson, PhD. (50% effort, 6 cal mos.) will serve as a Principal Investigator of this trial, providing 
oversight for all aspects of the design and performance of this project. In particular, Dr. Clemson is responsible 
for the pre-clinical analysis, clinical trial development and details, and all regulatory applications and 
reporting.   Dr. Clemson is completing an intensive 2 year  Masters Program in Clinical Investigation.  Dr. 
Clemson is combining this professional development with her 15 years of experience as a cell biologist to 
implement a “translational” approach to this clinical trial.  Her unique and broad set of skills is instrumental in 
the unique multi-layered study design which will allow a wealth of information on efficacy in RP patients in 
general and within specific mutation populations, as well as dose response and therapeutic dosing windows all 
within a relatively short period of time.  
She will also serve as the primary data analyst and will carry out the quantification of the diagnostic 
tests including visual field perimetry, visual acuity, Color Contrast Sensitivity, ERG and QOL.  The unique design 
and compressed timeline of this clinical trial allows much information to be extracted in a short period of time, 
so the success of this design hinges on rapid acquisition and analysis of the data. 
 
*The actual institutional base salary ($51,200) for Dr. Christine Clemson reflects her current status as a 
graduate student. Dr Kaushal, as Chair of the Ophthalmology department, has begun the process of promoting 
her to Asst. Professor, a position commensurate with her multiple degrees and length of experience.  The 
$98,000 salary requested reflects this impending promotion and is within the rate authorized by the NIH for 
this position.  
 
 
George Asdourian, M.D.  (20% effort, 2.4 cal mos.) as a co-investigator, will aid in the screening and baseline 
measurements of all participants, as well as help perform clinical diagnostic follow up of  participants during 
the study. Dr. Asdourian  will help provide pre and post test genetic counseling to participants who choose to 
be genotyped.   Dr. Asdourian has been a practicing ophthalmologist for 30 years, and has been the Director of 
Retina Service in the Ophthalmology program at UMMMC for over 20 years, as such he has extensive 
experience as a clinician. 
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*The actual institutional base salary for Dr. Asdourian exceeds the current NIH rate allowed, however the 
salary requested is within the rate authorized by the NIH. 
 
 
Margaret Humphries, R.N. (20% effort, 2.4 cal mos.) will serve as the nurse/coordinator, working with the 
Principal Investigators, in the design of the clinical trial, case report forms, standard operating procedures, 
interacting with and reporting to NIH, DSMB, IRB and FDA. She will be training personnel involved in the 
clinical trial, arranging parts of the study visits, organizing and assisting with procedures, reporting data, and 
interacting with Judith Colbert, the trial administrator.  Margaret has extensive experience in this capacity and 
is currently the senior research nurse on the NIH funded (National Eye Institute) study entitled “Clinical Trials 
of Gene Therapy for Leber Congenital Amaurosis". 
 
Judith Colbert, R.N. (30% effort, 3.6 cal mos) will serve as the trial administrator performing and overseeing 
many diagnostic procedures.  She will perform the visual acuity and color contrast sensitivity testing of all 
participants, and she will supervise the technicians performing the extensive ocular imaging. 
 
Elena Filippova, MD.  (30% effort, 3.6 cal mos) will serve as the clinician/research technician responsible for 
genotyping and drug dosing analysis.  She will be responsible for registering subjects with the NIH eyeGENE 
clinical coordinating center, collecting and coordinating NEI required participant documentation for all 
recruited patients; she will oversee the collection, storage and shipment of all blood samples for genotyping.  
Dr. Filippova will also be responsible for collecting and collating data on serum VPA levels for all patients, and 
for the escalating dosing in cohort 2; she will be responsible for reporting results back to principal 
investigators. 
 
Julie Wilson, (30% effort, 3.6 cal mos.) will serve as one of the ophthalmic imagers and technician.  Julie is 
highly trained on the imaging equipment that will be used during this study including static and kinetic 
perimetry, fundus photography, optical coherence tomography and submicrovolt ERG.   
 
Additional ophthalmic imager and technician (25% effort, 3 cal mos.) to be named later will be needed for the 
extensive diagnostic imaging that will be used during this study including static and kinetic perimetry, fundus 
photography, optical coherence tomography and submicrovolt ERG. 
 
Biostatistician (4% effort, .48 calendar months) A senior biostatistician to be named later will be hired from 
the University of Massachusetts Medical School Quantitative Health Sciences Core Facility to consult with Dr. 
Clemson. 
 
Travel. Year 1: For the PI or Co-PI to attend and report at scientific meetings.  Year 2:  For the PI and Co-PI to 
attend and report at scientific meetings. 
 
Patient Care:  The costs of safety labs (liver, renal and pancreatic function screening, CBC, chem7), pregnancy 
tests, VPA serum levels and supplies for preparing and mailing genotyping blood samples are included for the 
first and second year. 
 
Supplies: The cost for participant stipends and pharmacy set up in the first year and pharmacy maintenance 
and study medication (Valproic Acid) is included in the first and second year.  
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Figure 1:  Delayed Start Design 
 
 
CHAPTER 5:  ALTERNATIVE STUDY DESIGNS 
 
5.1 DELAYED START DESIGN 
In considering study design, I borrowed from the 
wealth of literature on Parkinson‟s Disease (PD) 
trials. I first contemplated a delayed start 
design.  This design is similar to a crossover 
design with some important differences. In a 
progressive neurodegenerative disorder it is 
important to tease out the symptomatic effects 
(like reducing inflammation) from the long term 
pathophysiology of the disease (like death of the 
photoreceptor cells). A crossover design has the 
potential to only measure the symptomatic 
affect in both arms since overall treatment time 
in both arms is shortened relative to other 
designs. This shortened time frame is may not 
allow enough time for the main outcome (ie. 
significantly fewer cells dying on treatment).  A 
delayed start design overcomes the 
complications of the crossover design and 
directly addresses symptomatic benefit versus 
neuroprotection.  I modeled my design after the 
PD ADAGIO study (Olanow et al., 2008).   The 
basic outline of this model (see Figure 1) is to 
divide the subjects into two groups.  The first 
treatment group receives the intervention for the 
entire 12 months, while the second group 
receives the placebo for the first 6 months.  At 6 
months, the control group would then be given 
the intervention for the remaining 6 months of the trial.  If the treatment provides merely a 
symptomatic benefit, then the outcome in the treated and control group would be indistinguishable.  If 
however, the study drug was neuroprotective, then the control group would never “catch up” to the 
treatment group.  Ultimately I decided that symptomatic benefit in RP was not as big of a concern as 
in PD, so I abandoned the delayed start design. 
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Figure 2:  Futility Study 
 
 
 
5.2 FUTILITY STUDY 
A futility study is another trial design borrowed from 
PD literature (see Figure 2).  This kind of study is 
generally used to rule out therapies with modest 
hypothetical effects on outcome measures.  They are 
typically short trials (6 to 18 months) and relatively 
inexpensive since historical controls are used for 
comparisons (Voss and Ravina, 2008).  These 
studies are well powered for their small sample size 
as their goal is to quickly rule out interventions (ie. 
prove futility), not prove efficacy.  Ultimately given 
the large effect on outcome predicted by our pilot 
analysis, this design was abandoned for a modified 
design (the one armed self controlled study below) 
that targeted efficacy.   
5.3 ONE ARMED SELF –CONTROLLED STUDY 
Given the promising nature of the pilot analysis, the 
futility study was abandoned in favor of a design that 
was powered to elucidate efficacy.  The historical control aspect was retained and modified, however 
to allow for a longitudinal analysis of baseline rate of vision loss for each subject (Figure 3).  Given 
the heterogeneity of the RP population, adequately controlling for the very different rates of vision 
loss that are associated with the different RP mutations (Berson et al., 2002; Hartong et al., 2006; 
Sandberg et al., 2005; Sandberg et al., 2007; Sandberg et al., 2008) was a significant concern.  This 
is the design that was developed 
and explained in detail in the 
Challenge Grant Application 
(Chapter 4, page 191).  In brief, 
subjects would be followed for at 
least 3 months prior to the start of 
the study to ascertain their 
baseline rate of vision loss.  This 
single arm of subjects would then 
be treated with the intervention for 
the entire 12 months.  The follow 
up visual field area for each 
subject would be compared to 
their predicted loss (calculated 
from their current rate of vision 
 
 
Figure 3 One armed self controlled study design.  
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FIGURE 4:   RANDOMIZATION SCHEME  
Accounts for a maximum of 45 patients per arm with no attempt to balance arms 
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loss ascertained during the longitudinal baseline analysis). Ultimately this trial design was abandoned 
in favor of the randomized placebo controlled design due to feedback from the FDA as described 
above in the introduction to Chapter 3 (page 40 above). 
5.4 STRATIFIED RANDOMIZATION BASED ON RP GENOTYPE. 
With the abandonment of the longitudinal self controlled aspect of the trial design, the heterogeneic 
nature of the RP diseases was a primary concern. Reports in the literature illustrate the varying rates 
of vision loss associated with the different RP genotypes.  For example, patients with X linked RP 
with RPGR mutations were found to have an annual rate of visual field loss of 4.7%, while those with 
the more common autosomal dominant RHO mutations have a predicted rate of loss of 2.9% 
(Sandberg et al., 2007).  To address this we proposed a stratified randomization schema. 
Patients included in our preliminary clinical analysis were not well characterized in regards to their RP 
genotype. To examine this in more detail, we proposed to perform molecular genotype analysis on 
each enrolled patient and target enrollment of approximately 20 patients with P23H opsin mutations.   
The genotyping would be done through the NEI eyeGENE protocol as described in the protocol 
above (page 60). Getting these results quickly was important to the feasibility of this kind of design, 
and we made arrangements with Stephen Daiger, PhD, the director of the Laboratory for the 
Molecular Diagnosis of Inherited Diseases in Houston Tx, (which is one of the EyeGENE testing 
centers) to have our subjects samples expedited.  Dr. Daiger estimated that he would be able to 
return genetic testing results within 3 weeks. 
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The block randomization would be stratified based on RP genotype (see Figure 4). The rationale for 
randomizing within the blocks is to more evenly distribute patients between the two experimental 
groups (VPA vs. placebo) and possibly eliminate differences in disease progression rates due to 
different mutations.  
Ultimately this stratified randomization was abandoned due to the FDA‟s concern over generalizability 
and reduction in power associated with this kind of recruitment schema. 
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CHAPTER 6:  CONCLUSIONS AND RECOMMENDATIONS 
 
6.1 GOAL 1: TO LEARN THE INSTITUTION INDEPENDENT CLINICAL TRIAL DEVELOPMENT PROCESS 
6.1.1 STRENGTHS 
The first goal of this project was to learn the institution independent clinical trial development process.  
I took this project from a pilot study to the final IND submission.  In doing this I considered and 
incorporated multiple study designs, established connections with personnel at the FDA and 
pharmaceutical companies and authored both a protocol and complete case report form data set. The 
measures of my accomplishment toward this goal include a successful IND submission, three 
approved IRB applications with associated consent forms and two submitted clinical manuscripts. 
6.1.2 FUTURE DIRECTIONS 
There were areas of drug development and human studies that were not covered in this project.  The 
initial in vitro and animal pharmacokinetic and safety studies, both short and long term were 
circumvented in this project due to the nature of the study drug.  Additionally, first in human Phase I 
and early Phase II studies were not necessary with this abbreviated trial development process.  
These are important aspects of clinical studies that I hope to learn and experience in my next 
endeavor. 
6.2 GOAL 2: INFORMAL AUDIT OF UMMMC’S CORE CAPABILITIES  
The next goal of this project was to understand and annotate the resources available at our institution 
for investigator initiated clinical trials.  To this end I collected a series of observations and 
recommendations to aid the institution as we develop the infrastructure to help many investigators 
initiate clinical trials.  Below are summaries of the recommendations detailed in the introduction 
sections to Chapter 1-4 above.  
6.2.1 RECOMMENDATIONS CONCERNING THE IRB SUBMISSION PROCESS 
 Centralize all information through a dedicated web portal with detailed, clear pathways for 
each step. 
 All forms for each stage of the submission process should be linked to these steps. 
 Electronic submission of forms will alleviate the administrative complications and confusion. 
 Online sample templates of protocols and case report forms (which are difficult to acquire 
due to intellectual property issues) should be available through the web portal. 
 
6.2.2 RECOMMENDATIONS CONCERNING THE RESEARCH PHARMACY 
 Drug source information needs to be centralized and readily accessible. 
 Outsourcing contacts for drug and placebo manufacture need to be developed and 
available as resources for investigators. 
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 The Research Pharmacy is understaffed and given inadequate resources for their existing 
capabilities. If the expectation is that they will be instrumental in the strategic push towards 
more clinical trials, this inadequacy needs to be addressed through hiring of more 
personnel and investment in equipment and space. 
 
6.2.3 RECOMMENDATIONS CONCERNING BIOSTATISTICAL SUPPORT 
 Dedicated core biostatisticians are needed. 
 These professionals are needed continuously throughout the entire dynamic process and 
should be able to immerse themselves in the relevant literature pertaining to the particular 
disease, outcome measure and testing equipment. 
 These biostatisticians should be part of the data management tool design process. 
 Statistical outcome of the data once the trial is completed should be an integral part of the 
study design process. 
6.2.4 RECOMMENDATIONS CONCERNING THE IND SUBMISSION PROCESS 
 A detailed step by step description of the IND Process needs to be incorporated into the web 
portal resource for investigators. 
 In-house experts on FDA processes should be developed and/or recruited and will be an 
important part of the internal FDA knowledge base development. 
 Relationships with key personnel at FDA need to be established and continuously cultivated. 
 The contact information for in-house and extramural FDA resources should be linked with 
every step in this pathway. 
 Enterprise solution for electronic clinical trial reporting requirements to the FDA should be 
established now. 
6.2.5 RECOMMENDATIONS CONCERNING CLINICAL TRIAL FUNDING 
 Sample and template clinical trial budgets for NIH proposals should be available as these are 
quite different from “typical” NIH research grant budgets. 
 Resources and forms associated with budget and contract negotiations need to be centralized 
and available through the web portal. 
 Procedure and laboratory costs are critical for creating relevant clinical trial budgets and 
should be readily available and accessible through the web portal. 
 
6.3 GOAL 3:  TREATMENT FOR A BLINDING DISEASE 
6.3.1 STRENGTHS 
This was clearly the most important and relevant goal of this proposal.  There was significant 
progress made toward this end.  The pilot analysis revealed the potential to reverse loss of visual 
field, which is a staggering clinical outcome for a disease that previously had no therapy that 
significantly affected progression. Dr. Kaushal and the UMMMC Ophthalmology community are now 
poised to implement this study protocol by virtue of the FDA and IRB‟s approval.  Additionally, the 
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manuscript in submission will inform others in the RP community of the potential benefit of this 
medication. 
6.3.2 FUTURE DIRECTIONS 
Efforts to procure funding for this trial are ongoing.  The extensive costs associated with this large trial 
mean that no intervention can occur until funding is secured.  We are actively pursuing both 
foundation and NIH funding.  In retrospect, a smaller less expensive pilot study that incorporated 
standard of care treatment would have been a valuable interim measure.  If prospects for funding the 
larger trial do not materialize, this will be an important future direction.  
6.4 INTANGIBLES LEARNED 
In this thesis I have attempted to comprehensively annotate the steps and overall process needed to 
take a drug into the clinic for a new indication.  There were four key lessons that may not be 
adequately documented in the applications and documents included above. These “intangibles” were 
hard fought lessons and are the final points that I feel are important to emphasize and pass on to 
others who may be embarking upon the process of the investigator initiated clinical trial.   
 
1. Talk to the FDA early and often – an accessible, knowledgeable, decision maker is key!!! 
2. “Perfect” study design often conflicts with what is feasible. 
3. Small changes in the trial design/protocol can have large implications. 
4.  Despite #3, be open to changes in direction at EVERY point in the pathway. 
 
 
  
 
